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Abstract 
 
Congenital myasthenic syndromes (CMS) are inherited disorders in which the safety 
margin of the neuromuscular transmission is compromised.  The clinical hallmark of 
CMS is fatigable weakness.  To date, nineteen genes have been implicated in causing 
this disorder, with most mutations located in postsynaptic proteins.  Nevertheless, a 
great proportion of patients remains with no molecular diagnosis and cannot therefore 
access optimum therapy.  In this thesis, each topic is summarized in one chapter that 
corresponds to one or part of a selected journal publication, or a book chapter. 
Chapter 1 is dedicated to the review of our current understanding of the different CMS 
subgroups based on their underlying molecular defects.  Chapter 2 focuses on the 
methodology used to acquire the data described in the subsequent chapters.  Chapter 3 
reports on the mutation distribution, clinical features and genotype phenotype 
correlation of CMS patients referred to one of the largest CMS diagnostic centres 
worldwide.  The phenotype genotype correlation and response to treatment in specific 
CMS subgroups are refined in chapters 4 and 5, including slow channel CMS and 
GFPT1 associated CMS respectively.  Chapter 6 focuses on the selection strategy of an 
undiagnosed CMS cohort for whole exome sequencing and reports on the candidate 
variants identified.  Finally, in chapter 7 and 8, detailed clinical and biological data are 
shown to demonstrate the pathogenicity of novel AGRN and SLC25A1 mutations 
identified using next generation sequencing. 
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CHAPTER1. INTRODUCTION
1 
 
 
Congenital myasthenic syndromes (CMS) consist of a rare group of genetic disorders in 
which the safety margin of neuromuscular transmission is jeopardized.  Typically, 
patients present with fatigable neuromuscular weakness; with ocular, bulbar and 
occasionally respiratory failure.  Although the phenotype is similar to the more common 
autoimmune myasthenia gravis, the early age of onset, a positive family history, the 
course of disease progression and the choice of therapy are distinctly different.  The 
precise prevalence of this condition is unknown and is likely to be underestimated.  A 
recent UK study reported a prevalence of 9.2 per million genetically confirmed CMS 
children under 18 years of age (Parr et al., 2014).  In Southern Brazil, the minimum 
prevalence was estimated at 1 in 1 million populations (Mihaylova et al., 2010).  
 
Understanding the fundamentals of neuromuscular junction structure, development and 
function has been key to establishing the molecular mechanisms underlying several 
CMS subtypes.  Generally, defects related to CMS can either target the efficiency of 
chemical transmission across the neuromuscular junction (CHAT, COLQ, CHRNE, 
CHRNB1 and CHRNA1) or prevent organized formation of neuromuscular synapses 
(AGRN, MUSK and DOK7).  To date, nineteen genes have been shown to cause CMS, 
with most patients exhibiting defects in the postsynaptic compartment.  Nonetheless, the 
genetic cause remains elusive in almost half of clinically diagnosed CMS patients, 
which may either suggest that patients harbor rare private mutations in known CMS 
genes or that more novel genes are waiting to be unraveled.  It seems likely that the 
introduction of next generation sequencing will help clarify the latter possibility. 
 
In this chapter, I first discuss the clinical diagnostic strategy of congenital myasthenia 
and the importance of particular ancillary tools in confirming the diagnosis.  I then 
review the salient morphological and functional characteristics of the neuromuscular 
junction (NMJ), illustrating how defects in particular proteins relate to distinct groups of 
CMS and influence the choice of treatment in patients.  Finally, I outline the main 
objectives of the work presented in the following eight chapters.  
                                                 
1
 Adapted from Chaouch, A. and Lochmüller, H. (2013) Congenital Myasthenic Syndromes, in Muscle Disease: 
Pathology and Genetics, Second edition.  John Wiley & Sons, Ltd, Oxford, UK.  
 
2 
 
1.1 Diagnostic strategy of CMS
2
  
 
Most CMS patients present in childhood; with fatigable weakness showing varying 
degree of ocular, bulbar as well as respiratory involvement (Beeson et al., 2005).  The 
pattern of muscle involvement can provide some useful diagnostic clues as to the 
underlying molecular diagnosis.  For instance, a proximal pattern of muscle weakness is 
usually seen in the limb girdle CMS phenotype.  The latter can be associated with a 
particular group of CMS genes such including DOK7, COLQ, GFPT1, ALG2, ALG14 
and DPAGT1.  On the other hand, a more distal pattern of muscle weakness can be seen 
in a rare subtype of CMS, namely slow channel CMS or the recently described AGRN 
associated CMS with distal muscle weakness and atrophy (Nicole et al., 2014).  The 
gold standard investigations to evaluate the integrity of neuromuscular transmission are 
repetitive nerve stimulation (RNS) and single fibre electromyography (SFEMG).  These 
should preferably be completed on both proximal and distal muscles (Chaouch et al., 
2012b).  More details on these tools will be discussed below. 
 
Though histochemical analysis of muscle biopsies is not specifically carried out to 
prove a diagnosis of CMS, this can offer valuable cues in terms of dismissing 
alternative neuromuscular conditions such as a myopathy or peripheral nerve disorder. 
Moreover, in the absence of significant structural abnormalities, particular muscle 
biopsy features such as type1 fiber predominance with type 2 fiber atrophy can be 
supportive of CMS.  Other potentially relevant histological clues include tubular 
aggregates, which have recently been associated with the limb-girdle CMS phenotype 
resulting from mutations in glycosylation genes (Senderek et al., 2011, Belaya et al., 
2012, Cossins et al., 2013).  Nevertheless, tubular aggregates are not a specific finding 
to CMS and have been reported in other neuromuscular disorders such as congenital 
myopathies, periodic paralysis and myotonic dystrophy.  Accordingly, one would often 
need to interpret this histological finding in the context of the clinical and 
electrophysiological evidence to establish accurate diagnosis (Schiaffino, 2011). 
 
                                                 
2
 Adapted from Chaouch, A. and Lochmüller, H. (2013) Congenital Myasthenic Syndromes, in Muscle Disease: 
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In terms of differential diagnosis of CMS, autoimmune myasthenia gravis in children 
and adults and congenital myopathies in infants are common and, at times, challenging 
diagnostic mimics of CMS.  Since some CMS patients can present late into adulthood 
and exhibit no positive family history, clinicians may consider a diagnosis of 
autoimmune myasthenia gravis, which is much more common than CMS and is also 
treatable.  Nevertheless, the presence of ophthalmoplegia with no associated significant 
diplopia, contractures and scapular winging are all features of a congenital disorder, not 
usually seen in the acquired autoimmune form of myasthenia.  Congenital myopathies 
have emerged as an important differential diagnosis of CMS, sometimes with 
significant clinical and neurophysiological overlap between the two entities.  Typically, 
congenital myopathies are associated with fixed neuromuscular weakness with evidence 
of skeletal deformities in most and occasional intellectual disability.  The muscle biopsy 
findings and more recently muscle MRI patterns of involvement have proved crucial to 
guide the diagnostic strategy of congenital myopathies.  Lastly, although RNS and 
SFEMG are usually normal in congenital myopathies, some reports have shown 
evidence of abnormal NMJ transmission in genetically confirmed cases Wattjes et al. 
(2010). 
 
 
1.2 Electrophysiological evaluation of neuromuscular transmission 
 
This investigation remains an essential part of the assessment of patients with suspected 
abnormal neuromuscular transmission and includes repetitive nerve stimulation and 
single fibre EMG. 
 
Repetitive nerve stimulation aims at measuring the amplitude (or area) of the compound 
muscle action potential (CMAP) of a muscle in response to the stimulation of the motor 
nerve being studied (Sanders, 2012).  Depending on the frequency of stimulation, 
different parameters can be assessed: 
a. Repetitive nerve stimulation at low frequency (3Hz) is usually carried out in 
search of decrement, which may reflect a postsynaptic defect. 
b. Repetitive nerve stimulation at high frequency (20 to 50Hz) is performed to 
assess for increment, which would be in favour of a presynaptic defect. 
 
4 
 
CMAP amplitude is measured before and immediately after brief muscle contraction 
(10-20 seconds); an increment of more than 80% is suggestive of a presynaptic defect.  
If decrement is not present, testing for post-exercise exhaustion can be done.  This 
relates to the development or exacerbation of decrement with sustained muscle 
contraction for 1 minute and after repetitive nerve stimulation at 3Hz (Sanders, 2012). 
 
Single fibre EMG (SFEMG) is carried out using a special electrode inserted into the 
muscle.  It is based on the principle that action potentials of muscle fibres of the same 
motor unit appear with consistent latencies.  The action potentials from two muscle 
fibres belonging to the same motor unit are captured.  Increased variability (jitter) of 
latencies across these two muscle fibres, sometimes leading to conduction block, is 
suggestive of impaired neuromuscular transmission.  Abnormal jitter on SFEMG is 
reported to be highly sensitive (more than 95%) but not specific to defects of the 
neuromuscular junction.  Indeed, abnormal jitter can occur in other neuromuscular 
conditions such as motor neurone disease or myositis (Sanders, 2012). 
 
There are two other neurophysiological evaluations carried out in most patients, which 
have some impact in terms of interpreting some of the above mentioned NMJ 
investigations.  Nerve conduction studies involve the measurement of conduction 
velocity of motor and sensory nerves whilst taking into account:  
 
1- The amplitude of CMAP in relation to single stimulation of the motor nerve.  
This amplitude can be reduced in presynaptic disorders. 
2-  The morphology of the CMAP such as repetitive CMAP on single nerve 
stimulation, which can be observed in some forms of congenital myasthenia.  
 
Of note, the motor and sensory motor conduction velocities are usually normal in 
disorders of the neuromuscular junction.   
EMG focuses on the characteristics of the motor units (amplitude, duration, 
morphology, etc.).  In disorders of the neuromuscular junction, some myopathic features 
can occasionally be observed (Sanders, 2012).  
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1.3 Neuromuscular junction organization
3
 
 
In vertebrates, a motor nerve fibre divides into several axonal terminal branches, which 
innervate a skeletal muscle.  The region of contact between the nerve terminal and the 
muscle fibre is termed the motor endplate.  Every muscle fiber is connected to one 
motor nerve terminal via one neuromuscular junction apart from some of the cranial 
muscles, where a single muscle fibre can contain several motor endplates (Happak et al., 
1997).  The latter probably reflects the intricate neuronal regulation required in these 
muscles.  Despite great heterogeneity in NMJ structure across muscle fiber types and 
across species, all NMJs consist of: 
1-  A Schwann cell process that wraps the nerve terminal without reaching the 
synaptic cleft. 
2- A presynaptic nerve bud in which special vesicles are filled with a 
neurotransmitter that is released into a synaptic cleft. 
3- A synaptic space that is filled with a myriad of extra cellular matrix proteins.  
4- The postsynaptic membrane that contains a receptor for the neurotransmitter 
released from the presynaptic vesicles as well as a sarcolamma that defines and 
maintain the structure and function of the postsynaptic compartment (Engel, 
2008). 
 
The presynaptic nerve terminal comprises great numbers of organelles such as 
mitochondria, which form up to 30% of the presynaptic compartment as well as 
numerous synaptic vesicles.  These are responsible for the uptake, concentration and 
storage of acetylcholine (ACh) and some usually cluster close to the active zone where 
the neurotransmitter is released into the synaptic space.  The synaptic space itself is a 
complex meshwork of structural proteins and enzymes such as laminins, collagen, 
proteoglycan, acetylcholinesterase (AChE) and neuronal agrin.  A unique feature of the 
neuromuscular junction is the presence of several junctional folds in the postsynaptic 
membrane.  The sarcolemma lining these junctional folds contains nicotinic 
acetylcholine receptors (AChRs) as well as other proteins shown to be important for the 
development and maintenance of the neuromuscular synapse (Engel, 2008). 
                                                 
3
 Adapted from Chaouch, A. and Lochmüller, H. (2013) Congenital Myasthenic Syndromes, in Muscle Disease: 
Pathology and Genetics, Second edition.  John Wiley & Sons, Ltd, Oxford, UK.  
 
6 
 
1.4 Neuromuscular junction development and maintenance
4
 
 
The functional properties of the NMJ are acquired through a complex but well-
orchestrated process involving close interaction between the muscle fibre and the motor 
nerve terminal.  “Pre-patterning” is a term coined to describe a critical step in the initial 
development of the NMJ and relates to the clustering and apposition of nascent 
acetylcholine receptors on the postsynaptic membrane.  This process was shown to be 
more reliant on muscle derived postsynaptic protein such as MuSK, which can enhance 
the transcription of postsynaptic receptors.  Interestingly, the nerve terminal seems to 
have little influence on this critical step of NMJ development.  On the other hand, 
further stabilization of pre-patterned AChR clusters does require neuronal regulation 
through the agrin protein, which can disperse any receptor clusters, placed outside the 
synapse.  Agrin can also regulate postsynaptic signals mediated via the AChRs.  Thus, 
during NMJ development, the specialization of the postsynaptic compartment precedes 
nerve terminal differentiation (Witzemann, 2006, Sanes and Lichtman, 2001). 
 
 
1.5 Transmission at the neuromuscular junction  
 
The release of acetylcholine from presynaptic vesicles via exocytosis is activated by 
depolarization of the terminal motor nerve membrane.  This in turn triggers entry of 
calcium into the presynaptic compartment.  Acetylcholine is then released into the 
synaptic space and binds to the postsynaptic nicotinic acetylcholine receptors.  The 
latter are ligand gated ion channels that allow entry of sodium, which in turn generates 
depolarization of the postsynaptic muscle membrane (endplate potential, EPP).  In the 
absence of an action potential, presynaptic vesicles can also spontaneously release their 
content into the synaptic cleft and generate a small electrical response named a 
miniature end plate potential (MEPP).  Simultaneous efflux of potassium in the 
postsynaptic compartment through activation of voltage gated K
+ 
channels permits 
repolarization of the membrane potential to baseline.  A fundamental principal 
underpinning the efficacy of neuromuscular transmission is the safety margin, which 
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corresponds to a threshold at which the synaptic machinery can operate without failure 
of transmission (Paton and Waud, 1967, Fagerlund and Eriksson, 2009). 
 
Patch clamp study of the neuromuscular junction allows the analysis of the functional 
properties of the NMJ based on its electrical properties.  It also provided the opportunity 
to examine the molecular basis of different CMS subtypes and the impact of new 
mutations on synaptic function.  Studies on sampled motor endplates (often taken from 
intercostal muscles) allow the measure of the kinetic characteristics of the nicotinic 
AChR.  This is achieved by the electrical isolation of a small number of ion channels 
and the record of current flowing through a single channel.  This in turn determines 
whether the channel is an open or closed state.  Variations in these different parameters 
offer the opportunity to refine the phenotype of CMS. 
 
Figure 1.1.  The neuromuscular junction and its three compartments.  Genes known to cause CMS are 
classified based on their location in the NMJ.  Modified from (McConville and Vincent, 2002) 
 
To date mutations in nineteen genes have been causally associated with CMS (figure 
1.1). These include the pre-synaptic acetyltransferase CHAT (Ohno et al., 2001), the 
gene COLQ encoding the triple stranded collagenic tail of the synaptic AChE (Ohno et 
al., 1998c), the genes encoding the four subunits of the nicotic postsynaptic AChR 
(CHRNA1, CHRNB1, CHRND) (Quiram et al., 1999) and CHRNE (Ohno et al., 1995), 
the RAPSN gene encoding the postsynaptic receptor related protein rapsyn (Ohno et al., 
8 
 
2002), the postsynaptic muscle specific kinase (MUSK) gene (Chevessier et al., 2004), 
the postsynaptic sodium channel SCN4 (Tsujino et al., 2003), the DOK7 gene encoding 
the postsynaptic downstream of kinase (Dok-7) protein (Beeson et al., 2006), the 
LAMB2 encoding the synaptic laminin β2 protein (Maselli et al., 2009), the AGRN gene 
encoding the synaptic agrin protein (Huze et al., 2009), the PLEC1 gene encoding the 
postsynaptic protein plectin (Forrest et al., 2010), the GFPT1gene encoding the 
Glutamine-fructose-6-phosphate transaminase 1 protein (Senderek et al., 2011), the 
DPAGT1 gene encoding the UDP-N-acetyl glucosamine-dolichyl-phosphate N-
acetylglucosaminephospho transferase (Belaya et al., 2012), ALG2 and ALG12 
encoding N-glycosylation enzymes (Cossins et al., 2013) and LRP4 encoding the low 
density lipoprotein receptor-related protein (Ohkawara et al., 2013).  It is worth noting 
that the CHRNG gene, which is the foetal isoform of CHRNE, encodes the γ subunit of 
the receptor and has been associated with an antenatal form of neuromuscular disorders 
(Hoffmann et al., 2006).  
 
 
1.6 Classification of CMS
5
 
 
Conventionally, CMS have been categorized based on the site of molecular defect in 
relation to the neuromuscular junction (table1.1). 
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Gene defect 
Percentage of CMS patients with 
mutations in the gene 
Presynaptic  
CHAT 5% 
Synaptic   
COLQ 12% 
AGRN <1% 
LAMB2 <1% 
Postsynaptic   
Primary AChR deficiency ± kinetic defects Up to 50% 
RAPSN  15% 
DOK7 10% 
MUSK <1% 
SCN4A <1% 
PLEC1 <1% 
GFPT1* 4% 
DPAGT1, ALG2 and ALG14 <1% 
 
Table 1.1.  The frequency of CMS based on the Munich CMS diagnostic database.  Adapted from 
Chaouch, A. and Lochmüller, H. (2013). Congenital Myasthenic Syndromes, in Muscle Disease: 
Pathology and Genetics, Second edition.  John Wiley & Sons, Ltd, Oxford, UK.  
 
 
 
1.6.1 CMS caused by presynaptic defects
6
 
 
Patients carrying CHAT mutations characteristically present in the neonatal period with 
respiratory and bulbar difficulties. Patients can experience multiple sudden apnoeic 
episodes over 24 hours and require intensive care support. Sometimes, specific triggers 
can be identified such as infection, fever, and excitement.  In between episodes, patients 
can be remarkably well with minimal neuromuscular weakness.  Several retrospective 
studies suggest that two subgroups of CHAT associated CMS can be identified based on 
the disease course.  In the first, patients present in the neonatal period with respiratory 
distress, which improves over time in term of frequency and severity of the attacks.  
                                                 
6
 Adapted from Chaouch, A. and Lochmüller, H. (2013) Congenital Myasthenic Syndromes, in Muscle Disease: 
Pathology and Genetics, Second edition.  John Wiley & Sons, Ltd, Oxford, UK.  
 
10 
 
However, some patients seem to further relapse in adulthood.  The second subgroup 
presents later, during infancy or childhood, with respiratory crises and seems to exhibit 
a more unpredictable course of disease from the outset.  AChE inhibitors have been 
shown to be of benefit in patients harboring CHAT mutations (Schara et al., 2010, Ohno 
et al., 2001). 
 
At the nicotinic presynaptic nerve terminal choline acetyltransferase (ChAT) mediates 
the biosynthesis of acetylcholine (Ach) from acetyl CoA and choline.  Most mutations 
are recessive private mutations, though there are some exceptions such as the missense 
mutation p.I336T reported in several independent Turkish families which may suggest a 
founder effect (Ohno et al., 1998a).  Of note, there are no anatomical footprints at the 
NMJ with this subtype of CMS.  Mutations in the CHAT gene have been the only 
known molecular cause of presynaptic CMS until the recent report of AGRN mutations 
associated with presynaptic CMS with distal muscle weakness and atrophy.  
 
 
1.6.2 CMS caused by synaptic basement membrane defects  
 
1.6.2.1 COLQ mutations
6
 
 
Patients with COLQ related CMS present usually in the neonatal period with delayed 
motor development, hypotonia and proximal neuromuscular weakness of the limbs.  
They often exhibit ptosis with ophthalmoparesis and occasionally show a delayed 
pupillary response to light.  Patient may also develop respiratory symptoms, which 
necessitate ventilator support.  Previous studies suggest significant clinical 
heterogeneity in relation to the course of the disease.  Indeed, patients can either present 
in the neonatal period with severe neuromuscular weakness and a progressive evolution 
of disease; whereas others may present later in childhood with milder symptoms and 
slower rate of progression.  In this category of CMS, AChE inhibitors are not beneficial 
and may worsen neuromuscular weakness.  Alternative agents such as ephedrine and 
salbutamol have been shown to be helpful (Liewluck et al., 2011, Bestue-Cardiel et al., 
2005).   
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The asymmetric AChE comprises one to three identical tetramers of globular subunits 
that mediate the rapid breakdown of acetylcholine in the synaptic space.  A triple-
stranded collagenic tail (ColQ) allows the anchorage of AChE to the synaptic basal 
lamina for its optimum function.  Molecular defects in COLQ lead to secondary AChE 
deficiency, which can be observed using immunohistochemistry.  No less than 30 
recessive loss of-function mutations have been reported in the COLQ gene (Donger et 
al., 1998).  Deficiency of AChE leads to accumulation of ACh in the synaptic space.  
This in turn generates prolonged motor endplate depolarization, which outlasts the 
refractory period of the muscle fiber, thus precipitating cationic overload and a 
secondary endplate myopathy. 
 
 
1.6.2.2 LAMB2 mutations
7
 
 
There has been one case in the literature of a female patient presenting with delay in 
motor milestones, global limb weakness, bilateral ptosis and ophthalmoparesis.  She 
was also noted to have macular changes and abnormal pupillary responses.  
Importantly, this lady had end stage kidney disease.  Neurophysiological studies showed 
decrement in keeping with abnormal neuromuscular transmission.  A trial with AChE 
inhibitors was of no benefit in contrast to ephedrine, which helped.  The patient carried 
compound heterozygous mutations in the LAMB2 gene. 
 
Laminins are extracellular matrix glycoproteins with several isoforms and comprise 
three subunits (α, β and γ).  Laminins are ubiquitous and represent an important 
component of the neuromuscular junction basement membrane.  LAMB2 gene codes for 
the β2 subunit, which is found in all laminins expressed in the neuromuscular junction.  
This subunit is thought to play part in synaptogenesis.  Mutations in the laminin β2 
subunit have previously been reported in association with Pierson syndrome, a fatal 
disease, which results in severe renal and ocular abnormalities (Maselli et al., 2009). 
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1.6.2.3 AGRN mutations
8
 
 
AGRN associated CMS appears to be rare and was until recently only reported in three 
patients.  All patients exhibited generalized fatigable limb weakness with ocular 
involvement.  The course of disease was mild in two of the patients.  One of the patients 
developed recurrent respiratory complications necessitating ventilator support and 
tracheostomy.  None of the patients exhibited clear improvement with conventional 
treatment including AChE inhibitors and ephedrine.  Agrin is a glycoprotein 
synthesized and released from the motor nerve terminal into the synaptic cleft.  Through 
binding to a postsynaptic transmembrane protein LRP4, agrin can activate the 
postsynaptic muscle specific kinase (MuSK) and trigger clustering of a number of 
postsynaptic proteins (Huze et al., 2009, Maselli et al., 2012).  I further discuss this 
particular CMS subgroup in chapter 7. 
 
 
1.6.3 CMS caused by postsynaptic defects 
 
This group of CMS accounts for most of CMS patients with an established molecular 
diagnosis.  Most postsynaptic defects appear to either directly or indirectly affect 
postsynaptic AChR. 
 
1.6.3.1 CHRNE, CHRNA1, CHRNB1, CHRND mutations
9
 
 
The nicotinic AChR is a pentameric structure that is expressed in two different forms.  
The first is a foetal form and comprises five subunits: 1α, 2 γ, 1 β and 1δ subunits.  It is 
expressed throughout embryonic development before being gradually replaced by the 
adult form (ε subunit) after thirty three weeks gestation.   
 
Defects in the adult form of AChR subunits lead to two different types of CMS 
categories.  The first is associated with kinetic mutations, which cause either gain or 
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loss of function of the receptor; the other subtype results from deficiency of the 
postsynaptic AChR.  
 
Escobar syndrome is a congenital disorder characterized by arthrogryposis, pterygia, 
and abnormal testicular development and breathing difficulties.  It was first described in 
association with defects in the foetal γ subunit of AChR but has since been linked with 
other CMS genes including other subunits of the AChR (CHRNA1, CHRNB1and 
CHRND) as well as RAPSN and DOK7.  Patients with mutations in CHRNG exhibit no 
myasthenic symptoms after birth. There is some suggestion that homozygous mutations 
in the γ subunit can lead to foetal akinesia and recurrent miscarriages.  
 
 
Kinetic defects in the subunits of AChR
9
 
 
Fast channel CMS is caused by recessive loss of function mutations in any of the 
subunits of the adult form of AChR.  Electrophysiology of the motor endplates typically 
shows abnormally brief channel opening events.  Fast channel CMS patients usually 
exhibit a more severe phenotype than in AChR deficiency CMS, often associated with 
early respiratory crises, ptosis and ophthalmoparesis, delayed motor development and 
global neuromuscular fatigable weakness.  AChE inhibitors can be helpful but not 
always.  More recently salbutamol was shown to be of benefit (Webster et al., 2014, 
Shen et al., 2002, Palace et al., 2012). 
 
Dominant gain of function mutations in AChR cause slow channel CMS.  Physiological 
study typically shows prolonged channel opening events.  These mutations have been 
reported in the transmembrane domains (M1, M2 and M4), the linker chain between M2 
and M3 and the extracellular N terminal domain. Often patients display selective 
cervical, wrist and long finger extensor neuromuscular weakness and can occasionally 
develop respiratory insufficiency.  Slow channel CMS patients either present in the 
neonatal period with significant morbidity or manifest later in adulthood showing a less 
aggressive disease course.  Single nerve stimulation can trigger repetitive CMAP 
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corresponding to over action of the receptor.  The prolonged endplate potential (EPP) 
lasts beyond the refractory period of the muscle fiber and results in cation overload and 
secondary endplate myopathy.  Patients do not usually show sustained response to 
AChE inhibitors and may in fact deteriorate on such treatment.  By contrast, quinidine 
or fluoxetine have been shown to be beneficial and shown to abort abnormal persistent 
channel opening in vitro.  It is worth noting that fluoxetine has been associated with 
suicidal ideation in children and should only be prescribed for adults.  Furthermore, 
quinidine can cause long QT syndrome and close cardiac monitoring is therefore 
advocated. 
 
 
Mutations causing AChR deficiency 
10
 
 
Mutations resulting in AChR deficiency are by far the commonest cause of CMS with 
most defects involving the ε subunit of the AChR.  Patients typically present at birth or 
in the first year of life with ptosis, ophthalmoparesis, poor cry and swallowing 
problems; in addition to more global fatigable neuromuscular weakness.  Respiratory 
complications and loss of ambulation are not usually seen in this CMS subgroup.  The 
majority of these patients exhibit a relatively mild phenotype with often improvement in 
fatigability over time.  The exquisite positive response to AChE inhibitors is a hallmark 
of this category of CMS.   
 
Previous reports have shown that some mutations in the ε subunit are more common in 
certain populations in keeping with a possible founder effect.  These include mutation 
CHRNE 1267delG in the Roma population, the CHRNE 1293insG mutation in North 
Africa, CHRNE 1293insG in Southern Europe and CHRNE 70insG in Southern Europe 
and Brazil (Muller et al., 2007b, Beeson et al., 2005). 
Most mutations in the AChR subunits are recessive and lead to AChR deficiency on the 
postsynaptic membrane. The latter can be confirmed using 125α-bungarotoxin labelling, 
which allows the quantification and localisation of these receptors.  It is worth noting 
that deficiency of AChR can be caused by mutations in any of the AChR subunits but 
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also in other postsynaptic proteins such as rapsyn, Dok-7, MuSK and Agrin. These 
proteins have been linked with the maintenance and stabilization of the neuromuscular 
junction.  
 
1.6.3.2 RAPSN mutations
11
 
 
RAPSN mutations are a relatively common cause of CMS.  By contrast to AChR 
deficiency CMS, patients with mutations in RAPSN do not exhibit ocular symptoms 
except for some ptosis.  In addition, two groups of patients were noted based on the age 
of onset of disease.  Indeed, patients can either present in the neonatal stage with 
significant fatigable neuromuscular weakness and recurrent apnoea or they can develop 
symptoms as adults and often exhibit a milder phenotype with better prognosis.  This 
CMS subgroup of CMS is responsive to AChE inhibitors and 3,4-DAP.  
 
The receptor related protein rapsyn ensures appropriate positioning and clustering of 
AChR at the postsynaptic membrane through interaction with MuSK and β-
dystroglycan.  Deficiency in rapsyn can be identified by immunostaining of the muscle 
endplate.  The majority of patients with RAPSN CMS have been either heterozygous or 
homozygous for the missense mutation, N88K (Richard et al., 2003).   
 
 
1.6.3.3 DOK7 mutations
11
 
 
Dok-7 is an essential postsynaptic downstream of kinase shown to activate MuSK, 
which triggers postsynaptic AChR clustering (Okada et al., 2006).  Defects in Dok-7 
were shown to lead to morphological abnormalities in the pre and postsynaptic 
compartments, simplified synapses and reduced AChR numbers.  Mutations in DOK7 
were detected in patients exhibiting predominant proximal muscle weakness (limb 
girdle phenotype) with a lack of response to AChE inhibitors (Beeson et al., 2006). 
These patients tended to exhibit ptosis without ophthalmoplegia.  Disease course was 
often progressive and disabling, resulting in respiratory failure.  Occasionally, patients 
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presented with vocal cord palsy and stridor in the neonatal phase.  Patients displayed 
improvement with ephedrine and salbutamol in contrast to AChE inhibitors, which can 
worsen neuromuscular symptoms (Liewluck et al., 2011, Schara et al., 2010, Schara et 
al., 2009).   
 
 
1.6.3.4 MUSK mutations
12
 
 
The biological importance of MuSK was recognized prior the identification of any 
patients with mutations in the encoding gene.  This muscle specific kinase is crucial to 
the development and differentiation of the neuromuscular junction through the 
activation of postsynaptic downstream kinases.  The latter mediate the clustering of 
essential postsynaptic proteins and the induction of NMJ specific gene transcription, 
thus indirectly providing a retrograde signal to the presynaptic part.  Experimental 
analysis of the patient motor endplate and establishing that this showed deficiency of 
MuSK protein was the lead to the correct genetic diagnosis in the first CMS family 
described with MUSK mutations (Chevessier et al., 2004).  However, MUSK mutations 
remains a very rare cause of CMS.  Despite significant variability in phenotype 
(Gallenmuller et al., 2014, Maggi et al., 2013, Maselli et al., 2010, Mihaylova et al., 
2009, Ben Ammar et al., 2013), most patients had ocular symptoms with fatigable limb 
weakness.  Respiratory complications were noted either in the neonatal period or later in 
adulthood.  AChE inhibitors and 3,4-DAP were of limited benefit for treatment but 
salbutamol was beneficial in some (Chevessier et al., 2004, Mihaylova et al., 2009, 
Gallenmuller et al., 2014). 
 
 
1.6.3.5 PLEC1mutations
12
 
 
Plectin is ubiquitous structural protein found in most epithelia tissues and muscle.  This 
protein is important in maintaining the stability of the cytoskeleton.  Defects in the 
encoding gene were shown to cause Epidermolysis Bullosa Simplex.  This condition is 
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primarily associated with skin lesions in combination with cardiomyopathy, respiratory 
failure and esophageal atresia.  Mutations in this gene have also been shown to cause 
adult onset limb girdle muscular dystrophy.  Very rarely, defects in PLEC1 can alter the 
morphology of the postsynaptic compartment and result in impaired transmission across 
the NMJ.  As such, clinical symptoms can include fatigable neuromuscular weakness.  
Of note, all patients with PLEC1 associated CMS showed abnormal cutaneous lesions 
and 3,4-DAP improved the patients’ neuromuscular symptoms (Forrest et al., 2010). 
 
 
1.6.3.6 SCN4 mutations
13
 
 
This is a very rare cause of CMS and has only been described in one patient in the 
literature.  This female patient developed global fatigable weakness in association with 
bulbar difficulties and frequent respiratory crises.  She also exhibited learning 
difficulties, a rare feature in CMS.  The patient required admission to intensive care for 
ventilator support.  Repetitive nerve stimulation showed decrement and the results of 
patch clamp analysis were key in targeting and sequencing the correct underlying gene 
defect. The study indicated preserved resting membrane potential, quantal release and 
normal MEPP amplitude that failed to trigger action potentials (Tsujino et al., 2003).  
This patient was a compound heterozygote for two missense mutations in the Nav1.4 
channel located on the postsynaptic folds. 
 
 
1.6.3.7 GFPT1 mutations
13
 
 
GFPT1 mutations were identified in a DOK7 negative LG-CMS cohort showing marked 
proximal muscle weakness with absence of ocular signs and a positive response to 
AChE inhibitors.  Almost all muscle biopsies analyzed showed tubular aggregates 
(Chevessier et al., 2005, Slater et al., 2006, Schiaffino, 2011, Senderek et al., 2011, Huh 
et al., 2012, Selcen et al., 2013). These are composed of packaged membranous tubule-
vesicular structures mainly derived from sarcoplasmic reticulum.  They are usually 
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recognized by their intense NADH-TR reactivity with negative SDH reaction and their 
characteristic electron-microscopic appearance.  GFPT1 is a cytoplasmic enzyme that 
catalyzes the first rate limiting step of the hexosamine biosynthesis pathway, which 
ultimately leads to the production of nucleotide sugar donor used as substrate for the 
glycosylation of proteins and lipids.  Altered GFPT1 function was recently shown to 
affect neuromuscular junction transmission by reducing cell surface AChRs at motor 
endplates (Zoltowska et al., 2013).  Interestingly, another study of motor endplate 
ultrastructure and function revealed marked variability with defects in synaptic response 
in some and quantal release in others.  A number of patients had preserved AChR 
content with some poorly developed endplate regions (Selcen et al., 2013).  This 
heterogeneous picture may reflect alternative, yet to be determined, pathomechanisms 
of GFPT1 associated CMS. 
 
 
1.6.3.8 DPAGT1mutations 
 
Defects in DPAGT1 were discovered using exome sequencing in a subgroup of CMS 
patients with a limb girdle phenotype, some of whom had tubular aggregates, and no 
mutations in GFPT1(Belaya et al., 2012, Finlayson et al., 2013, Basiri et al., 2013, 
Selcen et al., 2014).  All patients responded to AChE inhibitors, sometimes in 
combination with 3,4-DAP.  DPAGT1 mediates the first rate-limiting step in the N-
glycosylation pathway, which through a series of proteins, sequentially incorporates 
sugar moieties to the lipid dolichol.  Once the core glycan is formed, it is added to the 
asparagine residues of nascent proteins.  This step is an essential part of post-
translational modification and would normally dictate the structure, stability, location 
and function of a particular protein.  It is worth noting that the first sugar substrate used 
by DPAGT is the end product of the hexosamine pathway involving GFPT1.  The motor 
endplate of a DPAGT associated CMS patient showed reduced postsynaptic folding and 
density of postsynaptic AChRs.  Furthermore, inhibition of DPAGT using a selective 
enzyme inhibitor (tunicamicin) was shown to alter AChR subunit glycosylation and 
export to the cell surface (figure 1.2). 
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Figure 1.2. Glycosylation pathways associated with CMS.  Mutations in GFPT1, DPAGT1, ALG2 and 
ALG14 have all been associated with limb girdle CMS. .
 
 
Congenital disorders of glycosylation (CDG) have also been previously reported with 
mutations in DPAGT1.  These are multi system disorders, usually associated with 
intellectual disability, hypotonia, epilepsy and dysmorphic features, although some 
patients may present with the “form frustre” of this disorder and present with single 
organ disease.  Measurement of serum transferrin levels using column anion-exchange 
separation followed by immune turbidimetry showed abnormal levels in two out of five 
CMS patients.  Whether standard glycosylation assays used in most diagnostic 
laboratories would be sensitive to detect a change is unclear.  
 
 
1.6.3.9 ALG2 and ALG14 mutations 
 
Mutations in both genes were identified in three kinships, all presenting with a limb 
girdle CMS phenotype, minimal ocular weakness and a response to AChE inhibitors 
(Cossins et al., 2013, Monies et al., 2014).  The disease course was static. Intellectual 
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disability was associated with mutations in ALG2 with evidence of contractures 
proximally and distal laxity reminiscent of a collagen disorder.   
 
Both ALG2 and ALG14 are implicated in the initial steps of N-glycosylation (figure 
1.2) and knockdown of ALG14 expression, similar to DPAGT1, reduced AChR 
expression on the cell surface.  Patient’s tissue showed reduced expression of ALG2.  
The standard transferrin glycoform analysis did not detect any change.  Of note, defects 
in ALG2 have also been associated with congenital defects of glycosylation.  
 
 
1.6.3.10 LRP4 mutations 
 
This protein is expressed on the postsynaptic cell membrane and can activate MuSK 
after forming a complex with Agrin.  MuSK, in concert with Dok-7, induce Rapsyn 
mediated AChR anchorage and clustering on the postsynaptic membrane.  More 
recently, Lrp4 was shown to inhibit the Wnt/beta-catenin signaling pathways and to 
provide a retrograde signal to the pre-synaptic compartment.  Mutations in LRP4 were 
found using exome sequencing in one patient who presented with ocular, bulbar and 
respiratory difficulties soon after birth, with mainly proximal muscle weakness and 
reduced mobility over time. The patient’s symptoms deteriorated after receiving AChE 
inhibitors.  Although the nerve terminal and postsynaptic regions were reported to be 
small in size, patch-clamping studies were normal. Mutant Lrp4 was associated with 
reduced Agrin mediated MuSK signaling (Ohkawara et al., 2014). 
 
 
1.8 Animal models 
 
A number of animal models including mice, flies and more recently zebrafish have 
focussed on the study of the NMJ, in spite of clear differences between the human 
phenotype and the experimental models (Muller et al., 2007b). 
 
Transgenic mice harbouring epsilon null alleles exhibit a much more severe often fatal 
phenotype in contrast to the human phenotype.  These mice display delayed motor 
development with low weight and a reduced life expectancy of less than fourteen weeks 
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(Missias et al., 1997).  Some have hypothesized the lack of the γ subunit in adult mice 
may be the cause of this severe lethal phenotype.  Indeed transgenic mice lacking the ε 
subunit but constitutively expressing the human γ subunit exhibit a phenotype 
reminiscent of the human disease.  These mice are smaller than wild type littermates but 
exhibit normal development and have a normal life expectancy (Cossins et al., 2004).  
In keeping with AChR deficiency syndrome, these mice exhibit neuromuscular 
weakness, decrement on RNS with evidence of abnormal fragmented motor endplates 
deficient in postsynaptic AChRs.  
More recently, a slow channel CMS mouse model was generated.  In this AChR ε-
subunit knock out (KO) model, the human AChR ε subunit containing the L221F 
mutation tagged with EGFP is expressed under the AChR -subunit promoter.  The 
phenotype and neurophysiological features of these mice are reminiscent of the human 
disease.  
In addition, a MuSK mutant mouse model sharing the same genotype as a previously 
reported patient with MUSK associated CMS was shown to exhibit significant 
heterogeneity across different muscles and across motor endplates within the same 
muscle (Chevessier et al., 2008).   
Finally, an AGRN mouse model was recently reported and will be further discussed in 
chapter 7.   
 
The short life cycle and access to a large number of zebrafish embryos has attracted 
much interest of this model in spite the clear differences from humans.  The 
transparency of zebrafish embryos in association with its external embryonic 
development permits visualization and in vivo imaging of initial embryonic stages, 
which is often challenging in mammalian systems.  Another significant advantage is 
that zebrafish embryos can live independent of their respiratory or cardiovascular status, 
which offers the opportunity to the study embryos deficient in NMJ protein.  Knocking 
down protein expression using morpholino modified oligonucleotides into zebrafish 
offers the possibility of prompt and expedient examination of genes.  Selective 
restoration of protein expression or overexpression of a particular protein can be 
accomplished by injecting mRNA into zebrafish embryos.  Furthermore, numerous 
reports have exploited the zebrafish as a model for studying the neuromuscular junction 
with several mutant lines specifically generated with defects in NMJ proteins.  These 
include e.g. nic-1 and sop: AChRs subunit mutations; twitch once: rapsyn mutations, 
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unplugged: MuSK mutation; bajan: ChAT mutations (Muller et al., 2007b, Witzemann, 
2006, Chaouch et al., 2012b). 
 
 
1.9 Conclusions
14
 
 
CMS are rare inherited disorders in which the safety margin of neuromuscular 
transmission is compromised.  In clinical practice, most CMS patients will harbour 
mutations in the postsynaptic proteins. Accurate diagnosis can be challenging but 
remains crucial to instigating early suitable treatment, which should help prevent life 
threatening events and improve quality of life.   
 
Momentous progress towards refining the clinical phenotype, natural history and 
therapeutic strategies for CMS has been seen over the last 20 years.  Nevertheless, a 
proportion of CMS patients remain without molecular diagnosis (figure 1.4).  The 
recent advent of next generation sequencing has proved effective in unraveling novel 
CMS genes but has also exposed the complexity of the biological mechanisms of this 
disease and the unprecedented need for coordinated and collaborative research using the 
infrastructures available such as patient registries, shared genetic variant databases and 
through the exchange of experimental tools and animal models. 
 
 
                                                 
14
 Adapted from Chaouch, A. and Lochmüller, H. (2013) Congenital Myasthenic Syndromes, in Muscle Disease: 
Pathology and Genetics, Second edition.  John Wiley & Sons, Ltd, Oxford, UK.  
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Figure 1.4. Distribution and frequency of CMS gene mutations in the Munich CMS database 
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1.10 Objectives 
 
The objectives of this research project are: 
 
Part 1: 
A. To review the genotypic and phenotypic features of 680 suspected CMS patients 
referred to the Munich CMS diagnostic centre between 1997 and 2011 and be 
able to:  
 Report on the frequency and distribution of CMS gene mutations within 
this cohort.  
 Determine the mutation detection rate when specific clinical features are 
present. 
 Propose a diagnostic algorithm to improve efficiency of genetic 
screening of CMS patients. 
 Refine the clinical phenotype in a CMS cohort harbouring a novel CMS 
gene (GFPT1). 
 Review the clinical phenotype of a sizable slow-channel CMS cohort and 
retrospectively assess response to recommended therapy.  
 Select a cohort of genetically undiagnosed CMS patients suitable for 
exome sequencing aimed at novel gene discovery. 
 
Part 2:  
B. To identify the disease causing gene in a selected CMS cohort using exome 
sequencing and homozygosity mapping data when appropriate: 
 Test novel variants/gene in the undiagnosed CMS cohort.  
 Compile more detailed clinical data in the newly diagnosed patients and 
ascertain: 
 Phenotype variability. 
 Phenotype-genotype correlation. 
 Response to therapy.   
 Present in vitro / in vivo validation.
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Chapter 2. Materials and Methods 
 
 
2.1 Patient selection  
 
Patients were captured primarily from the Munich CMS cohort.  One family was 
selected from the Newcastle CMS cohort and two families were identified via the 
French CMS network.  
 
2.1.1 The Munich CMS cohort 
 
The Munich CMS diagnostic service is based in Friedrich-Baur-Institut, Ludwig 
Maximilians University, Germany.  The two key investigators for this cohort were 
Professor Hanns Lochmüller and Dr Angela Abicht from 1997 until 2007.  The Munich 
CMS service is primarily a genetic diagnostic service.  Clinical evaluation of patients is 
based on a questionnaire that captures the salient clinical features and any relevant 
family history (Appendix A1).  This questionnaire is subdivided into four main sections 
pertaining to the details of the referral centre, the demographic details of the patient, any 
relevant family history, consanguinity and ethnic origin.  In the clinical section, data 
pertaining to the onset and course of disease, the presence of exacerbating or relieving 
factors were included.  As regard the clinical examination findings, a particular attention 
was given to the distribution and degree of muscle weakness and the presence of 
additional clinical features.  The results of specific investigations, when available, were 
checked including repetitive nerve stimulation and SFEMG reports.  Levels of serum 
biomarkers like serum creatine kinase, AChR and MuSK antibodies and details of 
previous muscle biopsies were collated.  The questionnaire also explored the response 
to conventional CMS treatments like AChE inhibitors and 3,4-DAP as well as other 
therapies like steroids that may point towards an underlying autoimmune myasthenic 
syndrome.  It is worth noting that the information collected in the questionnaire was not 
always uploaded in full to the digital database.  This service was funded primarily by 
research grants and referrals were from senior clinicians from within and outside 
Germany.  A consent form was requested for each patient as per the local institutional 
ethical board.  
 
26 
 
The Munich database was the main source of clinical and genetic data for the work 
described in chapters 3, 4, 5, 6 and 7.  
 
 
2.1.2 The Newcastle CMS cohort 
 
Two affected siblings were selected from this cohort and are described in chapters 6 and 
7. 
 
In the UK, the national diagnostic and advisory service for CMS is based in Oxford.  
Any patient with a suspected diagnosis of CMS is referred to this unit for genetic testing 
and often clinical assessment.  The National Commissioning Group funds this service.  
Newcastle in collaboration with the Oxford service offers access to a specialist CMS 
clinic where a total of thirty-four patients (2012) are reviewed on a regular basis.  
Genetic testing of this cohort is carried out in Oxford.  Approximately, 50% of these 
patients have no molecular diagnosis.  Professor Hanns Lochmuller and Professor 
David Beeson coordinate the Newcastle service.   
 
 
The French CMS network   
 
This is another important clinical and genetic diagnostic centre of CMS in Europe.  
Most referrals are from France.  Two families were recruited from this cohort and the 
full details of these will be discussed in chapter 7.   
 
2.2 Cross sectional analysis of the Munich CMS cohort  
 
2.2.1 Clinical evaluation
15
 
 
For the purpose of this study, the clinical and genetic details of all patients referred 
between 1997 and 2010 were reviewed.  Patients were sub-classified based on whether 
                                                 
15
 Adapted from Abicht et al 2012 (URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
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they had a molecular diagnosis.  In the patients harbouring pathogenic mutations, the 
clinical data sent by the referring clinician were then reviewed.  In the undiagnosed 
group, a number of selection criteria were applied to exclude potential CMS mimics: 
 
1- Patients with positive anti AChR or anti MuSK antibodies. 
2- Patients with a positive response to immune-modulatory treatments including 
immunoglobulins and steroids. 
3- Patients with evidence of large fibre peripheral neuropathy on nerve conduction 
studies. 
4- Patients with significant myopathic or neuropathic changes on EMG. 
5- Patients with markedly elevated creatine kinase suggestive of a myopathy 
(>1000 IU). 
6- Patients with marked myopathic or neurogenic changes on muscle biopsy. 
7- Patients with marked intellectual disability. 
 
A few undiagnosed patients had no autoantibody screen completed.  In this instance, 
only patients with a clear positive family history and an early onset of disease (age less 
than two years) were analysed.   
 
 
 
 
2.2.2 Molecular analysis
16
 
 
2.2.2.1 DNA samples 
 
The Munich diagnostic Centre receives isolated human genomic DNA or EDTA 
samples for which genomic DNA extraction is carried out using a kit as per the 
manufacturer’s instructions (Promega, Mannheim, Germany).  
 
2.2.2.2 PCR amplification and Sanger sequencing 
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 Adapted from Abicht et al 2012 (URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
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PCR amplification and bidirectional Sanger sequencing were used to confirm mutations.  
The following ten CMS genes were available for sequencing at the time of this study: 
CHRNA1, CHRND, CHRNB1, CHRNE, RAPSN, CHAT, COLQ, DOK7, MUSK and 
GFPT1.  The following four genes AGRN, SCN4A, LAMB2 and PLEC1 were not 
routinely sequenced in the Munich CMS Centre as these were deemed too rare or to be 
associated with distinct phenotypes including renal disease with LAMB2 and skin 
involvement with PLEC1. 
 
Primers were designed to include the exons of each gene as well as its flanking regions. 
The latter were most relevant with CHRNE (Abicht et al., 2002, Nichols et al., 1999, 
Ohno et al., 1999) and RAPSN (Ohno et al., 2003) where a 5` non coding segment was 
added that includes important regulation elements of the genes where previously 
pathogenic mutations were reported.  The following transcripts were used in this study: 
CHAT (NG_011797.1; NM_020549.4); COLQ (NG_009032.1; NM_005677.3); 
CHRNE (NG_008029.1; NM_000080.2); CHRNA1 (NG_008172.1; NM_001039523.2); 
CHRNB1 (NG_008026.1; NM_000747.2); CHRND (NG_008028.1; NM_000751.1); 
RAPSN (NG_008312.1; NM_005055.3); DOK7 (NG_013072.1; NM_173660.4); 
GFPT1 (NG_029542.1; NM_001244710.1); LRP4 (AC021573; NM_002334); 
SLC18A3 (NT_017696, NM_020549.2); CNTN1 (NG_012058.1; NM_001843.2).  Of 
note, in genes where several transcripts exist, the longest isoform was sequenced.  For 
CHAT, the M variant (NM_020549.4; NG_011797.1) was sequenced as this encodes for 
a longer protein due to an alternate 5` exon.   
 
The nucleotide numbering was relative to the ATG translation initiation site with A 
being +1 of the corresponding cDNA sequences (www.hgvs.org/mutnomen).  As 
previously described, the nucleotide numbering for CHRNE was relative to the 1
st
 
nucleotide of the 1
st
 exon of the mature protein.  The pathogenicity of novel variants 
was ascertained by checking segregation with the disease in the family, in silico 
prediction and screening of at least fifty controls to ensure that the variant not a 
common polymorphism.  
 
As part of an exploratory gene discovery study, three candidate genes were screened in 
the Munich cohort: LRP4 (MIM# 604270), SLC18A3 (MIM# 600336) and CNTN1 
(MIM# 600016). 
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2.2.2.3 Genetic screening strategy
17
 
 
Based on the family history, ethnicity and clinical phenotype, a sequential approach was 
undertaken to screen for mutations in this cohort.  Patients were screened to varying 
degree for: 
 Particular mutations, including the common CHRNE (c.1267delG; exon 12), 
RAPSN (p.N88K; exon 2, and DOK7 (c.1124_1127dupTGCC; exon 7) 
 Particular exons, including a slow channel CMS panel encoding the M2 domain 
of CHRNA1, CHRNB1, CHRND and CHRNE as well as the N-terminal domain 
of CHRNA1. 
 One or several CMS genes.   
 
It is important to note that the extent of gene screening evolved with the discovery of 
novel genes and a better grasp of phenotype genotype correlation in particular CMS 
categories. 
 
 
  
                                                 
17
 Adapted from Abicht et al 2012 (URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
30 
 
2.2.2.4 Linkage Analysis
18
 
 
Forty-seven linkage studies were completed by Professor Angela Hubner at the 
Technical University Dresden, Germany.  The index cases were from multiplex families 
with more than one affected individual, sometimes in conjunction with a family history 
of consanguinity.  The microsatellite marker set included the gene loci of the following 
genes were screened: CHRNA1, CHRNB1, CHRNE, CHRND, CHAT, COLQ, RAPSN, 
DOK7, MUSK, SCN4A, AGRN and GFPT1.  It is worth noting that although SCN4A and 
AGRN were not routinely sequenced, the loci of both genes were included in the 
haplotype analysis after 2009.   
 
 
2.3 Clinical characterization of a slow channel CMS cohort
19
 
 
2.3.1 Patient data 
 
Patients were selected based on the mutations they harboured which were either known 
or predicted to cause slow channel CMS.  A total of fifteen patients were recruited via 
the Munich CMS database where genetic diagnosis was carried out. These patients had 
been referred between 1997 and 2012.  A questionnaire was designed to collate data on 
the clinical phenotype, disease progression, results of investigations and response to 
treatment (Appendix A2).  The latter focused on the therapeutic strategy for each 
patient.  Treatment choice, dose escalation and response including tolerability were 
documented.  The clinician involved in the care of each patient completed each 
questionnaire, which was circulated twice to ensure that all data was accurate and up to 
date.  
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 Adapted from Abicht et al 2012 (URL:http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
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 Adapted from Chaouch et al 2012 (URL:http://link.springer.com/article/10.1007%2Fs00415-011-6204-9) 
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2.3.2 Genetic analysis 
 
This was carried in The Munich diagnostic centre.  Genomic DNA extraction was 
carried out as above.  A slow channel CMS panel was used in some of the patients.  
This included the M2 domain of the AChR subunits and the N terminal part of the α 
subunit.  In others, the entire sequence of CHRNA1, CHRNB1, CHRND and CHRNE 
genes was analysed (Abicht et al., 1999).  To establish pathogenicity of novel variants, 
one hundred controls were screened by direct sequencing. 
 
 
2.4 Clinical characterization of GFPT1 CMS cohort
20
 
 
For this study, nine families were recruited from the Munich CMS cohort. These 
patients had been referred for genetic testing over the last fifteen years. Two families 
(LGM7 and 8) were recruited through the Oxford CMS National Service and were 
previously published (Palace et al., 2007).  Family LGM13 and LGM3 were reported in 
(Rodolico et al., 2002) and (Sieb et al., 1996) respectively.  
 
All the pedigrees in this report were previously reported in (Senderek et al., 2011) 
except for LGM17, which is novel. The details of mutations were discussed in this 
earlier publication and will not be re-discussed in this study.  It is worth noting that 
three of the pedigrees (LGM4, 15 and 16) discussed in (Senderek et al., 2011) did not 
carry mutations in GFPT1 gene and were not included in this study.   
 
All pedigrees were compatible with autosomal recessive inheritance; all parents of the 
probands were reported to be healthy.  Families LGM1, LGM4, LGM10 and LGM11 
were consanguineous. The patients from families LGM1, LGM3, LGM5, LGM12, 
LGM13 and LGM17 are siblings.  The age at examination varied between seven and 
sixty-three years. 
 
To define the genotype phenotype correlation in GFPT1associated CMS, an additional 
two patients previously published in (Palace et al., 2007) with a limb girdle phenotype 
and tubular aggregates were screened for mutations in GFPT1 and did not harbour any.  
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 Adapted from Guergueltcheva et al 2011(URL: http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
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Furthermore, a total of fifty-seven undiagnosed CMS patients exhibiting variable 
clinical phenotype with no predominant proximal involvement and no evidence of 
tubular aggregates as well a cohort of four patients with evidence of tubular aggregates 
on muscle biopsy without evidence of myasthenic symptoms or impaired 
neuromuscular transmission were screened and did not carry any mutations in GFPT1.   
 
Details of clinical history and examination findings were collected for each patient.  A 
particular attention was focused on the results of serum creatine kinase levels (CK) and 
titres of AChR antibodies.  Neurophysiological testing was carried out as per standard 
protocols.  Given the overlap of this category of CMS with limb girdle muscular 
dystrophy, the EMG reports, nerve conduction studies, repetitive nerve stimulation and 
SFEMG were carefully reviewed.  Muscle biopsies were performed by open or needle 
techniques and were analysed by Dr Anders Oldfors (Goteborgs University, Sweden).  
Following fixation in 2.5% glutaraldehyde and OsO4, muscle biopsies were embedded 
in resin before being analysed by electron microscopy.  Ultrathin sections were 
contrasted with uranyl acetate and lead citrate.  Out of the eighteen muscle biopsies 
available for analysis, tubular aggregates were identified in thirteen samples. 
 
 
2.5 Gene discovery using exome sequencing 
 
2.5.1 Patient selection  
 
I searched both the Newcastle and Munich databases for suitable families in whom 
existing CMS genes were excluded by conventional methods.  Newcastle had a cohort 
of thirty-one potential patients, with fourteen having a confirmed molecular diagnosis.  
This distribution was mirrored in Munich, where only 299 of the 680 patients with 
suspected CMS had a clear genetic defect.  
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The following inclusion criteria were used to capture this undiagnosed CMS cohort: 
1- Ready access to both clinical data and genomic DNA from patients and their 
relatives. 
2- A clinical phenotype strongly suggestive of CMS with objective evidence of 
neuromuscular transmission defect (abnormal neurophysiology and/or positive 
response to cholinesterase inhibitors). 
3- More than one affected individual in each family. 
4- Exclusion of all known CMS genes by conventional methods. 
 
2.5.2 DNA samples 
 
Genomic DNA was isolated from venous blood as per manufacturers’ 
recommendations, using the MagAttact DNA blood MiniM48 kit (Qiagen 951336) for 
the Newcastle patients and the Wizard Genomic DNA purification kit (Promega, 
Manheim, Germany) for patients selected from the Munich database.  For patients 
recruited through the French CMS network, standard phenol-chloroform procedures 
were used.  Sufficient amount (at least 10µg) of high quality genomic DNA (OD 
260/280 from 1.8-2.0) was obtained from each selected individual.   
 
2.5.3 DNA library preparation and whole-exome sequencing 
 
DNA library preparation and whole exome sequencing were outsourced to EuroFins 
MWG Operon (Germany) and IntegraGen (France).  Sequencing was achieved using 
Agilent SureSelect capture and Illumina HiSeq2000 (2x100bp reads) sequencing 
platforms (Appendix A3).  
 
Raw sequencing data were aligned to the human reference genome (hg19), sorted and 
converted to a BAM file using bwa. The BAM file was indexed and variants called 
using SAMtools (version 0.1.16) (Li and Durbin, 2009). The alignments were optimised 
for indel calling using dindel (version 1.0.12) (Albers et al., 2011). Variants called were 
annotated using ANNOVAR (figure 2.1) (Wang et al., 2010b).  
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Figure 2.1. Workflow used to process raw sequencing data before selecting good quality variants 
 
 
 
 
2.5.4 Filtering pipeline applied to prioritize called variants 
 
The filtering algorithm was applied to exclude non-coding frequent variants calls 
(MAF > 1%) found in public databases (dbSNP [http://www.ncbi.nlm.nih.gov/SNP/], 
the Exome Variant Server [http://evs.gs.washington.edu/EVS/], the 1000 Genomes 
Project [http://www.1000genomes.org]) and an in house list of common variants from 
unrelated controls (figure 2.2).  Given that the family history was highly suggestive of 
autosomal recessive inheritance (healthy parents, two affected children and parental 
consanguinity in half the pedigrees), and that most CMS are recessive in inheritance, the 
recessive model was applied to the search for genes containing homozygous, or at least 
two heterozygous changes, shared between siblings.  Variants were visualized and 
evaluated using the UCSC Genome Browser (Kent et al., 2002).   
 
 
 
35 
 
 
 
Figure 2.2. Filtering pipeline for called good quality variants 
 
 
2.5.5 Copy number variants analysis using exome sequencing
21
 
 
This analysis was carried out by Dr Helen Griffin at the Institute of Genetic Medicine, 
Newcastle University.  Copy number variant (CNV) analysis of Patients 1 and 2 was 
carried out using the ExomeDepth software (Plagnol et al., 2012).  The read depth per 
exon was compared with a pool of reference exomes from the same capture targets and 
the same sequence machine run.  Any CNV present in the test sample was detected as a 
deviation from the 1:1 ratio depth (0.5 = hemizygous deletion; 0.0 = complete deletion; 
1.5 = duplication of one exonic copy).  The CNV predictions from each sibling were 
combined and compared with an in-house control list (191 exomes).  A set of 
“common” CNVs from forty controls was used to exclude the predicted CNV 
overlapped by at least 50% (Conrad et al., 2010). CNVs were later confirmed by 
conventional CGH array.  
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 Adapted from Nicole et al 2014 (URL: http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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2.5.6 Verification of called variants 
 
Sanger sequencing was used to verify putative disease causing variants and their 
segregation with the disease. Primer sequences were designed using the Primer-3 Plus 
programme (http://www.genome.wi.mit.edu/cgibin/primer/primer3_www.cgi).  All 
primer sequences used are available on request. Sanger sequencing was performed using 
bi-directional fluorescent sequencing on an ABI 3730 XL 96 capillary sequencer, with 
BigDye Version 3.1 chemistry (Life Technologies).  Sequences were assembled and 
aligned against a reference sequence downloaded from GenBank using Chromas 
(Technelysium Pty Ltd) or Mutation Surveyor (SoftGenetics) programmes. 
 
2.5.6.1 PCR amplification 
 
Moltaq polymerase (Molzym) was used to amplify DNA templates via PCR.  The 
following was made up to 50µl with dH2O to carry out PCR 
 
 DNA template  1µl (variable concentration) 
 Forward primer 1 µl (50ng/ µl) 
 Reverse primer 1 µl (50ng/ µl) 
 10mM dNTP mix 2 µl 
 10x PCR buffer 5 µl 
 PCR enhancer  4 µl 
 Moltaq polymerase 1 µl 
 
Following gently mixing and spinning in the centrifugation, PCR reactions were 
incubated in a thermal cycler (Senso Quest, Labcycler) using the parameters in table 2.1 
 
Step number and 
name 
Temperature  Time  Cycle repeat 
1) Initialisation 94°C 2 minutes   
2) Denaturation 94°C 15 
seconds 
  
3) Annealing 58°C 30 
seconds 
  
4) Elongation 72°C 2 minutes Repeat steps (2-4) 40 
times 
5) Final elongation 72°C 7 minutes   
6) Termination 4°C ∞   
 
Table 2.1.  Programme used for PCR reactions  
37 
 
2.5.6.1 Gel Electrophoresis 
 
A 1% agarose gel was used for most PCR reactions.  1.5g agarose was heated with 
150ml TAE-buffer (Tris base, acetic acid and Ethylenediaminetetraacetic acid (EDTA)). 
1μl/ml of safe view nucleic acid stain (NBS biological) was mixed into the molten gel. 
After polymerization, the gel was placed on an electrophoresis gel-chambre and 
submerged with TAE buffer.  The PCR products were mixed with 1μl of loading dye 
(dH2O, 15% glycerol, 0.25% bromophenol blue, 0.25% xylene cyanol) and loaded onto 
the gel. Depending on the size of the PCR product, 1Kbp or 100bp ladder (NBS 
biological) was used as a molecular weight size marker. Electrophoresis was performed 
for a minimum of 30 minutes at 100V.  Gels were visualised under UV light and images 
were captured on a GelDoc-It 310 Imaging system (UVP).  QiaexIIGel extraction Kit 
from Qiagen (Qiagen, Valencia, CA) was used for the elution of PCR products from the 
agarose gel. 
 
 
2.5.7 CGH array analysis
2223
 
 
This study was carried by Dr Angela Abicht in Munich at the MGZ diagnostic 
laboratory, Germany. CGH array was carried out to analyse and confirm copy number 
variants. CytoChip ISCA 180K V1.0 oligonucleotide array (BlueGnome) was used 
according to the manufacturer´s instructions (BlueGnome). RsaI and AluI digested DNA 
products (patient´s DNA as well as reference DNA) from peripheral blood were labelled 
by random priming using either Cy3-dUTP or Cy5-dUTP and hybridized at 65°C for 
24h. Scanning and image acquisition was done on an Agilent microarray scanner.  Data 
analysis was performed using BlueFuse Multi software (BlueGnome). 
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2.6 Functional studies of the AGRN variants 
 
2.6.1 Patients data
24
 
 
In total five patients from three kinships were recruited for this study.  CMS-EN was 
chosen from the Munich congenital myasthenic syndromes diagnostic database whilst 
families 2 and 3 were recruited via the French congenital myasthenic syndromes 
network. Detailed information regarding the clinical phenotype, disease progression, 
investigations and treatment were collected for each patient.  EMG, SFEMG and 
repetitive nerve stimulation (3 Hz) were carried out in selected muscles as per 
standardized protocols (Bauche et al., 2013).  Patients 1 and 2 were investigated on a 
Keypoint machine (Medtronic) by Dr Sissel Loseth and Dr Torberg Torbergsen from 
Tromso University (Norway).  Patients 3, 4 and 5 were assessed by Dr Emmanuel 
Fournier at Inserm (Paris), using a Viking IV machine (Nicolet).  Motor conduction 
velocity studies were performed in the median, ulnar, tibial and peroneal nerves. 
Sensory neurographic studies were completed in the median, ulnar, radial and in the 
sural nerves.  The amplitude of the CMAP was recorded at rest and following exercise.  
Pathological decrement was considered when the amplitude and surface of the CMAP 
was decreased by 5% and an increment when this was increased by 20%.  A possible 
presynaptic origin was considered for an increment higher than 60% (Oh et al., 2005).  
SFEMG was carried out on patients 1 and 2 by Dr Sissel Loseth and Dr Torberg 
Torbergsen (Tromson University, Norway) and Professor Erik Stalberg (Uppsala 
University, Sweden) using concentric needle.  Criteria for abnormal jitter were 55 sec 
as the limit value.  Appropriate consent for research was obtained from each patient. 
 
  
2.6.2 Muscle biopsy
24
 
 
Muscle biopsies were acquired for Patient 2 at the age of thirty-three years (vastus 
lateralis) at the Tromso hospital (Norway) and reviewed by Professor Sigurd Lindal.  
This biopsy was also exported to Newcastle for review by Dr Louise Anderson for 
immune-staining of proteins associated with inherited myopathies.  The other two 
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biopsied were obtained via the French CMS network and the hitochemical analysis was 
carried out by Dr Romero at the Institut de Myologie, CHU Pitié-Salpêtrière, Paris.  
Deltoid biopsies were sampled from patient 3 at the age of thirty-six years, patient 4 at 
the age of eighteen years.  Patient 5 had two deltoid biopsies at the age of thirty-one and 
thirty-four years.  All biopsies were analysed using standard histochemical protocols on 
transversal cryostat sections and included staining for hematoxylin and eosin, Gomori 
trichrome, ATPase and oxidative enzymes.  
 
Electron microscopy was carried out on deltoid muscles biopsies containing NMJ-rich 
areas.  These were collected from patients 3 and 5(Bauche et al., 2013).  Fluorescent 
staining of NMJs on teased myofibers was carried out to ascertain the impact of the 
novel AGRN mutations on particular proteins.  The following antibodies were utilized 
on transverse muscle sections shown to contain motor endplates.  Antibody for agrin 
was kindly provided by Professor Markus Rüegg from the University of Basel, 
Switzerland.  LRP4 antibodies were supplied from (Ab1 antibody, Sigma-Aldrich), C4 
(LAMB2) and SV2 antibodies were purchased from The Developmental Studies 
Hybridoma Bank.  Stained sectioned were visualized using epifluorescent and confocal 
microscopy (Carl Zeiss LSM510 and Axiophot).  
 
 
2.6.3 Generation of wild-type and mutated agrin recombinant proteins
25
 
 
A construct coding for a mouse full length agrin cloned into the episomal expression 
vector pCEP-Pu was used (figure 2.3).  This was kindly provided by Prof Markus 
Rüegg (University of Basel, Switzerland) (Kohfeldt et al., 1997).  This construct 
encodes for the full-length NtA isoform with the 4- and 8-amino-acid inserts at the A/y 
and B/z sites corresponding to the neural isoform of mouse agrin with the signal peptide 
BM40 in the N-terminus and a His (6) tag in the C-terminus. The BM40 peptide allows 
for the secretion of the recombinant protein from the cells.  Site-directed mutagenesis 
was performed by Mutagenex Inc (Piscataway) to introduce the missense mutation 
found in kinship 1 (c.226G>A, p.G76S) and 2 (c.314A>T, p.N105I).  
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Figure 2.3. Modified pCEP Pu expression vector containing full length mouse agrin.  Kindly provided by 
Professor Markus Ruegg, Switzerland. Modified from ((Kohfeldt et al., 1997), 
 
 
2.6.3.1 Bacterial “heat shock” transformation with XL1-Blue chemically 
competent cells (Homemade) 
 
2 μl of plasmid DNA (up to 50ng) were gently mixed in with 50μl thawed competent 
cells and incubated on ice for 10 minutes. Transformation efficiency was tested using 
1μl of pUC18/19 plasmid at 0.01ng/μl in positive control. Cells were heat shocked at 
42˚C for 1 minute and returned to ice for 2 minutes. The cells were suspended in 150μl 
of LB medium then incubate at 37˚C for 1 hour. 100μl of the test transformations were 
spread onto LB plates containing appropriate antibiotic and incubated overnight at 
37˚C.  
 
 
2.6.3.2 Plasmid DNA extraction and purification  
 
A single colony was picked from 100μg/ml Ampicllin LB agar plate (10g Bacto-
tryptone, 5g yeast extract, 10g NaCl, 15g agar in 1litre dH2O, sterilised by autoclaving) 
and incubated in 5ml LB media (10g Bacto-tryptone, 5g yeast extract, 10g NaCl, in 
1litre dH2O). 50μg/ml Ampicillin was added to the mixture, which was incubated 
41 
 
overnight at 37
o
C in a shaking incubator (300rpm).  The cells were harvested by 
centrifugation at 5400g for 10minutes.  Plasmid DNA extraction and purification were 
completed as per the directions of Quiagen plasmid purification kit manual (QIAprep 
Spin Miniprep Kit; 27104).  The final product was eluted in 20μl of EB buffer (10mM 
Tris.Cl, pH8.5) or water.  The quality of the plasmid DNA was verified by gel 
electrophoresis (1µl product used) and the concentration was estimated on a NanoDrop 
(ND-8000, 8-Sample Spectrophotometer). The optical density of the DNA sample was 
measured at 260/280 nm.  A ratio of OD260 to OD280 of 1.8 or more was consistent 
with pure DNA. 
 
 
2.6.4 In vitro AChR clustering assay
26
 
 
The C2C12 mouse myoblast cell line was used.  Cells were cultured to form myotubes 
as previously described (Huze et al., 2009).  The clustering of AChR experiment was 
carried out by Yasmin Issop at the Institute of Genetic Medicine, Newcastle.  HEK293 
EBNA cells were transiently transfected with wild type or mutant agrin constructs.  
Following five days of incubation, the culture media containing the secreted neural 
agrin was incubated with myotubes in Opti-MEM reduced serum medium for twenty-
two hours at 37°C.  Myotubes were fixed with 4% paraformaldehyde (PFA) for thirty 
minutes then stained for AChR by incubation in 1mM BTX conjugated to Alexa Fluor 
594 (Life Technologies
TM
) for one hour.  Plates were then mounted in Vectashield 
mounting medium with DAPI (Vector Laboratories) and observed with a 40X objective 
lens under an Olympus IX70 inverted microscope (Olympus Europa) linked to a CDD 
camera (Princeton Cool SNAP Fx). The efficiency of AChR clustering was assessed by 
determining the number of AChR clusters in ten random fields and expressed in relation 
to the number of nuclei seen in the same field. This experiment was repeated on two 
occasions.  
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2.7 Functional studies of SLC25A1 variant 
 
2.7.1 Patient data
27
 
 
Appropriate consent for research was obtained from each patient and any family 
member involved in this study.  This novel homozygous variant was identified in CMD-
NO family.  The latter was identified via the Newcastle MRC Neuromuscular Centre, 
Institute of Genetic Medicine.  These two affected siblings were born to two healthy 
consanguineous parents (first cousins) and were originally from Durham in the North of 
England.  Based on the positive family history suggestive of recessive inheritance and 
the clinical phenotype, a diagnosis of CMS was suspected.  The elder brother was the 
index case and displayed from the age of five years, fatigable limb weakness.  Nerve 
conduction studies and EMG studies revealed no evidence of a large fibre neuropathy or 
significant myopathy.  Repetitive nerve stimulation showed no evidence of decrement.  
SFEMG on the other hand showed clear abnormal jitter with block in several muscles 
compatible with defective transmission across the neuromuscular junction.  The 
younger sister was also affected and presented with fluctuating neuromuscular weakness 
of all four limbs, more marked in the legs.  She also displayed moderate learning 
difficulties and attended a special need college.   
 
 
2.7.2 Neurophysiological and morphological study of the patient’s motor 
endplates
27
 
 
To assess the integrity of the neuromuscular junction, the affected brother underwent 
repetitive nerve stimulation and SFEMG at the Oxford CMS Centre led by Professor 
Beeson’s group.  Both investigations were performed on two separate occasions (age 
twenty and age twenty-one years).  Repetitive nerve stimulation at 3Hz was used on 
Abductor digiti minimi (ADM), anconeus and extensor digitorum communis (EDC) 
muscles to check for decrement.  The same muscles were also assessed for facilitation 
following 20 seconds of sustained maximum muscle contraction.   
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The morphology and functional properties of the motor endplates were assessed in the 
patient’s muscle (anconeus).  This work was also carried out in Oxford by Professor 
Beeson’s group.  The number of postsynaptic AChR was calculated as previously 
described (Vincent et al., 1981).  The anconeus muscle bundles were dissected stained 
with 125I-a-BuTX, before labelling for AChE.  The number of endplates in a given 
field was established in relation to 125I-a-BuTX binding to generate the number of 
receptors per endplate.  35 NMJs were tested to determine MEPPs and quantal content 
with between 1 and 62 MEPPS per NMJ. 
 
 
2.7.3 Homozygosity mapping
28
 
A recessive pattern of inheritance was suspected based on the pedigree of two healthy 
parents and two affected children.  This analysis was carried out by Professor Senderek 
in Aachen, Germany.  In order to restrict the chromosomal location of the disease 
causing mutation in this family, genome wide genotyping of SNPs was performed using 
Illumina 300K chip (Illumina, San Diego, Ca).  This test was implemented to identify 
regions of homozygosity shared by both affected sibling, which may contain a 
homozygous mutation segregating on the same ancestral haplotype.  
 
 
2.7.4 Verification of SLC25A1 variant 
 
PCR amplification and Sanger sequencing were used to verify and screen for variants in 
the SLC25A1 gene using primer sequences described in table 2.2.  
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SLC25A1 Forward primer 5´-3´ Reverse primer 5´-3´ Product 
size 
exon 1 ACAGTGCACCTTGACCCACT CAGCTGCGTCTTCACGTACTC 850bp 
exon 2 GGCCCCAGCCTATGTTCC CTAAGGCCGCGGTACAGG 386bp 
exon 3 & 4 CCCACCGAGTACGTGAAGAC GGCTGCCTTTAGCATAGACTC 683bp 
exon 5 & 6 CTTGGCTGCACTGCTTCCT CTGCAATAGCTCCGAAGACC 700bp 
exon 7 & 8 AGGTGTGTCTGCATCACAGG GGAGAGGAAGGCAGGTCAG 583bp 
exon 9 TGCCTCTCACTTCAGTATCTGG ATGCATAGATGGGTCCATACAG 795bp 
Table 2.2. Forward and reverse primer sequences for the 9 exons of SLC25A1 gene 
 
 
 
2.7.5 SLC25A1 constructs and expression in bacteria
29
 
 
This work was carried by Professor Luigi Palmieri’s group in Bari University, Italy.  
The coding sequence of the yeast orthologue citrate carrier CIC (CTP1, 
NM_001178639.1) was amplified from S. cerevisiae genomic DNA via PCR and the 
mutations were introduced by site-directed mutagenesis as described in QuikChange® 
Site-Directed Mutagenesis Kit from Stratagene. Ctp1p and its mutated form (p.R241Q, 
p.R276H and p.G117D) were overexpressed as inclusion bodies in the cytosol of E. coli 
strain BL21 (DE3).  Inclusion bodies were purified on a sucrose density gradient and 
washed at 4 °C, first with Tris-EDTA buffer (10 mM Tris–HCl, 1 mM EDTA, pH 7.0), 
then twice with a buffer containing Triton X-114 (3 %, w/v), 1 mM EDTA, 20 mM 
Na2SO4 and 10 mM PIPES pH 7.0, and finally with the Tris-EDTA buffer. The proteins 
were solubilized in 1.7 % sarkosyl (w/v). Eventual small residues were removed by 
centrifugation (20800 × g for 10 min at 4 °C). 
 
 
2.7.6 Transport assay of recombinant mutant SLC25A1 proteins
29
  
 
This work was carried by Professor Luigi Palmieri’s group in Bari University, Italy.  
The recombinant proteins solubilized in sarkosyl were reconstituted by cyclic removal 
of detergent as described (Fiermonte et al., 1993) with some modification. The 
reconstitution mixture consisted of phospholipids in the form of sonicated liposomes 
(10 mg), protein solution (25 µl, about 9µg), 10 % Triton X-114 (70 µl), 10 mM citrate 
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(35µl), cardiolipin (0.7 mg), 10 mM PIPES/NaOH pH 7.0 and water (final volume 700 
µl). The mixture was recycled 13-fold through an Amberlite column pre-equilibrated 
with 10 mM PIPES-NaOH (pH 7.0) and 50mM NaCl. All operations were performed at 
4 °C except the passages through Amberlite, which were carried out at room 
temperature. Approximately 20% of WT or mutated CIC proteins were reconstituted. 
External citrate was removed from proteoliposomes on Sephadex G-75 columns pre-
equilibrated with 50 mM NaCl and 10 mM PIPES at pH 7.0 (buffer A). Transport at 
25 °C was started by adding 0.1 mM [
14
C] Citrate (from PerkinElmer, Inc) to 
proteoliposomes and terminated by addition of 20 mM pyridoxal 5′ phosphate and 20 
mM of bathophenanthroline.  In controls, inhibitors were added with the labelled 
substrate. The external substrate was removed by Sephadex G-75 columns pre-
equilibrated with buffer A, and the entrapped radioactivity was counted. The 
experimental values were corrected by subtracting control values and the initial 
transport rate was calculated from the time-course of substrate uptake by 
proteoliposomes (Palmieri et al., 1995). 
 
 
2.7.7 Study of mitochondrial membrane potential in fibroblasts
30
 
 
This work was carried by Professor Luigi Palmieri’s group in Bari University, Italy.  
Fibroblasts from the affected sibling harbouring the SLC25A1 variant c.740G>A; 
(p.R247Q) and control fibroblasts were grown in DMEM (high glucose). Membrane 
potential was measured by fluorescence microscopy using the tetramethylrhodamine 
methyl ester (TMRM) probe (Scaduto and Grotyohann, 1999), while mitochondrial 
morphology was investigated using MitoTracker® Red CMXRos. MitoTracker® Red 
CMXRos and tetramethylrhodamine methyl ester (TMRM) were purchased from Life 
Technologies.  Fluorescent images of treated cells were acquired and fluorescence 
intensities were analyzed, as previously described (Lasorsa et al., 2004), using a Zeiss 
Axiovert 200 microscope equipped with a Photometrics Cascade 512B CCD camera 
(Roper Scientific) and the MetaFluor software (Universal Imaging). 
 
2.7.8 Western blotting
31
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This work was carried by Professor Luigi Palmieri’s group in Bari University, Italy.  
Immunoblotting analysis was performed using 100 x 10
3
 cells (patient and control 
fibroblast).  The cells were rinsed with ice-cold PBS and lysed using RIPA buffer. Total 
proteins were heated at 100 °C for 5 min, separated by SDS-PAGE and transferred to 
nitrocellulose membranes.  The membrane was then incubated at room temperature with 
anti-SLC25A1 polyclonal antibodies raised in rabbit against recombinant rat SLC25A1 
carrier or mouse monoclonal antibodies against the β subunit of human F1-ATPase (BD 
Biosciences).  Antigen–antibody complexes were detected using anti-rabbit or mouse 
IgG-coupled horseradish peroxidase (Pierce, Thermo Scientific), in combination with 
the ECL system (Merck Millipore). 
 
 
2.7.9 Multiple sequence alignment and in silico evolutionary pressure analysis
31
 
 
This work was carried by Professor Luigi Palmieri’s group in Bari University, Italy.  A 
multiple sequence alignment of citrate carrier (CIC) orthologues from various species 
and other mitochondrial carriers was obtained using ClustalW(Persson, 2000).  The 
functional or structural relevance of the mutated residues of the mitochondrial citrate 
carrier protein was estimated according to a scoring system based on the evolutionary 
pressure acting on each amino acid as described previously (Pierri et al., 2014). 
 
 
2.7.10 SLC25A1 knockdown in zebrafish embryos
31
 
 
This work was carried out by Dan Cox from the muscle group, Newcastle University.  
A BLAST search of zebrafish transcripts with the human SLC25A1 protein sequence as 
input revealed the presence of three homologues in the zebrafish genome: two on 
chromosome 10: SLC25A1a (NM_200607), SLC25A1b (XM_003199276.2) and one on 
chromosome 8 (SLC25A1c).  Only SLC25A1a and SLC25A1b from chromosome 10 are 
expressed in zebrafish. 
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 2.7.11 Zebrafish Husbandry and Observation
32
 
 
This work was carried out by Dan Cox from the muscle group, Newcastle University. 
The Golden strain (slc24a5
b1/+
) of zebrafish was used in this study (Zebrafish 
International Resource Centre (ZIRC), Oregon).  Zebrafish embryos were raised at 
28.5°C and staged hours or days post-fertilization (hpf or dpf) according to standard 
procedures.  Video recordings of embryos and larvae were taken with a Leica dissection 
stereomicroscope equipped with a Chameleon digital camera (model CMLN-13S2M, 
Chameleon).  Touch-evoked swimming response of embryos was elicited by touching 
the head or the tail of the embryos with a fine pipette tip. Light microscope images of 
injected and non-injected embryos were taken with a digital camera (model LEICA 
DFC 420C) mounted on a Leica dissection stereomicroscope.  Procedures involving 
experimentation on animal subjects were done in accordance with the local institutional 
guide.  
 
 
2.7.12 Antisense Morpholino Oligonucleotide Knockdown
32
 
 
This work was carried out by Dan Cox from the muscle group, Newcastle University. 
Antisense morpholino oligonucleotides (MOs) were purchased from Gene Tools LLC 
(Pilomath, OR). The MOs were designed with the mRNA sequence of the zebrafish 
SLC251A orthologues and genomic sequences available from public databases 
(SLC25A1A GeneID: 393579, accession number: NM_200607.1) and (SLC25A1B 
GeneID: 795332, accession number: XM_003199276.2) and the corresponding genomic 
DNA sequence obtained from the zebrafish chromosome 10 assembly.   
 
Two MOs were generated, one per gene orthologue.  Both MOs are splice-blocking and 
directed against the splice donor site of exon 3. The following two morpholinos were 
used: (MO1: zSLC25A1a 5’-AGATGAATCTTTCTTACCGTACTGC-3’ and MO2: 
zSLC25A1b 5’-GCGGGTTAGGAAACACTCACCTCAC-3’). Both MOs are expected 
to interfere with the splicing process and lead to a disruption of the protein open reading 
frame and premature translation termination after twenty-five missense amino acids. 
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The Gene Tools standard control MO (5’-CCTCTTACCTCAGTTACAATTTATA-3’) 
targeting a human beta-haemoglobin gene was used as a negative control for the effects 
of MO injection.  We also used the Gene Tools anti-p53 MO (5’GCGCCATTGCT-
TTGCAAGAATTG-3’) to suppress any non-specific apoptotic effects that can be 
induced by some MOs.  MOs were suspended in 1x Danieau solution (58 mM NaCl, 0.7 
mM KCl, 0.4 mM MgSO4, 0.6 mM Ca(NO3)2, 5 mM HEPES; pH 7.6) with phenol red 
as an injection indicator.  Embryos were injected with both morpholinos separately to 
determine the optimal concentration to produce the best range of phenotypes and then 
with both MOs simultaneously.  5ng SLC25A1a MO and 2.5ng SLC25A1b produced 
the best range of phenotypes.  Four independent MO injection experiments were 
performed for each MO and at least 500 injected embryos were evaluated in total for 
each MO.  
 
 
2.7.13 RNA Isolation and RT-PCR
33
 
 
This work was carried out by Dan Cox from the muscle group, Newcastle University.  
RNA from approximately thirty zebrafish embryos was isolated with Trizol reagent 
(Invitrogen, Life Technologies) following the manufacturer’s instructions. Reverse 
transcription was performed with 1 or 2 µg total RNA as template with the Superscript 
III First-Strand Synthesis System (Invitrogen, Life Technologies) and MolTaq DNA 
polymerase (Molzym). Regions of interest were amplified with compatible primers. 
 
 
2.7.14 Immunofluorescence Staining
33
 
 
This work was carried out by Dan Cox from the muscle group, Newcastle University.  
Whole-mount immunofluorescence staining and imaging of zebrafish embryos was 
conducted as previously described. In brief, NMJ were visualized with Alexa Fluor® 
594 conjugated alpha-bungarotoxin (Invitrogen, Life Technologies, 1 mg/ml) and a 
mouse monoclonal anti-SV2 (synaptic vesicle protein 2) antibody (Developmental  
Studies Hybridoma Bank, Iowa City, IA; dilution 1:200).  Alexa Fluor® 594 conjugated 
phalloidin (Sigma-Aldrich) was used at a concentration of 5 μg/ml to label actin.  
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Chapter 3.  Cross Sectional Study of the Munich CMS Cohort 
 
 
 
3.1 Introduction and Aims 
 
Genetic screening for CMS has been available in five major centres across the world: 
Oxford, Paris, Munich, California and Rochester. Until recently, these diagnostic 
laboratories have relied on traditional Sanger sequencing and linkage studies when 
appropriate, to establish a molecular diagnosis.  In all five centres, CMS associated with 
postsynaptic defects (table 3.1), and in particular low expressing alleles of the subunits 
of AChR were most frequent (Chaouch et al., 2012a).   
Although several studies had been published on genetically characterized individual 
CMS subgroups, there was no detailed cross sectional analysis of such a large CMS 
cohort like the Munich database.  
In this chapter, I report on the results of a collaborative study I carried out with the 
Munich CMS diagnostic centre.  Dr Angela Abicht and my supervisor Professor Hanns 
Lochmüller led this project.   
 
I have contributed to the analysis of the clinical data, phenotype genotype correlation 
and refining the proposed CMS diagnostic algorithm.  I was also a contributor to the 
manuscript detailing this collaborative work: Abicht et al: (URL: 
http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract)
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  Index cases 
Mayo Munich French network Oxford Total 
Pre-synaptic defects   
Choline acetyltransferase deficiency 17 15 4 8 44 
Lambert–Eaton syndrome like 1    1 
Other presynaptic defects 1       1 
Synaptic basal lamina-associated defects   
Endplate AChE deficiency (COLQ) 43 38 19 20 120 
Postsynaptic defects   
Primary kinetic abnormality of AChR 53 11 10 39 113 
AChR deficiency  109 147 40 138 434 
AChR mutations with unclear effects  1 19 1 21 
Rapsyn deficiency 48 43 28 71 190 
b2-laminin deficiency 1    1 
MuSK deficiency  1 3  4 
Na channel myasthenia 1  1  2 
Agrin deficiency   1  1 
Plectin deficiency 2    2 
DOK7 deficiency 31 31 28 67 157 
GFPT1 2 12   4 18 
 
Table 3.1.  Total numbers of index cases with mutations in known CMS genes. Data from four major CMS diagnostic centres in Europe and North America are presented.  
Reproduced from Chaouch et al 2012 (URL: http://www.sciencedirect.com/science/article/pii/S0960896611014210#)
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3.2 Patient data
34
 
 
In this study, I focused on patients with a high clinical suspicion of CMS.  In total, 680 
patients were selected.  Referrals were primarily from Europe (87%), with additional 
clusters noted in the Middle East, North Africa and South America (figure 3.1).  It is 
worth noting that 17% of patients were from South East Europe and were mainly of 
Roma ancestry.  There was no record of the gender distribution of patients in this 
database.  
 
 
 
Figure 3.1: Geographical distribution of patients referred to the Munich CMS diagnostic database.  
 
 
3.2.1 Clinical phenotype
34
 
 
The largest proportion of patients presented at birth (42%).  A significant proportion 
developed symptoms in the first two years of life (29%) or later between 3 and 10 years 
of age (15%) (figure 3.2).  Fifty-seven patients (8%) were reported to have antenatal 
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complications such as reduced fetal movements.  Of note, details of age at onset of 
disease were only available in 511 patients out of the total cohort of 680 patients. 
 
 
 
Figure 3.2: Distribution of patient numbers based on age at onset of disease 
 
 
 
 
Figure 3.3: Pattern of muscle involvement in both genetically diagnosed and undiagnosed patients. 
 
  
53 
 
Most patients presented in childhood with generalized fatigable limb weakness, ptosis 
and evidence of decrement on neurophysiology. Some patients exhibited additional 
clinical features such as delayed motor milestones, marked bulbar difficulties, 
respiratory insufficiency, sometimes requiring ventilator support, congenital 
contractures of the fingers, wrists and elbows and high arched palate.  Response to 
treatment was variable and not necessarily sustained over time.  
 
In terms of pattern of muscle involvement, ptosis was by far the commonest clinical 
sign reported in 502 patients (figure 3.3).  Ophthalmoparesis was reported in 279 
patients, apnoeic episodes in 152 and a limb girdle pattern of muscle weakness in 105.  
Mutations were detected in 58% of patients presenting with ophthalmoparesis, 56% of 
patients with isolated ptosis, 54% of patients presenting with apnoea and 43% of 
patients with a limb girdle phenotype.  275 patients presented with combined ptosis and 
opthalmoparesis with 55% genetically diagnosed, a figure similar to the subgroups of 
patients exhibiting either clinical sign in isolation.  
 
 
3.2.2 Ancillary investigations
35
 
 
Four main criteria were used to exclude potential mimics of CMS and to provide 
supportive evidence of impaired neuromuscular transmission.  These included 
negativity for anti-AChR and anti-Musk antibodies, normal or mildly elevated creatine 
kinase (less than 5 times normal range), and absence of large fibre neuropathy or 
significant myopathic changes on neurophysiology and muscle biopsy.  In the muscle 
biopsy, the presence of tubular aggregates and type 2 fibre atrophy were specifically 
sought.  These structures have recognized as an important pathological hallmark of a 
particular CMS subgroup associated with glycosylation gene defects.  Type 2 fibre 
atrophy was reported in a number of CMS subtypes regardless of the underlying 
molecular diagnosis.  
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Figure 3.4: Decrement and response to AChE inhibitors in both genetically diagnosed and undiagnosed 
patients. 
 
 
Almost two third of the patients in this cohort (387) had detailed neurophysiological 
studies, including repetitive nerve stimulation. 234 had evidence of decrement in 
keeping with impaired neuromuscular junction transmission (figure 3.4). 53% of 
patients shown to have decrements were genetically diagnosed in contrast to 18% with 
no decrement.  By contrast, fewer patients had a muscle biopsy (197 patients), which 
was reportedly normal in most, or showing non-specific abnormalities such as type 2 
fibre atrophy or mild myopathic changes.  It is worth noting that the questionnaire did 
not allow for detailed description of the muscle biopsy findings, in particular it was 
often unclear how detailed was the study and whether specific stains such NADH or 
EM analysis were carried out.  Both of these are usually required to ascertain the 
presence of tubular aggregates. 
 
 
3.2.3 Treatment response
36
 
 
413 patients (60%) received a course of AChE inhibitors (figure 3.4).  This treatment 
was beneficial in 271 patients (65%) and was unhelpful in 142 patients.  51% of patient 
with a positive response to AChE inhibitors were genetically confirmed in contrast to 
39% with negative response. 
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3.3 Genetic data
37
 
 
3.3.1 Inheritance pattern 
 
 
 
Figure 3.5 Consanguinity or a positive family history, regardless of inheritance pattern 
 
 
 
133 patients were reported to have a positive family history with most showing a 
recessive pattern of transmission (89 patients).  A dominant inheritance pattern was only 
reported in 27 patients.  Consanguinity was reported in 94 index cases, accounting for 
14% of the total cohort (figure 3.5). 
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3.3.2 Mutations analysis
38
 
 
 
 
 
Figure 3.6: Mutation distribution in the Munich CMS database 
 
 
 
A molecular diagnosis was confirmed in 299 out of 680 index cases (44%).  Patients 
were screened for mutations in the following known CMS genes: CHRNA1, CHRNB1, 
CHRNE, CHRND, CHAT, COLQ, RAPSN, DOK7, MUSK, and GFPT1 (figure 3.6) 
Mutations in the subunits of AChR were by far the commonest, followed by mutations 
in RAPSN, COLQ, DOK7 and CHAT (figure 3.7). 
 
 
Mutations in CHRNE, accounted for 49% of all mutations identified in the diagnosed 
cohort of 299 patients.  Additionally, RAPSN, COLQ and DOK7 mutations occurred 
relatively frequently accounting for 14%, 13% and 10% of all mutations respectively 
(figure 3.7).  
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Figure 3.7: Mutation distributions across known CMS genes in the Munich database. 
 
Most mutations were missense exonic changes.  For novel variants, pathogenicity was 
assessed by checking segregation of the variant with the disease phenotype, in silico 
predictions and determination of variant frequency in control samples (at least 50).  The 
majority of variants were private mutations arising in independent kinships, although 
occasionally, these occurred in several unrelated families, suggesting a possible 
common founder effect (table 3.2). 
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  Gene Mutation Patients Ethnic origin 
Recurrent 
mutations 
CHRNE c.70insG 16 
Spain, Portugal, 
Hungary, Brazil, Chile 
 
 
CHAT c.T1007C; p.Ile336Thr 6 Turkey 
 
COLQ 
c.1082delC, 
p.Pro361Leufs∗65 
5 
Turkey, Italy, Georgia, 
Czech 
  COLQ 
c.1289A>C; 
p.Tyr430Ser 
4 Spain 
 
Table 3.2: Private mutations shared between more than three independent kinships.  Adapted from Abicht 
et al 2012 (URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
 
 
 
Furthermore, known common mutations were identified in the CHRNE, DOK7 and 
RAPSN genes (table 3.3). These often correlated with particular geographical or ethnic 
origins: CHRNE; c.1267delG7 in the Roma population, CHRNE; c.1293insG29 in North 
Africa, Southern Europe and Brazil, DOK7; c.1124_1127dupTGCC
 
and RAPSN; 
c.264C>A (p.N88K) in Europe. Of note, 89 out of 148 patients (60%) with mutations in 
the CHRNE gene carried the common Roma mutation (c.1267delG7).  
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Gene 
Total  number of 
patients with gene 
defect 
Common Mutation 
Patients with 
mutation 
Ethnic origin 
CHRNE 148 c.1267delG7 89 
South East Europe, 
Roma 
 
CHRNE 148 c.1293insG29 14 
North Africa, southern 
Europe, Brazil and 
Russia 
DOK7 31 c.1124_1127dupTGCC19 25 Europe, Brazil 
RAPSN 43 
c.264C>A 
(p.Asn88Lys)
10, 35
 
39 Europe, Canada 
 
Table 3.3: Common mutations identified in CHRNE, DOK7 and RAPSN genes. Adapted from Abicht et al 
2012 (URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
 
 
 
3.3.3 Common mutations identified in the Munich database 
 
3.3.3.1 CHRNE, CHRNA1, CHRNB1, CHRND
39
 
 
Mutations in the different subunits of AChR were most frequent (figure 3.7).  These 
were identified in 159 patients out of 299 diagnosed patients and accounted for 54% of 
all patients.  Most mutations were recessive low expressing alleles, predicted to result in 
deficiency or loss of the different subunits of AChR. Mutations were identified across 
the length of the genes.  
 
Remarkably, mutations in the epsilon subunit (CHRNE) represented 49% of all patients 
and were detected in 148 out of 299 patients.  In accordance with the geographical bias 
of this cohort, the common Roma mutation CHRNE; c.1267delG was the predominant 
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variant, occurring either homozygously or heterozygously in 89 patients.  The 
remaining 59 patients harbored other known founder mutations, seen in North Africa, 
Brazil and Southern Europe, or private mutations.  
 
Occasionally, mutations known to cause kinetic defects in the different subunits of 
AChR were identified.  These were either recessive, fast channel mutations or dominant 
mutations causing slow channel syndrome.  In five patients, fast channel mutations were 
identified in CHRNE (p. P121L, p.A411P and p.N436del).  Only two mutations in 
CHRNE (p.V259L, and p.L269F) were associated with slow channel CMS.  Mutations 
in the other subunits of AChR were less frequent, with five patients harbouring 
mutations in CHRNA1, three patients with mutations in CHRNB1 and three patients 
with mutations in CHRND.  All mutations identified in CHRNA1 (alpha subunit of 
AChR) were autosomal dominant mutations associated with a classical slow channel 
CMS phenotype.  Mutations in CHRNB1 and CHRND were either recessive low 
expressing mutations or kinetic defects predicted or known to cause fast channel CMS. 
Some of the defects were dominant mutations predicted to result in slow channel 
syndrome.  Clearly, the exact pathomechanism of these rare mutations is dependent on 
further detailed functional studies.  
 
 
3.3.3.2 RAPSN
40
 
 
RAPSN mutations accounted for 14% of all identified patients (figure 3.7).  A total of 
369 patients were screened for RAPSN and 43 patients were found to be mutation 
positive.  This corresponds to a mutation detection rate of 11%.  Invariably, exon 2 was 
initially sequenced as this included the common mutation (p.N88K) which was detected 
in 38 out of the 43 patients either in a homozygous (18) or compound heterozygous 
state (20).  In effect, 90% of the patients harboured this mutation in at least one allele.  
In one patient the p.N88K mutation was found on one allele but no second mutation was 
detected.  Furthermore, a 4.5kb heterozygous deletion was detected in another patient 
spanning exon 7 and 8.  None of the patients were homozygous for a null allele and the 
distribution of mutations across RAPSN is shown in figure 3.8.  
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Figure 3.8: Mutations in RAPSN identified in patients of this study. Frame shift, nonsense, and splice-site 
mutations are listed below the gene diagram.  Reproduced from Abicht et al 2012  
(URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
 
 
3.3.3.3 COLQ
41
 
 
COLQ mutations accounted for 13% of all mutations (figure 3.7).  Often the same 
mutation occurred independently in different kinships which may suggest a distant 
shared haplotype in these families or a mutational hotspot in the COLQ gene.  A total of 
126 patients were screened and 38 patients were mutation positive.  This corresponded 
to a mutation detection rate of 30%.  Out of the 17 mutations identified, only 6 were 
missense mutations which were almost exclusively located in the C terminal domain of 
the colq protein.  The remaining mutations, which spread across the length of the gene 
were either frameshift, nonsense or splice site mutations (figure 3.9).  By contrast to 
RAPSN, 20 patients were homozygous for nonsense alleles predicted to result in 
complete loss of protein.  
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Figure 3.9: Mutations in COLQ identified in patients of this study.  Frameshift, nonsense, and splice-site 
mutations are listed below the gene diagram. Reproduced from Abicht et al 2012 (URL: 
http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
 
 
 
3.3.3.4 DOK7
42
 
 
Mutations in DOK7 accounted for 10% of all mutations (figure 3.7).  Of the 373 
patients screened, 31 patients were DOK7 mutation positive. This corresponded to a 
mutation detection rate of 8%. The common mutation c.1124_1127dupTGCC was 
present on one or both alleles in 25 out of 31 patients. Only 5 patients were compound 
heterozygous for defects other than the common DOK7 mutation.  It is worth noting that 
a second mutation was not detected in 7 patients who were heterozygous carriers for the 
frameshift mutation c.1124_1127dupTGCC despite the full sequencing of the coding 
regions (exons) of the DOK7 gene. 
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Figure 3.10: Mutations in DOK7 identified in patients of this study.  Frameshift, nonsense, and splice-site 
mutations are listed below the gene diagram.  Reproduced from Abicht et al 2012 (URL: 
http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
 
 
 
3.3.3.5 CHAT
43
 
 
Mutations in CHAT accounted for 5% of all patients. A total of 82 patients were 
screened and 15 patients were mutation positive.  This corresponds to a mutation 
detection rate of 18%.  13 missense and 1 frameshift mutation were identified.  These 
were dispersed throughout the gene.  None of the patients were homozygous for 
nonsense or frameshift mutations. A recurrent mutation was identified in several 
independent families from Turkey which may point towards a founder effect (table 3.2). 
 
 
 
Figure 3.11. Mutations in CHAT identified in patients of this study. Frameshift, nonsense, and splice-site 
mutations are listed below the gene diagram.  Reproduced from Abicht et al 2012 (URL: 
http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
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3.3.3.6 GFPT1
44
 
 
This gene had only recently been discovered using positional cloning (Senderek et al., 
2011).  GFPT1 was screened for mutations in 39 patients and 12 patients were mutation 
positive.  GFPT1 accounted for 4% of all mutations found. A detailed description of the 
clinical phenotype of this cohort will be presented in chapter 5. 
 
 
 
 
 
 
 
 
 
 
Figure 3.12. Mutations in GFPT1 identified in patients of this study. Frameshift, nonsense, and splice-site 
mutations are listed below the gene diagram.  Reproduced from Senderek et al 2011 (URL: 
http://www.sciencedirect.com/science/article/pii/S0002929711000097). 
 
 
 
3.3.3.7 MUSK
44
 
 
MUSK was screened for mutations in 24 patients and only one had a clearly pathogenic 
homozygous mutation, MUSK; p.P344R which had been previously identified in a 
consanguineous Sudanese kinship (Mihaylova et al., 2009).  Since this study was 
completed another Turkish family has been shown to be compound heterozygous for a 
missense mutation (p.R38E) and a heterozygous deletion (Gallenmuller et al., 2014). 
Nevertheless, MUSK mutations remain rare and accounted for less than 1% of all 
patients. 
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3.3.3.8 Unknown sequence variants 
 
A number of novel sequence variants were identified that had not been reported as 
polymorphisms or pathogenic mutations.  The significance of these defects was unclear 
(data not shown). 
 
 
3.3.4 Mutation detection
45
 
 
 
 
Figure 3.13: Mutation detection rate across all genes analysed. 
 
 
The mutation detection rate (number of patients with mutations divided by the total 
tested) is given in figure 3.13 and table 3.4.  This was highest for CHRNE (42%), 
followed by GFPT1 (31%), COLQ (30%) and CHAT (18%).  This figure should be 
interpreted in the context of a logistically restrained strategy based on our understanding 
of genotype phenotype in different CMS categories, common mutations related to either 
a founder effect in particular populations or specific hot spots.  This is in part reflected 
in the high mutation detection rate in CHRNE, which probably related to the ethnic bias 
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with 39% of patients referred from South East Europe, many of whom were of Roma 
ancestry. 
 
 
Gene 
Number of index patients with 
mutations 
Number of patients 
analysed 
Mutation detection in % of 
analyzed patients 
CHAT 15 82 18% 
COLQ 38 126 30% 
CHRNE 148 350 42% 
CHRNA1 5 77 6% 
CHRNB1 3 50 6% 
CHRND 3 54 6% 
RAPSN 43 369 11% 
DOK7 31 373 8% 
MUSK 1 24 4% 
GFPT1 12 39 31% 
All genes 299     
 
 
Table 3.4:  Mutation detection based on gene tested. Total of number of patients screened and found to be 
mutation positive for each of the 10 CMS genes screened in the Munich CMS cohort.  Adapted from 
Abicht et al 2012 (URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
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3.3.5 Targeted CMS gene sequencing (gene panels)
46
 
 
Three sets of gene panels were applied as part of the diagnostic strategy at the Munich 
centre (table 3.5).  These were primarily designed to include common CMS gene 
mutations. Single gene panels for CHRNE and CHAT were associated with the highest 
mutation detection rate at 88%, followed by the COLQ single gene panel (76%).  Two-
gene panels (CHRNE/RAPSN) and three-gene panels (CHRNE, RAPSN and DOK7) had 
much lower detection rates. 
 
 
  Mutation detection: Number of patients with 
mutation/ Number of tested patients 
Mutation 
positive (%) 
Single 
gene 
CHRNE only 120/136 88% 
 
RAPSN only 30/63 48% 
 
DOK7 only 12/45 26% 
 
COLQ only 19/25 76% 
 
CHAT only 7/8 88% 
2 genes CHRNE/RAPSN 15/33 45% 
3 genes CHRNE/RAPSN/DOK7 8/46 17% 
 
Table 3.5: Mutation detection rate in different gene panels tested.  Reproduced from Abicht et al 2012 
(URL: http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
 
 
 
The CHRNE gene was entirely sequenced in 156 patients whilst targeted sequencing of 
the CHRNE; c.1267delG was carried out in 241 patients.  For the slow channel panel, 
the focus was on specific exons coding for the M2 functional domain and the binding 
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site of α subunit in the N terminal domain.  For RAPSN, the entire gene was screened in 
156 patients and targeted screening (c.264C>A; p.N88K) undertaken in 213 patients.  
For DOK7, the entire gene was sequenced in seventy-one patients whilst targeted 
sequencing of exon 7 was done in 302 patients. 
 
 
3.3.6 Haplotype analysis in informative families 
 
Haplotype analysis was carried out in informative families with more than one affected 
individual.  Regardless of the phenotype, fifteen out of forty-seven patients (32%) 
initially screened with haplotype analysis were subsequently shown to have pathogenic 
mutations in known CMS genes.  This figure is lower than without haplotype analysis.  
One possible explanation is that these families may harbour mutations outside the 
regions frequently Sanger sequenced in Munich or that the patients share the same 
phenotype of CMS but have an alternative neuromuscular condition (phenocopy). 
 
 
3.4 Genotype phenotype correlation
47
 
 
Ideally, one would explore several parameters simultaneously to assess genotype 
phenotype correlation.  However, the choice of these factors in this study was often 
limited by the lack or variable quality of the clinical and investigation reports.  
Therefore, analysis focussed on six specific features: 1) presence or absence of 
decrement, 2) positive or negative response to AChE inhibitors, 3) presence or absence 
of ptosis, 4) presence or absence of ophthalmoparesis, 5) presence or absence of apnoeic 
episodes, 6) ethnic origin and in particular, presence or absence of Roma ancestry, 7) 
presence or absence of consanguinity and lastly 8) presence or absence of a positive 
family history (table 3.6 and figure 3.14) 
Once a particular parameter was selected, patients were categorised based on the 
presence or absence of this feature and calculated the total number of mutation positive 
or negative patients. A Chi Square test was used to assess whether there was any 
difference between these two unpaired groups. 
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The presence or absence of consanguinity and isolated ptosis had no impact on the 
mutation detection rate.  By contrast, all other parameters were associated a significant 
difference as regard the mutation detection rate.  This was most notable in patients of 
Roma descent, patients with evidence of decrement on repetitive nerve simulation and 
clinical evidence of ophthalmoparesis. Other subgroups, namely, patients presenting 
before the age of two years, patients developing apnoeic episodes and patients 
responding to AChE inhibitors also exhibited a clear difference in mutation detection. 
The positive predictive value of ethnic origin in our cohort is probably related to the 
prevalent Roma founder mutation (CHRNE, 1267delG), primarily found in South East 
Europe.  
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  Mutation identified No mutation detected  Total 
Positive family history  73 (55%) 60 133 
Negative family history 178 (31%) 289 467 
  
  
P 0.0005                   
Consanguinity 41 (46%) 48 89 
No consanguinity 210 (41%) 301 511 
  
  
P 0.38 not significant 
Geographical origin: South-East Europe/Roma 106 (57%) 79 185 
Other countries 193 (39%) 302 495 
  
  
P 1.9E-05 
Age at onset (0,1,2 yrs)  151 (41%) 214 365 
Age at onset (3yrs and >3yrs)  45 (31%) 101 146 
  
  
P 0.026 
Positive response to AChE-Inhibitors 138 (51%) 133 271 
Negative response to AChE-Inhibitors 56 (39%) 86 142 
  
  
P 0.026 
Decrement 125 (53%) 109 234 
No decrement 27 (18%) 126 153 
  
  
P 0 
Apnea reported  82 (54 %) 70 152 
No apnea reported  217 (41%) 311 528 
  
  
P 0.0049 
Ptosis reported  230 (46 %) 272 502 
Ptosis not reported  69 (39%) 109 178 
  
  
P 1.03 not significant 
Opthalmoparesis reported  163 (58 %) 116 279 
No Opthalmoparesis 136 (34%) 265 401 
  
  
P 0 
Ptosis with Opthalmoparesis  152 (55 %) 123 275 
No Ptosis with Opthalmoparesis  147 (36%) 258 405 
  
  
P1E-06 
Limb girdle phenotype 45 (43%) 60 105 
No limb girdle phenotype 254 (44%) 321 575 
  
  
P 0.8 not significant 
Predominant ocular symptoms 1 (4%) 23 24 
No predominant ocular smptoms 298 (44%) 358 656 
  
  
P6.3E-05 
 
Table 3.6: Mutation detection based on distinct phenotypic features.  P values calculated using Chi Square 
test.  Modified from Abicht et al 2012 (URL: 
http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
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Figure 3.14:  Predictive value of particular phenotypic features.  The number of patients with a particular 
phenotype tested for a particular gene (blue) were compared to the mutation positive patients with the 
same phenotype (red) and in turn this was compared to the total number of mutation positive patients in 
the total cohort regardless of the phenotype (green).  Reproduced from Abicht et al 2012 (URL: 
http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract) 
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3.5 Discussion
48
 
This observational cross sectional study was important in terms of determining the 
distribution and frequency of mutations, ascertaining whether phenotype and genotype 
can be correlated in a large CMS cohort and to help design a better diagnostic strategy.  
This seems even more relevant in the context of a rising number of novel CMS genes, 
and in particular in a disorder like CMS where particular molecular defects require 
particular therapeutic approaches (Schara and Lochmuller, 2008). 
In this study, stringent selection criteria were used to include patients with a clinical 
diagnosis highly suggestive of CMS and exclude potential phenocopies such as 
congenital myopathies and autoimmune myasthenia (see chapter 1).  Only fourteen 
known CMS genes were known when this work was carried out and only ten genes 
were routinely screened for mutations.  With a candidate gene approach, disease causing 
mutations were successfully established in 299 out 680 patients, representing 44% of 
the total cohort. It is worth noting that this figure is lower than that described in other 
cohorts.  In the UK,  a figure of 60% (Palace and Beeson, 2008) has been reported and 
more recently up to 70-80% of patients have a molecular diagnosis.  The discrepancy in 
mutation detection rates between the Munich and Oxford centres is remarkable and may 
be due to a number of factors:  
1- Some of the undiagnosed patients may have autoimmune myasthenia gravis. 
Although antibody screening for anti AChR and anti-MuSK antibodies was 
routinely checked in the undiagnosed patients, a number of these patients may 
carry low titres of antibodies that would only be detected in specialist centres 
like the Oxford National laboratory (Leite et al., 2008).  
2- Some of the undiagnosed patients may have an alternative genetic 
neuromuscular disorder. 
a.  Variations in clinical protocols and expertise in performing repetitive 
nerve stimulation and SFEMG may result in misinterpretation of results.   
 
b. The use of a questionnaire to collect data, instead of formal assessment 
of patients, has its own limitations.  
 
c. The clinical criteria suggestive of CMS such as the presence of fatigue, 
jitter on SFEMG and even a positive response to AChE inhibitors are not 
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specific and may be found in other disorders such as congenital 
myopathies and mitochondrial disorders. 
 
3- The Munich CMS database may be more ethnically heterogeneous than the 
Oxford CMS cohort.  Indeed only 39% of all referrals to the Munich Centre 
were from central Europe.  This ethnic heterogeneity may be associated with a 
wider range of mutations, which are not necessarily excluded with the current 
strategy or may be due to novel genes awaiting to be unraveled.  
 
Regarding the relative mutation frequency across the different CMS genes, the Munich 
cohort (299 diagnosed patients) showed similar trends as reported in the Mayo clinic 
cohort, which contained 295 genetically confirmed cases (Engel et al., 2010, Chaouch et 
al., 2012a) and in the UK cohort which contained 189 mutation-positive patients 
(Beeson et al., 2005, Beeson et al., 2008).  Indeed, postsynaptic defects and in particular 
defects in the subunits of AChR accounted for most mutations in the Munich cohort 
(54%).  This was mirrored in the Mayo CMS cohort and the UK cohorts.  Most of the 
mutations were recessive missense mutations predicted to result in AChR deficiency at 
the motor endplate.   
A founder effect in different populations was associated with a number of common 
mutations in shared distant haplotypes.  The common Roma mutation (CHRNE; 
c.1267delG) was most prevalent.  This mutation was found either homozygously or 
heterozygously in eighty-nine patients (30% of the diagnosed cohort).  It is worth noting 
that other common mutations were also detected: the CHRNE; c.1293insG29 in North 
Africa, Southern Europe and Brazil as well as the DOK7; c.1124_1127dupTGCC and 
the RAPSN; c.264C>A mutations in Europe and North America.  These mutations were 
found in 14 out of 148 CHRNE positive patients, 25 out of 31 DOK7 positive patients 
and 39 out of 43 RAPSN positive patients. 
The mutation distribution, should the 89 patients harbouring the Roma founder mutation 
be removed, were closer to reports from other large CMS cohorts.  A proportional 
increase in the frequency of mutations in other CMS genes was also noted: 5 to 7% in 
CHAT gene, 10 to 15% in DOK7, 12 to 17% in COLQ gene and 15 to 20% in RAPSN 
gene.  In the Mayo clinic, CHAT accounted for 5% of the diagnosed cohort whilst 
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DOK7, COLQ and RASPN mutations were detected in 8%, 15% and 15% of the 295 
genetically confirmed patients (Engel et al., 2010): 
At the time of this study, GFPT1 was a newly discovered gene which was shown to be 
associated with a limb girdle CMS phenotype with tubular aggregates (Senderek et al., 
2011, Guergueltcheva et al., 2011). Based on this phenotypic picture, a total of thirty-
nine independent individuals were selected for GFPT1 mutation screening and twelve 
were mutation positive.  
In general, exclusion criteria have been relaxed in the Munich diagnostic centre due to 
concerns of dismissing atypical or novel CMS phenotypes.  Although patients were 
referred by experienced clinicians, these were not assessed by CMS experts and 
therefore the accuracy of the described phenotype will depend on the quality of the data 
received on a particular patient.   
Furthermore, it is well recognized that the CMS phenotype can be difficult to 
distinguish from other neuromuscular entities.  This has been a particular issue with 
congenital myopathies in which, occasionally, patients can present with neuromuscular 
symptoms since birth, with ptosis, fluctuations, decrement and even some response to 
treatment (Alseth et al., 2011, Munot et al., 2010, Srour et al., 2010, Robb et al., 2011).  
Such patients would be very difficult to detect unless other ancillary tools are included 
such as detailed muscle biopsy analysis and muscle MRI.  
As described earlier, the screening strategy relied on PCR amplification and Sanger 
sequencing of exonic regions of ten known CMS genes.  However, this strategy is 
inherently limited by its inability to detect large scale deletions as well as intronic 
defects that may be crucial in the regulation of a gene or its splicing.  Moreover, 
sequencing was often targeted to recurrent mutations or hot spots like the Roma founder 
mutation in CHRNE, exon 2 in RAPSN or exon 7 in DOK7.  Thus, it is probable that 
some undiagnosed CMS patients who had a robust clinical diagnosis would carry novel 
CMS genes as yet to be unraveled.  
 
As part of a novel candidate gene search, three functional genes were screened in this 
cohort: LRP4, which encodes for a transmembrane receptor that binds agrin and forms a 
complex with MuSk; SLC18A3, which encodes a transmembrane vesicular transporter 
of acetylecholine and CNTN1, which encodes neuronal membrane protein that may 
function as an adhesion molecule. No mutation positive patients were identified in any 
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of these genes.  It is worth noting that since this work was completed, LRP4 mutations 
were shown to be disease causing in one kinship (Ohkawara et al., 2014).  Therefore, it 
is plausible that some of the Munich centre patients may still harbour mutations in this 
gene since the phenotype reported had no characteristic features. 
In the second part of this study, we ascertained whether particular clinical features or 
ancillary investigation provided more robust evidence to support a diagnosis of CMS 
and when possible, determine which parameter had the best predictive value.  A number 
of clinical cues were shown to be more prevalent in certain CMS subgroups (see chapter 
1).  For instance, the presence of ophthalmoplegia is well documented in patients with 
mutations of AChR subunits, while apnoeic episodes have typically been associated 
with CHAT and RAPSN mutations (Beeson et al., 2005, Engel, 2012).  On the other 
hand, the limb girdle phenotype was shown to be associated with DOK 7 mutation 
(Palace et al., 2007) and more recently with several glycosylation gene defects (Belaya 
et al., 2012, Cossins et al., 2013, Senderek et al., 2011). 
Particular neurophysiological and histochemical findings such as evidence of repetitive 
CMAPs in patients with COLQ related CMS and slow channel syndrome, the presence 
of tubular aggregates in muscle biopsies of patients with defects in GFPT1 and other N-
linked glycosylation genes have certainly helped delineate and refine the clinical 
phenotype of the patients and sometimes facilitated molecular diagnosis.  The response 
to AChE inhibitors was also a useful tool to stratify patients and can correlate with 
particular gene defects with DOK7 and COLQ related CMS being typically associated 
with a detrimental response to AChE inhibitors.  Of note, the role of muscle MRI in 
refining the phenotype of CMS patients remains to be determined.  
The correlation between the presence of a particular phenotypic feature and mutation 
detection rates was also assessed.  Consanguinity and isolated ptosis had no impact on 
the mutation detection rate in the Munich cohort.  By contrast, presence of 
ophthalmoparesis, apnoeic episodes, age at onset before two years, evidence of 
decrement, response to AChE inhibitors and ethnicity (Roma ancestry) were associated 
with a significant difference in the mutation detection rate.  
In the Munich cohort, a total of 152 patients were reported to have apnoeic episodes and 
82 of these were diagnosed.  Most defects were detected in RAPSN, CHAT then COLQ 
genes.  Although, apnoeic episodes are well recognized in patients with CHAT and 
RAPSN related CMS, mutations in COLQ have not necessarily been known to be an 
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important cause of this clinical phenotype.  In this cohort, sudden respiratory crises 
were documented in twelve out of thirty-eight patients (31%) with COLQ mutations.  
Therefore, in the presence apnoea, one may need to consider screening for COLQ 
mutations if RAPSN and CHAT sequencing be negative.  CHAT mutations accounted for 
5% of all mutations in the Munich cohort.  The mutation detection rate for CHAT was 
18% ranking second only to CHRNE (42%).  Two out of the fifteen patients with CHAT 
positive mutations presented at birth but did not develop apnoeic episodes at the time of 
referral and would have been missed if testing had solely relied on the presence of this 
feature to proceed with genetic testing. 
The distinct proximal pattern of muscle weakness and atrophy with minimal ocular 
involvement seen in limb girdle CMS has attracted great interest over the years.  This 
phenotype can be associated with DOK7 mutations, when patients show a negative 
response to AChE inhibitors or alternatively glycosylation genes (GFPT1, DPAGT1, 
ALG2 and ALG14) when AChE inhibitors are beneficial to patients.  It is worth noting 
that GFPT1 was the only known glycosylation gene when this study was completed and 
this may well influence the mutation detection rate in this subgroup.  A total of 105 
patients were referred with a limb girdle phenotype, forty-five of these were mutation 
positive.  In this study, a limb girdle phenotype on its own was not sufficient to 
influence the mutation detection rate.  However, if one combines this particular pattern 
of muscle weakness with a positive response to AChE inhibitors and ptosis, the 
predictive value improved.  In a total of thirty patients with this constellation of 
features, twelve were mutation positive.  Two patients were DOK7 carrier and ten had 
mutations in GFPT1 gene. 
Furthermore, if one focusses on the patients with limb girdle phenotype in whom a 
muscle biopsy was available, fifty-nine individuals (56%) were identified.  A total of 
eleven patients were shown to have tubular aggregates and seven of these harboured 
mutations in GFPT1.  Nevertheless, one should interpret these figures with caution 
given the relatively large number of patients who did not have a muscle biopsy but also 
in terms of the technical difficulties in recognizing tubular aggregates in muscle 
biopsies and their variable distribution in different muscles groups and over time in the 
same patient (see chapter 5). 
This study correlated with previous reports in terms of the importance of 
neurophysiological studies to explore whether there is impaired neuromuscular 
transmission (decrement or abnormal jitter) but also in terms of the usefulness of a trial 
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with AChE inhibitors, if deemed safe, in pointing towards a neuromuscular defect and 
potentially particular candidate genes, e.g. negative response in COLQ and DOK7 
patients.  
In this study, haplotype analysis was not suitable in most kinship because of their small 
size, often including single affected individuals with no positive family history.  This 
method uses microsatellite DNA markers and has been shown to be a cost effective 
screening method to determine the molecular diagnosis of neuromuscular disorders 
including CMS (von der Hagen et al., 2006).  This indirect genetic strategy allows the 
restriction of candidate gene by excluding potential candidate genes for subsequent 
Sanger sequencing.  Nevertheless, the application of this approach can be restricted by 
the small size of informative families, the inability to cope with de novo mutations and 
recombination events near to or within the candidate gene locus.  A total of forty-seven 
index cases were analysed using this strategy.  All had other affected first-degree 
relatives with some being derived from consanguineous parents.  An average of three 
genes had to be screened before reaching the correct genetic diagnosis.  Overall, a 
molecular diagnosis was successfully established in 32% of this subgroup. 
 
In this cohort, more than 80% of all mutations were located in five CMS genes: 
CHRNE, RAPSN, COLQ, DOK7 and CHAT.  The probability of identifying the genetic 
defect was highest in patients with only one gene sequenced.  This was most notable 
with screening for CHRNE and in particular with the Roma founder mutation 
c.1267delG.  Clearly, this trend may vary in other CMS cohorts with different ethnic 
distribution with other genes in which there no clear hotspots.  A smaller number of 
patients were first screened for CHAT and COLQ mutations.  However, the mutation 
detection rate in these patients was substantial, 88% and 78% respectively.  The distinct 
phenotypic clues associated with these two genes, namely the apnoeic episodes in 
CHAT CMS and a negative response to AChE inhibitors in COLQ patients, may have 
been useful pointers to the correct molecular diagnosis.  
Based on the above observations, one can distinguish four important factors that can 
determine the likelihood of establishing a molecular diagnosis (figure 3.14):  
1) Ethnicity.  
2) A positive family history.  
3) Presence of apnoeic episodes. 
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4) Response to AChE inhibitors.  
 
 
 
Figure 3.15: Algorithm for genetic testing.  Entry points according to available clinical and 
electrophysiological data are given as black squares.  Reproduced from Abicht et al 2012 (URL: 
http://onlinelibrary.wiley.com/doi/10.1002/humu.22130/abstract).
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The recent discovery of more CMS genes using next generation sequencing will 
undoubtedly influence the diagnostic strategy for CMS (figure 3.15).  In clinical 
practice, most CMS patients will present soon after birth or in the neonatal period with 
hypotonia and fatigable weakness.  The differential diagnosis of such symptoms is wide 
and one would need to search for additional clinical clues to determine the precise 
genetic aetiology.  Such features may include recurrent apnoeas, which can be seen in 
several subtypes of CMS including defects in CHAT, RAPSN, COLQ, DOK7 and fast 
channel CMS.  In this instance, the presence of finger contractures and minimal ocular 
symptoms, may suggest RAPSN CMS, proximal weakness may suggest COLQ and 
DOK7 mutations and evidence of minimal neuromuscular weakness between episodes 
may suggest CHAT mutations.  In the presence of apnoeas, an important step to help 
clarify the cause is a trial with AChE inhibitors:  This treatment should be administered 
in a safe setting where patients can be monitored for potential deterioration in their 
neuromuscular symptoms.  Patients with RAPSN, CHAT mutations and fast channel 
CMS tend to respond favourably to AChE inhibitors in contrast to DOK7 and COLQ 
associated CMS patients, who exhibit no sustained response to this treatment and may 
even deteriorate.   
Although ptosis is a common symptom in CMS, it is rather non-specific.  On the other 
hand, ophthalmoparesis can be more suggestive of a particular subgroup of CMS 
including mutations in the subunits of AChRs, COLQ, MUSK and some AGRN 
mutations.  In this instance, response to AChE inhibitors can be extremely helpful to 
narrow the differential diagnosis since mutations in AChR, except for slow channel 
mutations, respond to this treatment whilst CMS associated with COLQ, MUSK and 
AGRN mutations do not. 
Most CMS patients present with global fatigable weakness, however, some may show 
distinct patterns of muscle involvement.  Proximal weakness with minimal ocular 
symptoms may be in keeping with defects in DOK7 and other glycosylation genes 
(GFPT1, DPAGT1, ALG2 and ALG14).  COLQ CMS patients can also present with 
proximal involvement but ophthalmoplegia is usually present.  A positive response to 
AChE inhibitors and presence of tubular aggregates on muscle biopsy may point 
towards mutations in glycosylation genes rather than DOK7-mediated CMS.  Another 
distinguishing pattern of muscle involvement includes distal muscle weakness that can 
be consistent with either slow channel or AGRN mutations.  The latter may also be 
associated with evidence of increment on repetitive nerve stimulation.  Intellectual 
disability is a rare feature in CMS but mutations in ALG2 were recently shown to be 
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associated with this phenotype.  Finally, other clues such as a dominant mode of 
inheritance and particular ethnic origins have been reported in association with slow 
channel CMS and particular common mutations respectively.  
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Chapter 4.  Clinical characterization of a slow channel CMS cohort 
 
 
4.1 Introduction and aims
49
 
 
Mutations in the subunits of the AChR are responsible for the majority of CMS cases 
and can result in deficiency of AChR subunits or alter the kinetic characteristics of the 
ligand gated ion channel.  (Engel and Sine, 2005, Hantai et al., 2004, Muller et al., 
2007b).   
 
Slow channel CMS is a rare CMS category and the only known autosomal dominant 
form.  Mutations are associated with sustained channel opening and destabilized 
channel closure with higher receptor affinity for acetylcholine (ACh) (Engel and Sine, 
2005).  These aberrant properties compromise efficient and reliable transmission across 
the neuromuscular synapse.  Characteristically, patients present with global fatigable 
neuromuscular weakness with a predilection for the cervical and extensor forearm 
muscles.  Single nerve stimulation can trigger a repetitive CMAP response.  
Furthermore, an endplate myopathy can be a distinctive morphological footprint.  The 
latter is thought to be secondary to sustained postsynaptic activation and excess calcium 
influx (Engel et al., 1982). 
 
To date 20 mutations have been reported to cause slow channel CMS (Engel et al., 
1996b, Croxen et al., 1997, Sine et al., 1995, Milone et al., 1997, Shen et al., 2006, 
Gomez et al., 2002, Croxen et al., 2002, Ohno et al., 1995, Vohra et al., 2004, Vohra et 
al., 2006).  These have been identified in the α, β, δ and ε subunits of the AChR.  All 
mutations have primarily been located in the transmembrane domains of the different 
subunits: M1, M2 and more recently M4 domains and a few were located in the 
extracellular domain of M1 as well as the N terminal part near the binding site of the 
receptor.”   
 
Because of its distinct molecular mechanism, slow channel CMS patients have required 
alternative treatments and indeed do not usually benefit from AChE inhibitors (Schara 
and Lochmuller, 2008).  Based on previous published evidence, long acting open 
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channel blockers like fluoxetine and quinidine were prescribed in such patients with 
some benefits (Harper et al., 2003, Harper and Engel, 1998b).   
 
It is worth noting that fast channel CMS is also caused by kinetic mutations in the 
AChR subunits (Palace et al., 2012).  This entity however is autosomal recessive in 
inheritance and mutations lead to brief channel opening events and occasionally 
diminished affinity to its substrate.  There are no anatomical footprints with these 
mutations (Engel and Sine, 2005).  
 
The main objectives of this study were to refine the clinical phenotype of a sizeable 
cohort of slow channel CMS patients and determine the efficacy of recommended 
therapies.  This cohort was identified via the Munich CMS diagnostic database.  
For details of patient selection, clinical assessments and mutation analysis please see 
Chapter 2 (Methods).  Briefly, I generated and circulated a questionnaire to all the 
referring clinicians to capture relevant information.  The results of this study were 
published in Chaouch et al 2012 (URL:http://link.springer.com/article/10.1007%2Fs00415-011-
6204-9). 
 
 
4.2 Patient data 
 
4.2.1 Clinical phenotype
50
 
 
Fifteen slow-channel CMS patients from families were identified in the Munich CMS 
centre.  Patients referred from1997 to 2010 (table 4.1and figure 4.1).  Nine female and 
six male patients, of varied ethnic backgrounds, were monitored over a period extending 
from 5 to 20 years.  Patient 3 deceased in 2009 subsequent to a car accident and patient 
14 was deceased in 2011 following complications from a lower respiratory tract 
infection. Patients 3, 4 and 10 were previously published (Colomer et al., 2006, 
Mihaylova et al., 2010).   
 
The patients presented either in early infancy or later as adults.  The majority of patients 
demonstrated selective neuromuscular weakness of the upper limbs and neck muscles.  
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 83 
Patients 7, 8, 10, 13 and 15 showed prominent wrist and finger extensor muscle 
weakness.   
More than half of the patients exhibited facial, ocular and bulbar involvement.  Striking 
masseter muscle atrophy was noted in patients 12, 13 and 14, who were from the same 
pedigree.   
Patients 10 and 11, developed neonatal respiratory complications necessitating 
ventilator support and have remained on this treatment since. 
Most patients’ neuromuscular symptoms fluctuated from days to weeks with a clear 
progressive trend over time except for patient 9 who reported improvement in her 
muscle weakness later in life, without administration of any medication.   
Interestingly, 3 of the 9 female patients (patients 8, 9 and 13) developed their symptoms 
subsequent to giving birth and patients 2 and 11 described temporary exacerbation of 
neuromuscular weakness in relation to menstruation.   
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  Age/Gender 
/ethnicity 
Mutation Onset Disease course 
Age  Symptoms Signs Static Progre-
ssive 
Fluctu-
ating 
FVC Ocular 
muscles 
Cervical 
muscles 
Prox   
UL 
Dist   
UL 
Prox   
LL 
Dist   
LL 
Fatigue Other features 
1 44/F/African CHRNA1 
G153S  
25y Gen limb weak, 
occasional dyspnoea 
69% - +++ ++ + ++ + + Scap wing + - + 
2 46/F/Swedish CHRND 
S268Y 
6y Neck and gen limb 
weak and 
thyrotoxicosis age 
13  
103% - + ++ +++ ++ ++ + - - + + 
3 31/M/ 
Portuguese 
Lebanese  
CHRNB1 
V266M 
Birth Ocular, bulbar and 
proximal limb weak 
ND + + + ++ - - + Bulbar weak, 
scap wing, 
scoliosis, hand 
atrophy 
- + + 
4 16/ F/ Spanish 
Italian 
CHRNA1 
G153S 
1y Ocular, neck and 
proximal limb weak 
ND - + + + + - + - - + + 
5 19/F/German CHRNE 
V259L 
2y Ocular and prox 
limb weak 
79% + + - + + - +  + - + 
6 15/ F/ German CHRNE 
V259L 
Birth Ocular, prox limb 
weak and recurrent 
chest infections 
81% + + ++ ++ + + + Facial diplegia - + + 
7 44/M/ German CHRNE 
V259L 
20y Gen limb weak ND - - + + - + + Left hemiparesis 
after stroke 
+ - - 
8 47/ F/Serbian CHRNB1 
T265S 
38y Ocular and gen limb 
weak  
110% + + ++ ++ + + +   - + - 
 
Table 4.1. (page 84-85).  Clinical features of the slow channel CMS cohort.  F; female, M; male, ND; not done, y; year, Gen; generalised, FVC; forced vital capacity, Prox; proximal, 
Dist; distal, scap; scapular, wing; winging, UL; upper limbs, L; lower limbs, +; mild, ++; moderate, +++; severe.  Adapted from Chaouch et al 2012 
(URL:http://link.springer.com/article/10.1007%2Fs00415-011-6204-9) 
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  Age/Gender/ 
ethnicity 
Mutation Onset Disease course 
Age  Symptoms Signs Static Prog-
ressive 
Fluctu-
ating 
FVC Ocular 
muscles 
Cervical 
muscles 
Prox 
UL 
Dist 
UL 
Prox 
LL 
Dist 
LL 
Fatigue  Other 
features 
9 73/F/Serbian CHRNB1 
T265S 
26y Gen upper 
limb weak 
ND - + + + - - +  - - + 
10 20/ M/Spanish CHRNE 
L269F 
Birth Hypotonia, 
failure to 
thrive, 
ocular and 
gen limb 
weak 
ND + ++ + ++ - - + Facial weak, 
gen muscle 
atrophy 
scoliosis 
- + + 
11 18/ F/Spanish CHRNE 
L269F 
Birth Hypotonia, 
failure to 
thrive, 
ocular, 
facial, gen 
limb weak  
35% + ++ ++ + ++ + + Facial weak, 
gen muscle 
atrophy 
scoliosis       
- + + 
12 48/M/Ashkenazi 
Jewish 
CHRNA1 
G153S 
43y Chewing 
difficulties, 
involuntary 
mouth 
opening, 
gen fatigue 
ND + ++ - + - + + Facial weak, 
masseter 
atrophy high 
arched palate 
- + + 
13 74/F/Ashkenazi 
Jewish 
* 28y Chewing & 
speech diff, 
gen limb 
weak  
ND + + - ++ + ++ - Facial weak, 
UL atrophy, 
masseter 
atrophy 
- + + 
14 70/M/Ashkenazi 
Jewish 
* 15y Hand weak,  
diff 
standing on 
tiptoes, 
chewing 
diff 
ND - + - + - + + Masseter 
atrophy 
- + - 
15 19/M/Ashkenazi 
Jewish 
* 15y Hand weak ND - + + ++ - - - Facial weak, 
high arched 
palate, 
micrognathia 
+ - - 
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4.2.2 Ancillary investigations
51
 
 
In terms of investigations, most patients had normal creatinine kinase levels and 
undetectable AChR antibodies titres.  Two patients were noted to have moderately 
elevated creatine kinase levels.  Repetitive nerve stimulation at 3Hz showed decrement 
in all the 9 patients tested.  Notably, 7 had demonstrated repetitive CMAPs on single 
nerve stimulation.  Unspecific myopathic features were reported in all 5 muscle biopsies 
carried out as part of the initial assessment of these patients (table 4.2).   
 
Patient/Age/Gender CK 
AChR 
Abs 
Nerve stimulation 
Muscle 
biopsy 
1/44y/F ↑ - 
Decrement, double 
CMAPS 
NS 
2/46y/F - - 
Decrement, double 
CMAPS   
ND 
3/31y/M  - - 
Decrement, double 
CMAPS  
NS 
4/16y/ F - - 
Decrement, double 
CMAPS     
NS 
5/19y/F - - Decrement  NS 
6/15y/ F - - Decrement  ND 
7/44y /M ND ND ND ND 
8/47y/ F ↑ - 
Decrement, double 
CMAPS  
NS 
9/73y/F ND - ND ND 
10/20y/ M - - 
Decrement, double 
CMAPS   
NS 
11/18y/ F - ND ND ND 
12/48/M - ND 
Decrement, double 
CMAPS   
ND 
13/74/F ND ND ND ND 
14/70/M ND ND ND ND 
15/19/M ND ND ND ND 
 
Table 4.2. Results of ancillary investigations in slow channel CMS cohort. M; male, F; female, ↑; 
elevated, - ; normal, ND; not done, NS; nonspecific, CMAP; compound muscle action potential, Abs; 
antibodies.  Adapted from Chaouch et al 2012 (URL:http://link.springer.com/article/10.1007%2Fs00415-
011-6204-9) 
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4.2.3 Mutation analysis
52
 
 
Ten patients from four families exhibited autosomal dominant inheritance while five 
cases were sporadic.  Genetic testing was carried out in the Munich diagnostic centre.  
Patients were screened using a slow channel CMS panel that included exons encoding 
the M2 domain of the ε, α, β, δ subunits of the receptor.  In the α subunit, exons 
encoding the N terminal region were also sequenced.  In total, six missense mutations in 
the α, β, δ and ε subunits were detected: αG153S, βT265S, εL269F, εV259L and 
δS268Y.  Mutations βT265S and δS268Ywere not previously reported.  Most mutations 
were located in the channel pore M2 functional domain (figure 4.1). 
 
 
Figure 4.1.  Slow channel mutations in relation to the functional domains of the AChR. 
 
 
4.2.4 Treatment regimens  
 
Choice of therapy was dependent on whether molecular diagnosis was established (table 
4.3).  In the eight patients with no initial molecular diagnosis available, AChE inhibitors 
were prescribed with no reported clinical benefit.  3,4-DAP was initiated as substitute in 
two patients and prednisolone was added as an adjunct to AChE inhibitors in a further 
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two patients. Though well tolerated, prednisolone, 3,4-DAP and AChE inhibitors were 
ineffective and were later stopped.
 89 
 
Patient/Age/Gender 1
st
 line therapy (max dose) Response to therapy 
1/44y/F Age 30y. Pyridostigmine 60mg tds  No benefit, worsening fatigue 
2/46y/F Age 38y. Pyridostigmine 120mg tds  No benefit  
3/31y/M  Age 20y. Pyridostigmine 60mg tds Initial benefit then relapse 
4/16y/ F Age 5y. Pyridostigmine 20mg tds  No benefit, side effects (headache) 
5/19y/F Age 17y. Quinidine 150mg tds Clear benefit 
6/15y/ F Age 13y. Quinidine 150mg tds Clear benefit, mild side effects (vertigo and tachycardia) 
7/44y /M Never treated  
8/47y/ F Age 39y. Pyridostigmine 60mg qds  No benefit 
9/73y/F Never treated  
10/20y/ M  Age 1y. Pyridostigmine 60mg qds No benefit  
11/18y/ F Age 1y. Pyridostigmine 60mg qds   No benefit  
12/48/M Pyridostigmine 180 mg/d No benefit  
13/74/F Age 70. Fluoxetine 40mg/d Clear benefit with no side effects 
14/70/M Age 67. Fluoxetine 40mg/d Clear benefit with no side effects 
15/19/M Never treated   
 
Table 4.3. Summary of therapies prescribed. M; male, F; female, y; year, bd; twice a day, tds; three times a day, qds; four times a day Adapted from Chaouch et al 2012 
(URL:http://link.springer.com/article/10.1007%2Fs00415-011-6204-9)  
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Patient/Age/Gender 2
nd
 line therapy (max 
dose) 
Response to therapy 3
rd
 line therapy (max 
dose) 
Response to therapy 
1/44y/F  Age 30y. 3,4-DAP 15mg 
x 6/d 
Initial benefit, then relapse Age 40y. Fluoxetine. 
40mg/d  
Clear benefit but significant side 
effects (serotoninergic crisis 3 
months after starting treatment) 
2/46y/F Quinidine 200mg bd  No benefit  Age 43y. Fluoxetine 20mg 
od 
No benefit and significant side 
effects (lethargy and hypotension) 
3/31y/M  Age 23y. Pyridostigmine 
with prednisolone 20mg/d  
No benefit, symptoms worse Age 25y. Fluoxetine 
20mg/d 
Some benefit but unable to tolerate 
higher dose (40mg/d)  
4/16y/ F Age 6. 3, 4 DAP 
25mg/day  
No benefit Age 13y. Fluoxetine 
60mg/d  
Clear benefit with no side effects 
5/19y/F     
6/15y/ F     
7/44y /M     
8/47y/ F Age 40y. Pyridostigmine 
with prednisone 60mg alt 
days 
No benefit Age 43y. Fluoxetine 
80mg/d 
Clear benefit with no side effects 
9/73y/F     
10/20y/ M Age 15y. Fluoxetine 
60mg/d 
Clear benefit but relapsed after 
2 years of therapy. Remains on 
fluoxetine but reliant on NIV 
  
11/18y/ F Age 12y. Fluoxetine 
60mg/d 
Clear benefit   
12/48/M Age43. Quinidine 400 
mg/d 
No benefit Age43. Fluoxetine 
(60mg/d) 
Clear benefit with no side effects 
13/74/F     
14/70/M     
15/19/M         
Table 4.3. (Cont) Summary of therapies prescribed. Adapted from Chaouch et al 2012 (URL:http://link.springer.com/article/10.1007%2Fs00415-011-6204-9) 
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Subsequent to establishing a molecular diagnosis, fluoxetine was prescribed in patients 
1, 3, 4, 8, 10, 11, 13, 14 and quinidine was introduced in patients 2, 5, 6 and 12.   
Notably, three patients received no treatment. In patients 9 and 15 neuromuscular 
weakness was deemed too mild to warrant therapy.  Patient 7 was still undergoing 
assessments to decide on optimum management (table 4.3).  Patients 5 and 6 reported 
definite amelioration in their neuromuscular weakness after receiving quinidine.  On the 
other hand, patients 2 and 12 showed no benefit and were later switched to fluoxetine.  
It is worth noting that quinidine was well tolerated in all patients.   
 
Fluoxetine was prescribed in a total of ten patients but had to be withdrawn in patients 
1, 2 and 3 due to side effects.  The latter comprised life threatening serotonergic crisis, 
symptomatic hypotension that failed to improve by reducing treatment dose.  In patients 
in whom fluoxetine was tolerated, all reported clear benefit in their neuromuscular 
weakness.  Sustained improvement with fluoxetine was reported up to six years after 
instigating treatment although one patient (patient 10) developed significant respiratory 
insufficiency two years after instigation of fluoxetine.  Only one patient (patient 1) had 
ephedrine as 4
th
 line therapy and showed clear benefit though he reported excess 
lethargy and malaise.
53
 
 
 
5.3 Discussion
53
  
 
The findings from this study, which describes a sizeable cohort of patients, were 
comparable to previous reports of slow channel CMS cohorts as regard the preferential 
involvement of cervical and upper limb muscle groups with clear inter familial and intra 
familial variability (Beeson et al., 2005, Engel and Sine, 2005).  Craniofacial weakness 
was a common feature and the degree of ophthalmoparesis was less severe than what is 
normally seen in AChR deficiency CMS. The age at onset of disease was also distinctly 
variable with some patients presenting in infancy while others manifesting often mild 
symptoms late in life.  I was interested to note that 50% of the female patients reported 
exacerbation of their myasthenic symptoms in relation to hormonal changes and 
pregnancy. 
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Repetitive nerve stimulation consistently revealed decrement suggestive of impaired 
NMJ transmission.  Furthermore, repetitive CMAPs were detected in several patients, 
which can reflect aberrant sustained stimulation of the postsynaptic membrane.  It is 
important to emphasize that repetitive CMAP are not pathognomonic of slow channel 
CMS and can be found in other conditions like COLQ CMS (or treatment with AChE 
inhibitors).  Nonetheless, neurophysiological studies were helpful in supporting the 
diagnosis of CMS.   
 
Predictably, unravelling the exact genetic diagnosis had substantial effect on choice of 
treatment and clinical response. Out of the six dominant missense mutations identified, 
five had previously been published and one was novel.  CHRNB1 T265S is the novel 
mutation and was shown to modify a conserved residue at the pore forming M2 domain 
thus delaying channel opening events on patch clamp study (Hoellen, unpublished).  
The mother and daughter from the Serbian kinship (patients 8 and 9) were 
heterozygotes for this mutation.  They both developed adult onset neuromuscular 
weakness, which was comparatively mild and improved with fluoxetine in the daughter.  
The mother never wished to be treated given her mild symptoms.    
 
Mutation αG153S is the commonest slow channel mutation in the UK.  It is located near 
the extracellular AChR binding domain and was reported to impede the disconnection 
of ACh from its binding site (Sine et al., 1995).  In this cohort, this mutation was also 
the most frequent and occurred in patients of different ethnic origin.  There were clear 
differences with respect to age at disease onset and response to fluoxetine in patients 
sharing mutation αG153S.  Remarkably, all individuals from the Ashkenazi Jewish 
family demonstrated the common feature of atrophied masseter muscles.  This clinical 
feature may well be a clinical sign specific to this family, as it was not observed in other 
cases. 
 
The other two known mutations identified in this cohort are mutations βV266M and 
εL269F.  These are positioned in the M2 domain and have been shown to prolong 
channel opening events (Engel et al., 1996b).  In contrast to βV266M, mutation εL269F 
also enhanced the affinity of the receptor for ACh.  In this study, both mutations were 
associated with a relatively disabling phenotype with neonatal onset neuromuscular 
weakness and a good response to fluoxetine.   
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Mutation εV259L was reported in a French family with a slow channel phenotype.  This 
mutation is also positioned in the M2 domain (Outteryck et al., 2009) and was shown to 
augment AChR permeability to calcium.  In this study, this mutation was detected in the 
same kinship from Germany in which the father and both daughters were affected.   
There was evidence of intra familial phenotypic variability with both daughters 
presenting at much earlier stage than their father and demonstrated moderate fatigable 
weakness.  Both daughters had a beneficial response to quinidine.   
 
Mutation in the δ subunit (S268F) was formerly shown to prolong channel opening 
events (Gomez et al., 2002).  In this study, a mutation (δS268Y) at the same position 
was detected in patient 2, but the resulting amino acid is altered and the exact functional 
consequence is unclear.  Although no functional work was carried out to assess the 
kinetic properties of this mutation, this patient had a positive family history compatible 
with dominant transmission, and showed selective distal extensor forearm and neck 
muscle weakness.  Of note, this patient was unable to tolerate several therapies and 
reported no clear benefit with any.  
 
Overall, the site and kinetic properties (when available) of the slow channel CMS 
mutations did not correlate with the clinical phenotype in any of the fifteen patients 
assessed in this study. 
  
This study also underlined the prolonged time interval in reaching the precise molecular 
diagnosis, which predictably prevented prompt and appropriate treatment in several 
patients.  In some patients particular features such as a dominant pattern of inheritance, 
selective distal extensor forearm and neck muscle weakness, a clear negative response 
to AChE inhibitors are useful clues that could guide clinicians towards the correct 
diagnosis.  
 
Choice, titration and escalation of treatment were explored in the second part of this 
study. It is worth noting that AChE inhibitors, usually contra indicated in slow channel 
CMS, were introduced as first line therapy in most patients.  This highlights the 
importance of a detailed neurological examination to depict any preferential muscle 
involvement and neurophysiology at the time of presentation.  In this cohort, fluoxetine 
was the most frequently used agent once genetic diagnosis was confirmed.  Although 
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fluoxetine had a favourable outcome in several patients, often harbouring different 
mutations; its effectiveness was restricted by substantial side effects.  Furthermore, 
fluoxetine was associated with clear improvement in one patient which was not 
sustained after three years.  It would be helpful to prospectively monitor this cohort to 
ascertain whether this is a common feature with fluoxetine usage or whether this in fact 
relates to a more severe relapsing phenotype in that particular patient.  
 
Fluoxetine is a long acting open channel blocker that curtails the periods of channel 
opening in a concentration dependent fashion (Engel, 2007, Schara and Lochmuller, 
2008).  This agent has been endorsed for the treatment of slow channel CMS based 
upon a prospective study on two patients who were heterozygotes for slow channel 
mutations εT264P and εL269F respectively.  This open label study ran over three years, 
during which patients were assessed both clinically and neuro-physiologically (Harper 
et al., 2003).  Patients were prescribed doses of fluoxetine ranging from 80 to 120mg 
per day and exhibited clear improvement in their neuromuscular weakness.  However, 
in one patient escalation of his fluoxetine dose above 80mg per day was limited by side 
effects including sleep fragmentation and excess sedation as well as loss of appetite. 
An additional concern with fluoxetine, especially in children, is the development of 
suicidal ideation (Whittington et al., 2005).  This was indeed noted in a child with slow-
channel CMS who developed mood disturbance and ideas of self-harm subsequent to 
the introduction of fluoxetine (Kinali et al., 2008).   
 
Quinidine was used either as first line or second line treatment in a small group of 
patients in this study.  This medication was associated with a favourable outcome and 
good side effects profile with most patients tolerating this treatment, which correlated 
with better concordance.  Quinidine is also a long acting open channel blocker 
recommended in slow-channel CMS.  Similar to fluoxetine, it shortens the duration of 
channel opening events in a concentration dependent manner (Engel, 2007, Schara and 
Lochmuller, 2008).  This treatment was shown to improve significantly both functional 
and electrophysiological measurements at a dose of 1-2.5µg/mL (Fukudome et al., 
1998, Harper and Engel, 1998a).  In this prospective open label therapeutic trial, a total 
of six patients were recruited and evaluated over 8 to 14 months.  All patients carried 
known slow channel mutations: βV266M, αN217K, αG153S, αV249F, εL269F and 
εT264P (Harper and Engel, 1998a).   
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Four patients were able to tolerate treatment titration and reported clear benefit.  In two 
patients, a hypersensitivity reaction and deranged liver tests were reported.  Both 
complications resolved once quinidine was withdrawn.  Moreover, one patient 
deteriorated while on treatment and necessitated ventilator support. Of note this patient 
exhibited borderline low respiratory function at the time of recruitment.   
 
In conclusion, the present study provides a useful overview of the clinical phenotype 
and prescribed treatments of a sizeable slow channel CMS group as well as highlights 
potential treatment complications in clinical practice.  Nonetheless, this study is limited 
by its retrospective observational nature, which did not permit for any standardization of 
assessment tools or randomization of patients to different treatment arms, including a 
placebo group.  Accordingly, a collaborative multicentre approach would be key in 
recruiting a sufficient number of subjects to establish a prospective randomized 
controlled study or a head to head trial that would provide a better appreciation of 
optimum therapy for this rare CMS subtype.   
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Chapter 5 Clinical Characterisation of A GFPT1 Related CMS Cohort 
 
 
5.1 Introduction and Aims
54
 
 
The limb girdle CMS (LG-CMS) phenotype is a distinct clinical entity attracting much 
attention since the mid-1960s (McQuillen, 1966).  Perhaps, this is in part due to the 
phenotypic overlap with limb girdle muscular dystrophies, which in contrast to CMS, 
are not treatable.  LG-CMS is associated with marked muscle wasting and weakness of 
the shoulder and hip girdle muscles with minimal ocular, bulbar and facial involvement. 
Patients are noted to exhibit variable response to AChE inhibitors, with some showing 
clear benefit while other exhibiting clear deterioration in neuromuscular symptoms. In 
addition, several patients reported fluctuation in their symptoms over days and weeks 
instead of the typical diurnal variation seen in myasthenia gravis.  At an ultra-structural 
level, abnormalities of varying extent, in the pre and postsynaptic compartment were 
detected in all patients (Slater et al., 2006). 
 
The significant discovery that DOK7 mutations are disease causing in some of these 
patients allowed a better clinical stratification of LG-CMS patients and the realisation 
that some cues, such as a negative response to AChE inhibitors, presence of ptosis and a 
progressive, often disabling course, were an integral part of the DOK7 phenotype 
(Beeson et al., 2006, Palace et al., 2007, Muller et al., 2007a, Anderson et al., 2008).  
Furthermore, some distinct ultra-structural features were recognized with DOK7 
mutations (Beeson et al., 2006), namely, the presence of small motor endplates with 
preserved expression and localisation of crucial endplate proteins as well as intact 
kinetic properties of AChR. This discovery also underscored the functional importance 
of the Dok7 and MuSK signalling pathway in NMJ development (Beeson et al., 2006, 
Bergamin et al., 2010, Yamanashi et al., 2008). 
 
                                                 
54
 Adapted from Guergueltcheva et al 2011(URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
and Chaouch et al (URL: http://jnnp.bmj.com/content/83/3/e1.79) 
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More recently, GFPT1 mutations have been shown to be another important cause of 
LG-CMS in a cohort of 22 patients (Senderek et al., 2011).  Using genome wide linkage 
in a large Libyan consanguineous family, a locus was mapped on chromosome 2p13.3 
and subsequent Sanger sequencing of this region revealed mutations in GFPT1 in this 
family and several other kinships (figure 5.1).  GFPT1 (glutamine-fructose-6-phosphate 
transaminase 1) is the first and rate-limiting step of the hexosamine pathway that leads 
to the biosynthesis of UDP-N-acetylglucosamine.  The latter is an essential substrate for 
protein glycosylation (Haltiwanger and Lowe, 2004).  
 
In this section, I focus on the clinical phenotype and genotype phenotype correlation of 
a sizable GFPT1 associated CMS cohort. My contribution was focussed on analysing 
the clinical data and refining the phenotype genotype correlation.  I have also 
contributed to the draft of the manuscript (Guergueltcheva et al 2011(URL: 
http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) and presented the data 
at the Annual British Association National meeting in 2012 (Chaouch et al (URL: 
http://jnnp.bmj.com/content/83/3/e1.79). 
 
 
5.2 Patient data
55
  
 
A total of fifteen kinships were included in this study with several derived from the 
original cohort described by (Senderek et al., 2011).  From the Senderek cohort, a new 
genetically confirmed family was incorporated into this analysis: LGM 17 and three 
families: LGM4, LGM15 and LGM 16 were excluded as they did not carry GFPT1 
mutations.  In total, 17 males and 7 females with a mean age at report of 31 years were 
studied.  Most patients were Caucasian referred primarily from Europe.  Additional 
families from Iran, Libya, Senegal and Turkey were also included (figure 5.1).  
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 Adapted from Guergueltcheva et al 2011(URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
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Figure 5.1 Pedigrees shown to carry GFPT1 mutations.   Please note that LGM17 is a new family with 
GFPT1 mutations not reported in the original cohort.  Adapted from Senderek et al 2011 (URL: 
http://www.sciencedirect.com/science/article/pii/S0002929711000097) 
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All patients reported normal motor milestones except patients LGM10.4, LGM12.3, 
LGM17.3 and LGM17.4 (table 5.1).  21 out of 24 patients developed neuromuscular 
weakness before or at age 10 years with a range 1- 40 years across the cohort. Patients 
invariably presented with proximal muscle weakness, reporting difficulties climbing 
stairs, lifting the arms above the head and lifting heavy objects.  Patients LGM5.3, 
LGM5.4 and LGM3 displayed upper limb weakness at presentation (Sieb et al., 1996) 
while patient LGM7.3 and LGM8.3 reportedly had equal weakness of the shoulder and 
hip girdle muscles but had first noted difficulties in the hip muscle before progressing to 
the shoulders six years later.  Five patients suffered several falls prior to presentation. 
Most patients reported clear fluctuation in their neuromuscular weakness except patients 
LGM5.3, LGM5.4, LGM7.3, LGM11.3, LGM13.3 and LGM13.4, who had a fixed 
pattern of weakness, reminiscent of limb girdle muscular dystrophies. Patients LGM1, 
LGM2.4, LGM3 family and LGM8.2 reported certain triggers to their weakness such as 
hot weather and infective episodes.  The course of disease was slowly progressive in 
most, often preceded by a static phase in the first 10-20 years. Twenty-one out of the 
twenty-four patients remained ambulant.  Neurological assessment revealed minimal 
ocular involvement with only one patient (LGM7.3) noted to exhibit mild bilateral 
ptosis. None of the patients showed ophthalmoparesis.  Facial weakness was rare with 
only five patients being affected: LGM1.4, LGM1.5, LGM5.4, LGM7.3 and LGM8.3 as 
was neck flexion weakness noted in patients LGM7.3, LGM12.3, LGM12.4 and 
LGM5.4 (table 5.1).  
None of the patients were reported to have bulbar difficulties.  In the limbs, shoulder 
and hip girdle muscle involvement was a consistent finding in all patients. Distal muscle 
weakness, affecting long finger flexors, extensors as well as foot extensors muscles, was 
observed in the following patients: LGM1, LGM5.3, LGM5.5, LGM7.3, LGM8.3 and 
LGM12.3.  Patient LGM7.3 suffered a more severe phenotype, losing ambulation at 4 
years and exhibiting more generalised muscle weakness.  He also developed respiratory 
insufficiency but has yet to require respiratory support.
56
  
 
Additional features were noted in some patients: Patients LGM17.3 and LGM17.4 were 
both reported to exhibit intellectual disability. Patient LGM7.3 developed early 
strabismus and was later diagnosed with retinitis pigmentosa at the age of 5 years. Both 
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 Adapted from Guergueltcheva et al 2011(URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
 
   
100 
 
LGM1.4 and LGM1.5 were reported as visually impaired and had an established 
diagnosis of macular degeneration.  In this cohort, no other patients were reported to 
have visual impairment or retinal disease, although formal retinal assessments were not 
routinely carried out
57
. 
 
 
 
 
                                                 
57
 Adapted from Guergueltcheva et al 2011(URL: http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
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Kinship/gender Mutation  Age at onset / 
age at report  
Symptom at onset / motor 
milestones 
Facial / bulbar / respiratory 
muscle weakness / other 
Limb girdle weakness / 
fluctuations / course 
Response to 
AChE 
inhibitors 
LGM1.4/m p. D348Y  6y/31y Muscle weakness, fatigue, 
worse in summer/normal 
Yes/no/no/no/distal limb Yes/yes/improving after age 20 Positive but side 
effects 
LGM1.5/m p. D348Y  6y/26y Muscle weakness, fatigue, 
worse in summer/normal 
Yes/no/no/no/distal limb Yes/yes/improving after age 20 Positive but side 
effects 
LGM2.4/f p. W240X  6y/26y Muscle weakness, fatigue 
and pain/normal 
None Yes/yes/worsening Positive 
LGM3.3, LGM3.5, 
LGM3.6, LGM3.8, 
LGM3.9/2m, 3f 
p. R111C  6y/23-35y Muscle weakness, 
fatigue/normal 
None Yes, shoulder>pelvic 
girdle/ND/ND 
Partially 
positive 
LGM5.3/m p. M492T; c. 
*22C>A 
14y/55y Weakness in the upper 
limbs/normal 
No/no/no/distal limb Yes/no/slight worsening Positive 
LGM5.4/f p. M492T; c. 
*22C>A 
40sy/54y Weakness in shoulder 
girdle/normal 
No/no/no/neck muscles Yes/no/slight worsening  
LGM5.5/m p. M492T; c. 
*22C>A 
10y/50y Muscle weakness, 
falls/normal 
No/no/no/distal limb Yes/yes/slight worsening Positive, +3,4 
DAP 
LGM6.4/m p. D43V; p. 
I121T 
5y/16y Muscle weakness/normal None Yes/yes/slight worsening Positive 
LGM7.3/m P.R385H; p. 
R434H 
8y/23y Fatigue on walk/slight 
delay 
Yes/no/slight/slight neck and 
distal limb weakness 
Yes, shoulder and pelvic 
girdle/no/worsening 
Positive +3,4 
DAP 
LGM8.3/m p. T15M; p. 
R496W 
6y/37y Repeated falls/normal Yes/no/no/ distal limb Yes, shoulder and pelvic 
girdle/yes/ improving after age 
20 
Positive +3,4 
DAP 
LGM9.3/f p. V199F; c. 
*22>A 
13y/26y Fatigue/normal None Yes/yes/stable Positive 
 
Table 5.1 Clinical features of patients with GFPT1 mutations. m; male, f; female, y; year, ND; not detected, AChE ; acetylcholinesterase. Adapted from Guergueltcheva et al 
2011(URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
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Kinship/gender Mutation Age at onset / 
age at report  
Symptom at onset / motor 
milestones 
Facial / bulbar / 
respiratory muscle 
weakness / other 
Limb girdle weakness / 
fluctuations / course 
Response to ache 
inhibitors 
LGM10.4/f p. R512W  1y/7y Muscle weakness, 
falls/normal 
None Yes/yes/worsening Positive +3,4 DAP 
LGM11.3/m p. M491T  7y/19y Muscle weakness/normal None Yes/no/stable Positive +3,4 DAP 
LGM12.3/f c.1278_1281dup; 
c.*22C>A 
1y/37y Muscle weakness, falls/slight 
delay 
No/no/no/neck and distal 
muscles 
Yes/yes/worsening Positive +3,4 DAP 
LGM12.4/m c.1278_1281dup; 
c.*22C>A 
10y/39y Muscle weakness /normal No/no/no/neck muscles Yes/yes/worsening Not known 
LGM13.3/m c. T15A; 
c.621_622del 
10y/55y Muscle weakness/normal None Yes/no/ worsening Positive 
 
LGM13.4/m DNA not available 7yr/36y Muscle weakness/normal None Yes/no/ND Positive 
 
LGM14.3/m p.222_223ins;  
p.R111C 
10y/40y Muscle weakness/normal None Yes/yes/worsening Positive +3,4 DAP 
 
LGM17.3/f p. M491T; 
c.714_715ins 
8y/9y Frequent falls, fatigability, 
when, walking/delayed 
Learning difficulties Yes/yes/worsening Positive at first, but effect 
lost after 3 years despite 
adding 3,4 DAP 
LGM17.4/m p. M491T; 
c.714_715ins 
7y/13y Difficulties in running, 
fatigability when walking/ 
normal 
Learning difficulties Yes/yes/worsening Positive at first, but effect 
lost after 3 years despite 
adding 3,4 DAP 
 
Table 5.1(cont.) Clinical features of patients with GFPT1 mutations.  Adapted from Guergueltcheva et al 2011 (URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z)
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5.3 Ancillary investigations
58
 
 
Before screening for any mutations in CMS genes, patients were checked for anti-AChR 
antibodies to exclude autoimmune myasthenia gravis. Three main investigations were 
reviewed in this cohort: creatine kinase (CK) levels, neurophysiological studies and 
muscle biopsies (table 5.3).  
 
Kinship CK  Decrement/muscle sampled 
Myopathic 
EMG  
Tubular aggregates on 
muscle biopsy 
LGM1.4 X1.5 Yes/proximal ND Yes 
LGM1.5 X1.5 Yes/deltoid Yes ND 
LGM2.4 No Yes/distal Yes Yes 
LGM3.3, LGM3.5, 
LGM3.6, LGM3.8, 
LGM3.9 
No Yes/trapezius Yes 
Yes, biopsy performed in 
one of the siblings 
LGM5.3 X1.5 Yes/deltoid Yes TAs 
LGM5.4 No Yes/deltoid ND ND 
LGM5.5 X1.5 Yes/deltoid Yes TAs 
LGM6.4 X2-8 Yes ND Yes, on re-revision 
LGM7.3 X2 Yes/anconeus ND Yes 
LGM8.3 X5-10 Yes ND Yes 
LGM9.3 No Yes/trapezius Yes Yes, on revision 
LGM10.4 No Yes/trapezius Yes Suggestive 
LGM11.3 No No/distal Yes One inclusion 
LGM12.3 No Yes/proximal Yes ND 
LGM12.4 No Yes/deltoid Yes Yes 
LGM13.3 Minimal Yes/trapezius Yes Yes 
LGM13.4 Minimal Yes/proximal Yes Yes 
LGM14.3 X12 Yes/proximal and distal Yes Yes 
LGM17.3 Minimal No/distal ND/ND No 
LGM17.4 Minimal ND ND/ND No 
 
Table 5.3: Results of ancillary investigations in GFPT1 CMS cohort. ck; creatine kinase, ND; not done, 
EMG; electromyography, TA; tubular aggregates. Adapted from Guergueltcheva et al 2011(URL: 
http://link.springer.com/article/10.1007%2Fs00415-011-6262-z). 
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 Adapted from Guergueltcheva et al 2011(URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
 
   
 104 
Creatine kinase levels were available in 12 patients and ranged from normal to 12 times 
the upper limit of normal.  Indeed, three patients, LGM6.4, LGM8.3 and LGM14.3, 
were reported to have levels between 8 and 12 times the normal range.   
 
Neurophysiological reports were available in 19 patients. None had evidence of a large 
fibre neuropathy on nerve conduction studies.  EMG reports were accessible in 13 
patients. These revealed mild myopathic features with no spontaneous activity. 
Repetitive nerve stimulation reports were available in 19 patients. These showed 
decrement in all patients when the proximal muscles were sampled.  In patients 
LGM1.4, LGM1.5, LGM5.4, LGM10.4, LGM11.3 and LGM17.3, no decrement was 
detected in the distal muscles. On the other hand, abnormal jitter (when SFEMG was 
done) was observed in all patients.  One patient showed double CMAP on single nerve 
stimulation, typically seen in COLQ and slow channel CMS. This finding was detected 
on two separate occasions and reproducible on and off AChE inhibitors (table 5.3).  
 
A total of 18 muscle biopsies were available.  These were from, biceps brachii, vastus 
lateralis, biceps brachii, deltoid, and quadriceps muscles. The site of the muscle 
biopsies was not documented in three patients. Most muscle biopsies showed non-
specific or mild myopathic changes. Three patients showed type 1 fibre predominance.  
The muscle biopsy findings (NADH and EM appearances) of LGM3 and 4 families 
were previously published (Rodolico et al., 2002, Sieb et al., 1996).  Tubular aggregates 
(TAs) were confirmed in 13 biopsies (figure 5.2, table 5.3 and 5.4).  These were 
visualized using NADH staining in 7 patients and EM in 5 patients.  In patients 
LGM5.3, LGM5.5 and LGM12.4, several small subsarcolemmal aggregates were noted 
on NADH staining but were subsequently confirmed to be tubular aggregates.  These 
would have been overlooked should a second evaluation with EM have not been carried 
out.  In two patients, NADH staining was inconclusive and no further EM study was 
performed. Morphological review of the motor endplates was available in only one 
patient and showed simplified postsynaptic membranes with seemingly preserved 
presynaptic architecture. 
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Figure 5.2: Example of tubular aggregates. (arrow). Top image: NADH staining of tubular aggregates in 
muscle biopsies of GFPT1 patients.  Bottom image:  Electron microscopy appearance of tubular 
aggregates beneath the sarcolemma.  Reproduced from Chaouch and Lochmuller 2013, 86 -94, © John 
Wiley & Sons, Ltd 
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Patient Muscle 
sampled 
NADH and EM 
findings 
Other findings 
LGM1.4 Biceps brachii Yes, NADH staining Fibre size variation, type 1 fibre 
predominance, round or angular 
fibres 
LGM2.4 Vastus 
lateralis 
Yes, TAs exclusively in 
type 2 fibres 
Chronic myopathic changes 
LGM3  Biceps brachii Yes, small 
subsarcolemmal 
aggregates (NADH), 
TAs in EM 
- 
LGM5.3 Deltoid Yes, subsarcolemmal 
aggregates (NADH), 
TAs in EM 
Mild myopathic changes, type 1 
fibre predominance and ragged red-
like fibres 
LGM5.5 Deltoid Yes, subsarcolemmal 
aggregates (NADH), 
TAs in EM 
Unspecific myopathic changes, type 
1 fibre predominance, ragged red-
like fibres 
LGM6.4 Unknown Yes, NADH staining Unspecific myopathic changes 
LGM7.3 Unknown Yes Muscle atrophy, multiple internal 
nuclei, vacuoles, features consistent 
with denervation 
LGM8.3 Unknown Yes - 
LGM9.3 Biceps brachii Yes - 
LGM10.4 Deltoid Unclear suggestive of 
TAs (NADH) 
Uneven oxidative staining, 
accumulation of mitochondria 
LGM11.3 Deltoid Probably no, one fibre 
with a possible inclusion 
(NADH) 
- 
LGM12.3 Deltoid NADH and EM not done Unspecific myopathic changes 
LGM12.4 Biceps brachii Yes, enhancement and 
subsarcolemmal 
aggregates (NADH), tas 
in EM 
Unspecific myopathic changes 
LGM13.3 Vastus 
lateralis 
TAs in EM - 
LGM13.4  Vastus 
lateralis 
Yes - 
LGM14.3 Deltoid Yes, frequent fibres with 
TAs, TAs in EM 
Increased fibre size variability. 
Frequent fibres with internalized 
nuclei and autophagic vacuoles 
LGM17.3 Quadriceps No Fibre size variability, oxidative 
enzyme staining showed type 2 
predominance with occasional core-
like areas and subtle uneven staining 
LGM17.4 Quadriceps No Fibre size variability, oxidative 
enzyme staining was pale and 
inconclusive 
 
Table 5.3. Muscle biopsy findings in GFPT1 cohort.  TAs; tubular aggregates. Adapted from 
Guergueltcheva et al 2011(URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
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5.4 Treatment response
59
  
 
All patients received a trial of AChE inhibitors except patients LGM5.4 and LGM12. 
(table 5.1).  AChE inhibitors were used as monotherapy in thirteen patients and in 
combination with 3,4-DAP in nine patients: LGM 5.5, LGM7.3, LGM8.3, LGM10.4, 
LGM11.3, LGM12.3, LGM14.3, LGM17.3 and LGM17.4.  The introduction of 3,4-
DAP was helpful in all patients except two (LGM17.3 and LGM17.4).  Treatment was 
beneficial in 20 out of the 22 treated patients.  Patients received a dose of AChE 
inhibitors ranging from 80 to 540 mg.  In patients LGM1.4 and LGM1.5, dose titration 
was limited by side effects.  Indeed, although AChE inhibitors led to significant 
improvement at a dosage of 2.8mg/kg/day in the older brother and 2.4mg/kg/day in the 
younger brother, treatment was withdrawn due to increased muscle twitching as well as 
mood disturbance.  Patients LGM17.3 and LGM17.4 showed a clear but transient 
benefit from AChE inhibitors with evidence of relapse after three years (table 5.1).  
 
 
5.5 Discussion
59
 
 
This clinical study was primarily based on the cohort first described in the seminal 
paper (Senderek et al., 2011), reporting novel mutations in GFPT1 in a sizeable cohort 
of patients with a LG-CMS phenotype.  Three case series have since described 
additional patients with both known and novel GFPT1 mutations (Huh et al., 2012, 
Selcen et al., 2013, Maselli et al., 2013).  Furthermore, three other glycosylation genes 
have been implicated with a similar LG-CMS phenotype: DPAGT1, ALG2 and ALG14 
(Belaya et al., 2012, Cossins et al., 2013). 
 
For this study, a total of 15 independent kinships were recruited from different 
geographical origins including Europe, North Africa and Sub-Saharan Africa, Asia and 
the Middle East with no particular clustering or founder effect reported.  
 
I was interested to note the relatively early age at onset of most patients, presenting in 
their first decade of life, but also the delay in diagnosing CMS in such patients, with a 
mean time to diagnosis of 21.5 years.  This clearly may have implications in terms of 
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 Adapted from Guergueltcheva et al 2011(URL:  http://link.springer.com/article/10.1007%2Fs00415-011-6262-z) 
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instigating early therapy and potentially reducing long-term disability.  Fluctuation in 
neuromuscular weakness was present in three quarters of the patients and the course of 
disease was relatively mild with most patients retaining ambulation 20 years after 
presentation.  In this cohort only one patient was reported to have lost ambulation at the 
age of 4, and went on to develop early respiratory insufficiency.  
 
In this study, all patients exhibited a distinctive and relatively homogenous phenotype, 
with a predominant proximal pattern of muscle weakness with minimal ocular 
involvement, a positive response to AChE inhibitors and evidence of tubular aggregates 
on muscle biopsy.  This constellation of clinical and histological features has been a 
consistent finding in other newly reported GFPT1 patients (Huh et al., 2012, Selcen et 
al., 2013, Maselli et al., 2013).  These features were also key in the identification of 12 
mutation positive patients out of 39 screened in the Munich cohort, corresponding to 
one of the highest mutation detection rate (31%) in the Munich database.  Interestingly, 
sequencing of another cohort of 52 undiagnosed CMS patients, with variable phenotype 
and no tubular aggregates, did not yield any mutation positive patients, which reinforces 
the hypothesis that there is a strong genotype phenotype correlation with GFPT1 
mutations.  I was interested to note evidence of retinitis pigmentosa in LGM1and 
macular degeneration in LGM7.3.  Since no additional GFPT1 patients have been 
reported with these clinical features, it seems reasonable to speculate that such findings 
are either incidental or a very rare association with GFPT1 mutations.  
 
In terms of ancillary tests, the levels of creatine kinase were moderately elevated in a 
few patients (LGM 6.4, LGM 8.3 and LGM 14.3).  However these did not correlate 
with the extent and severity of muscle disease nor did they correspond to evidence of 
significant myopathic or dystrophic changes on muscle biopsy. Nonetheless, a 
myopathic EMG was reported in more than half of our cohort which can certainly 
mislead clinicians to consider a primary myopathy as a diagnosis; as was the case in 
several of our patients initially diagnosed with limb girdle muscular dystrophy.   
The presence of decrement was key in ascertaining that patients had a neuromuscular 
junction disorder.  In this study, decrement was always present when proximal muscles 
were assessed.  However, repetitive nerve stimulation of the distal muscles showed no 
decrement in a quarter of all patients.  By contrast, abnormal jitter was detected in all 
patients tested.  This highlights the importance of extensive sampling, of both proximal 
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and distal muscles and SFEMG in confirming any defect related to the neuromuscular 
junction.  
 
Furthermore, a clear genotype histo-pathological correlation was noted in most patients 
since all muscle biopsies, except two, contained tubular aggregates either on NADPH or 
EM analysis.  The two patients with no TAs on muscle biopsy were some of the 
youngest in this cohort and may therefore develop these tubular structures later in life 
since TAs form in an age dependent fashion in inbred male mice (Agbulut et al., 2000).  
GFPT1 mutations seem to be directly linked to defects in NMJ function, but the 
formation of tubular aggregates is not predictive of NMJ dysfunction since screening of 
patients with muscular weakness and tubular aggregates without evidence of impaired 
NMJ transmission did not detect mutations in GFPT1.   
Indeed, tubular aggregates are a nonspecific histo-pathological finding associated with a 
variety of muscle conditions including alcohol and drug induced myopathies, inherited 
myopathies, inflammatory myositis, periodic paralysis, dyskalaemia, myotonia 
congenita (Funk et al., 2013, Engel et al., 1970, Pavlovicova et al., 2003).   
 
TAs have previously been shown to represent re-organization of the sarcoplasmic 
reticulum and manifest as densely packed tubular membrane structures of variable 
shape and size (Pavlovicova et al., 2003, Chevessier et al., 2005). A number of proteins 
have been consistently present in TAs, including SAR-1 thought to reflect the 
involvement of the endoplasmic reticulum in the formation of these tubular structures 
and proteins participating in calcium homeostasis (Chevessier et al., 2005). The recent 
discovery of mutations in the main Ca2+ sensor on the endoplasmic reticulum (Stromal 
interaction molecule 1 (STIM1)), in association with a dominant congenital myopathy 
with tubular aggregates (Bohm et al., 2013), seems to reinforce the idea that both the 
ER and calcium may be important players in TAs formation.   
 
Another important cause of LG-CMS includes mutations in DOK7 (table 5.5), which 
accounted for 10% of all mutations in the Munich database (see chapter 3).  These 
mutations were shown to account for half of all patients exhibiting an LG-CMS 
phenotype (Palace et al., 2007). Other rare causes of proximal fatigable limb weakness 
include RAPSN and COLQ mutations, which accounted for 15% and 12% of all 
mutations in the Munich database and should be considered in the differential diagnosis 
(Mihaylova et al., 2008, Muller et al., 2003).   
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Several reports have highlighted a number of distinct characteristics that can allow 
physicians to distinguish the DOK7 and glycosylation defect linked CMS (Beeson et al., 
2006, Muller et al., 2007a, Palace et al., 2007, Selcen et al., 2008, Huh et al., 2012, 
Selcen et al., 2013, Cossins et al., 2013, Monies et al., 2014, Maselli et al., 2013, 
Guergueltcheva et al., 2011).  Indeed, DOK7 mutation positive patients were shown to 
present earlier, usually in the first 2 years, and often have clear ptosis with facial and 
bulbar weakness.  In addition, DOK7 associated CMS seems to result in a more 
aggressive disease course with several patients reported to lose ambulation and require 
ventilator support over time (Eymard et al., 2013). The negative response to AChE 
inhibitors is significant and can be utilized as an objective tool to distinguish DOK7 
from GFPT1 linked CMS.  The former is usually treated with ephedrine and salbutamol 
(Schara et al., 2009, Lashley et al., 2010).  Lastly, tubular aggregates have never been 
reported in association with DOK 7, RAPSN or COLQ mutations and should raise the 
clinical suspicion of glycosylation defects. 
 
 
  GFPT1 DOK7 
Onset 1
st
 decade (birth – forties) 2nd year of life (birth – late 20s) 
Ocular involvement No Ptosis with no ophthalmoparesis 
Facial muscles Rarely affected Affected 
Bulbar muscles Not affected Affected 
Respiratory problems No Can be affected 
Course of disease 
Progressive in half but all 
retained ambulation 
Progressive with loss of ambulation 
in some 
CK Can be elevated Can be elevated 
Tubular aggregates Present None 
Endplate pathology Unspecific changes Small simplified endplates 
Treatment Pyridostigmine Ephedrine, salbutamol 
 
Table 5.4: Comparison of GFPT1 CMS with DOK7 CMS phenotype. CK; creatine kinase.  Reproduced 
from Chaouch and Lochmuller 2013, 86 -94, © John Wiley & Sons, Ltd. 
 
Since the publication of our report,  Selcen et al., 2013 described 11 patients with LG-
CMS with GFPT1 mutations and provided valuable details in terms of the homogenous 
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clinical phenotype, the ultra-structural appearance at the motor endplates and kinetic 
abnormalities.  Remarkably, one patient was heterozygous for a null allele and a splice 
site mutation disrupting the muscle specific exon.  This patient exhibited the most 
severe and disabling phenotype described so far in association with GFPT1 mutations.  
In addition to reduced foetal movements in the antenatal period, the patient was 
arthrogrypotic and suffered apnoeic episodes soon after birth, with marked bulbar and 
limb weakness. The patient was non-ambulant and showed little response to AChE 
inhibitors.  In this particular patient, glycoprotein expression was absent in muscle 
tissue.   
In addition to tubular aggregates, rimmed vacuoles in three out of nine muscle biopsies 
were observed.  At an ultra-structural level, abnormalities within the muscle fibres were 
also observed including apoptotic nuclei and autophagic vacuoles.  The motor endplates 
were often poorly developed with synaptic contact of small and varying morphology 
ranging from single to grape-like appearance.  The density of AChR was comparable to 
controls in all but one study.  Patch clamp analysis showed a presynaptic defect in 
some, with reduced quantal release, and postsynaptic changes in others with impaired 
response to acetylcholine.  This study underscored the significant ultra-structural 
variability at the NMJ in spite of a clinically homogeneous phenotype.  
 
GFPT1 is ubiquitously expressed and mediates the biosynthesis of N-acetylglucosamine 
(UDP-GlcNAc), which is a substrate for N-linked and O-linked protein glycosylation 
(Wellen and Thompson, 2012, Haeuptle and Hennet, 2009).  Morphological studies of 
the motor endplate of patient LGM14.3 showed non-specific abnormalities and the 
ultra-structural data were unable to define the primary defect underlying impaired 
neuromuscular transmission.  Mutations in GFPT1 have since been shown to affect 
neuromuscular junction transmission by reducing cell surface muscle AChRs at motor 
endplates (Zoltowska et al., 2013). 
 
Importantly, three glycosylation genes, DPAGT1, ALG2 and ALG14, have since been 
identified in patients with LG-CMS with minimal ocular and facial involvement and a 
beneficial response to AChE inhibitors (Belaya et al., 2012, Selcen et al., 2014, Cossins 
et al., 2013).   
 
All DPAGT1 patients had LG-CMS with tubular aggregates, abnormal jitter with block, 
and a good response to AChE inhibitors.  The latter was sometimes prescribed in 
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conjunction with 3,4-DAP and salbutamol.  Ultra structural studies revealed reduced 
postsynaptic folding and AChR density. Pharmacological inhibition of DPAGT1 was 
shown to reduce cell- surface AChR expression in vitro (Belaya et al., 2012, Finlayson 
et al., 2013).   
 
ALG14 mutations were described in an affected sib pair presenting in infancy with 
predominant proximal weakness, contractures, evidence of abnormal jitter and block 
and a good response to AChE inhibitors.  No Tubular aggregates were detected (Cossins 
et al., 2013).  
 
ALG2 mutations were reported in 2 consanguineous kinships of Saudi Arabian and 
Italian descent respectively (Cossins et al., 2013). Both had an LG-CMS phenotype with 
abnormal jitter, minimal facial, bulbar and ocular weakness and evidence of tubular 
aggregates in one family.  Remarkably in the Saudi family, patients were also noted to 
have proximal contractures with distal laxity, reminiscent of an extra cellular matrix 
disorder (Bushby et al., 2014). They were non ambulant and had learning difficulties. 
The patient’s biopsy showed myopathic changes but no tubular aggregates.  ALG2 
expression levels in patients’ muscle were significantly reduced compared to controls 
and knockdown of ALG14 expression impaired AChR expression on the cell surface 
(Cossins et al., 2013). 
 
There are several reports in the literature that have described patients with LG-CMS 
with no tubular aggregates (Palace et al., 2007, Rodolico et al., 2002, Chevessier et al., 
2005, Slater et al., 2006, Azulay et al., 1994, Dobkin and Verity, 1978, Furui et al., 
1997, Zephir et al., 2001).  It seems reasonable to consider screening these patients for 
DPAG1, ALG2, ALG14 and GFPT1as absence of TAs does not exclude an underlying 
glycosylation defect.  
 
In conclusion, defects in GFPT1 and N-linked glycosylation genes have reinforced the 
paradigm in which ubiquitous proteins can selectively alter the structure and function of 
the neuromuscular junction.  Despite the relatively homogeneous clinical phenotype, we 
noted striking ultra-structural variability of motor endplates, encompassing both the pre 
and postsynaptic compartments. In vitro work so far has shown the important role of 
impaired AChR glycosylation in causing NMJ dysfunction.  Nevertheless, the preserved 
postsynaptic AChR density in several patients suggests that other mechanisms are at 
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play and require further study.  Furthermore, evidence of intellectual disability and 
retinal disease in occasional patients may suggest that a deeper phenotyping of patients 
is required to look for other organ involvement which may be subclinical.  
Glycosylation is a crucial posttranslational modification step that dictates the structure; 
location, stability and function of proteins and one may speculate that several aspects of 
the NMJ may be deranged at any one particular time and patient. 
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Chapter 6. Gene Discovery Using Exome Sequencing 
 
 
6.1 Introduction and aims  
 
Gene identification is an essential step to the understanding of disease biology, which 
could point towards potential drug targets, ultimately resulting in better care for 
patients.  Conventional gene discovery has relied on either candidate gene approaches, 
which require a comprehensive understanding of the biology of the disease or positional 
cloning, based on linkage analysis that defines a candidate region likely to include the 
disease gene.  The main caveat to this approach has been the need for large families to 
increase statistical power, and failure of linkage studies to cope with phenocopies and 
incomplete penetrance.  
 
Most CMS genes have been identified using position independent strategies, which 
requires a deep understanding of the disease pathophysiology and biology (Sine et al., 
1995, Engel et al., 1996a).  Only two genes (GFPT1 and CHRNE) were discovered by 
linkage studies in large consanguineous families (Senderek et al., 2011, Ohno et al., 
1998b).  More recently exome sequencing has allowed four additional disease causing 
genes to be unravelled (figure 6.1) (Belaya et al., 2012, Cossins et al., 2013). 
 
 
 
Figure 6.1. Strategies applied for CMS gene discovery.  
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Until recently, only half of all inherited Mendelian disorders were associated with a 
gene defect and in particular, with mutations found in the coding regions of the genome 
(exome) (Chen et al., 2010).  Thus, whole exome sequencing has been proposed as an 
alternative screening strategy for disease gene identification; with clear advantages over 
conventional sequencing, being able to sequence all genes in one run and only requiring 
a few patients.  
 
Ng and colleagues were able to show in a proof of concept study that whole exome 
sequencing combined with a filtering methodology can accurately determine the 
molecular basis of a known disease gene (Ng et al., 2009). This approach relied on 
targeted exome capture with oligonucleotide probes.  Target sequences were amplified 
in a massively parallel fashion and unwanted sequences were discarded (Mamanova et 
al., 2010). Predictably, a colossal number of sequencing data were generated through 
this process, which proved to be an inherent challenge to this technique.  The same 
authors were first to describe a stepwise filtering approach to analyse sequencing 
variants whereby genes containing non synonymous changes, splice site mutations or 
coding indels (small nucleotide deletions and insertions) were prioritized, while 
common variants that were presumed to be non-pathogenic were excluded.  Variants 
predicted to be non-deleterious were also removed during this process (Kuhlenbaumer 
et al., 2011).  
 
Depending on the number of individuals available for exome screening, different 
approaches have been applied by different groups to isolate disease-causing variants in a 
candidate gene. Although possible, disease gene discovery based on a single affected 
individual remains very difficult (Pierce et al., 2010).  Alternatively, the “intersecting” 
filtering method aiming at detecting mutations shared between several affected 
individuals has been more effective. Indeed, Ng and colleagues applied this strategy to 
identify DHODH and MLL2 as the disease causing genes in Miller and Kabuki 
syndromes respectively (Ng et al., 2010a, Ng et al., 2010b).   
 
Another important group of patients where a linkage approach has not been possible 
includes sporadic cases in whom de novo mutations are presumed to be the culprit. 
Recently, exome sequencing on several “trios” composed of both parents and an 
affected child successfully isolated a convincing candidate gene (Vissers et al., 2010).   
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Lastly, family based filtering strategies have been shown to be successful in disease 
gene identification.  These focus on shared homozygous or heterozygous genomic 
regions between related individuals.  This approach has also been combined with 
linkage or homozygosity mapping in consanguineous families with positive results 
(Vermeer et al., 2010, Rehman et al., 2010, Wang et al., 2010a).  
 
In this chapter, the clinical details of a cohort of undiagnosed CMS patients selected for 
exome sequencing are reviewed along with the results of prioritized variants identified 
through exome sequencing.  I searched the Munich and Newcastle CMS cohorts for 
suitable patients for novel gene discovery and ensured that known CMS genes 
corresponding to the phenotype were excluded.  I designed a strategy to analyse the data 
and carried out all the sequencing of candidate variants, segregation analysis and 
screening of variants in undiagnosed patients.  I also identified independent kinships 
that were later shown to share the same genotype.  The bioinformatics work was carried 
out by Dr Helen Griffin and Dr Steven Laval at the Institute of Genetic medicine, 
Newcastle University.  
 
 
6.2 Patient selection 
 
The first step for patient selection was to focus on families in whom more than one 
individual was affected.  The rationale for this was to limit data analysis to 
chromosomal regions shared between two or more siblings.  In consanguineous 
families, the focus was on shared homozygous segments. 
 
Both the Munich and Newcastle CMS cohorts were searched for suitable patients. In the 
Munich undiagnosed cohort, seventy-two kinships were reported to have more than one 
affected individual and twenty-five of these were consanguineous.  In Newcastle, one 
consanguineous family with two affected siblings was captured out of a cohort of 
fourteen kinships.  An important criterion in this selection process was access to both 
clinical and genetic data of patients.   
 
The next step was to evaluate the robustness of the clinical diagnosis of congenital 
myasthenic syndrome in this subset of patients, based on the reported clinical phenotype 
and in conjunction with the results of their ancillary investigations.  Certain clinical 
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features such as neonatal onset disease, ocular involvement, apnoeic crises in the 
neonatal period, a response to AChE inhibitors and evidence of decrement were sought.  
Table 6.1 shows the clinical details of the six sibpairs selected for exome sequencing.   
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Patient  Age at 
onset 
(yrs) 
Motor 
delay 
Pattern of muscle involvement Other features Fatigability Decrement CK Muscle 
biopsy 
Positive response to 
AChE inhibitors 
Ocular Bulbar Limbs Respi-
ratory  
Global 
weak 
Prox > 
Dist 
Dist > 
Prox 
CMS-OV1 Birth + Ptosis  + + + - + Pseudoesterase 
deficiency 
+ NA NA  NA + 
CMS-OV2 Birth  - Ptosis  + + + - - High arched palate + - N N + 
CMS-MA1 Birth  - Ptosis + + - - -  Unclear + N NA - 
CMS-MA2 Birth  - Ptosis + + - - -  Unclear + N NA - 
CMS-GH1 1 + - + +  - - + Hypercalciuria - NA N NA + 
CMS-GH2 Birth  + - + + -  -  - Hypercalciuria and 
premature puberty, 
scoliosis 
- + N NA  + 
 
Table 6.1. Clinical details of the six families selected for exome sequencing. Yrs; years, Prox; proximal, Dist; distal, NA; not available, N; normal, CK; creatine kinase, - absent, +; 
present. 
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Patient  Age 
at 
onset 
years 
Motor 
delay 
Pattern of muscle involvement Other features Fatigability Decrement CK Muscle biopsy Positive 
response to 
AChE 
inhibitors Ocular Bulbar Limbs Respi-
ratory  
Global 
weak 
Prox 
> Dist 
Dist > 
Prox 
CMS-NO1 1  + Ptosis  + + - - - Obsessive 
compulsive 
disorder, 
autonomic 
dysfunction 
+ No, increased 
jitter 
N Possible 
transmitter release 
defect on patch 
clamp 
-, (on 3,4-DAP) 
CMS-NO2 1   + Diplopia - + - - + Moderate 
Learning 
difficulties 
+ NA N NA Equivocal 
CMS-SC1  3-6  + Ptosis  + + - - - Muscle 
atrophy 
- - ↑ Neurogenic, 
normal staining of 
AChE 
+ 
CMS-SC 2 3-6  + Ptosis  + + - - - Muscle 
atrophy 
- - ↑ Neurogenic, 
normal staining of 
AChE 
+ 
CMS-EN1 14-15  - - - + - + - Distal limb 
atrophy 
- Yes with 
facilitation  
N Myopathic NA 
CMS-EN2 17 - - - + - + - Distal limb 
atrophy 
- Yes with   
facilitation  
N Myopathic NA 
 
Table 6.1. (cont.).  
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The final step was to ensure that most known CMS genes were excluded either via 
direct sequencing or linkage based on the reports available in the Munich diagnostic 
centre, Dresden and Oxford. Table 6.2 provides details of the genes excluded in 
individual kinship. Three of the families were noted to be consanguineous. 
  
By process of elimination, a total of 12 affected individuals from 6 unrelated kinships 
were deemed suitable for exome sequencing.  Of these, one consanguineous family was 
from Newcastle (CMS-NO) and 5 from the Munich CMS database (figure 6.2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.2.  Pedigrees of the six undiagnosed families selected for exome sequencing, Details of the 
patients’ geographical origin also included
CMS-NO 
UK 
CMS-GH 
Iran 
CMS-OV 
Turkey 
CMS-EN 
Norway 
CMS-SC 
Germany 
CMS-MA 
Italy 
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Kinship Ethnicity Consanguinity Presumed 
inheritance 
Genes excluded  Other features 
    Direct sequencing Linkage  
CMS-NO United 
Kingdom 
+ (1st cousins) Recessive  CHRNA1, CHRNB1, CHRND, 
CHRNE, RAPSN, CHAT, DOK7, 
COLQ, MD1 
COLQ, CHRNA1, CHRNB1, 
CHRNE, CHAT, RAPSN, MUSK, 
SCN4A, CNTN1, DOK7, GFPT1  
CMS-NO2 has microdeletion on 
X chromosome 
CMS-OV Turkey  + (1st cousins) Recessive  CHAT, COLQ, CHRNE, 
CHRNA1, CHRNB1, CHRND, 
DOK7, RAPSN 
CHRND, CHRNE, SCN4A, 
MUSK, CNTN1, AGRN, GFPT1 
Paternal grandparents also first 
cousins and father may be 
symptomatic (ptosis and 
decrement but no limb weakness).  
Father also has pseudoesterase 
deficiency 
CMS-EN Norway No  Recessive CHRNE, CHRNB1, COLQ, 
RAPSN, DOK7, CNTN1 
All excluded except CHRNE, 
CHRNB1 and COLQ 
 
CMS-SC Germany No  Recessive but in 
database father 
affected! 
CHRNE, CHRNA1, CHRNB1, 
CHRND,  DOK7 
COLQ, CHAT, RAPSN, SCN4A, 
DOK7, GFPT1 
3 affected siblings (monozygotic 
twins)  
CMS-GH Iran + (2
nd
 cousins) Recessive CHAT and COLQ ACHE, CHRNA1, CHRNB1, CHRND, CHRNE, RAPSN, MUSK, 
DOK7 CNTN1, SCN4A, AGRN, GFPT1 
CMS-MA Italy No  Recessive  CHRNE, COLQ, DOK7, MUSK ACHE, COLQ, CHRNA1, CHRNB1, CHRND, CHRNE, CHAT, 
RAPSN, CNTN1 
 
Table 6.2.  CMS genes excluded by Sanger sequencing or linkage in the undiagnosed CMS cohort selected for exome sequencing.
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6.3 Patient data 
 
Patients were of diverse ethnic origins including the UK, Germany, Norway, Italy, 
Turkey and Iran.  As often seen with rare genetic disorders, the pedigrees were 
relatively small with only two affected offspring.  In CMS-SC, three offspring were 
reported to be affected but two of these were identical twins. Only one of the twins 
was selected for exome sequencing.  
 
Age of onset of disease ranged from birth to 17 years and motor development was 
delayed in four patients (table 6.1).  In CMS-NO, the affected sister exhibited 
moderate intellectual disability.  Patients presented with global weakness, sometimes 
associated with fatigability.  CMS-EN was noted for selective distal muscle atrophy 
and weakness in both upper and lower limbs.  Ptosis and bulbar difficulties were 
common clinical features in all individuals.  The twelve selected patients were 
ambulant and none required ventilator support. Patients either had evidence of 
decrement on repetitive nerve stimulation or a positive response to AChE inhibitors in 
keeping with impaired neuromuscular transmission.  Creatine kinase levels were 
within the normal range in all families except CMS-SC.  Muscle biopsy reports were 
available in three of the families and showed unspecific changes in all with no tubular 
aggregates.  In addition to exhibiting myasthenic symptoms, some families were 
noted to have other medical conditions.  CMS-OV had a diagnosis of pseudoesterase 
deficiency typically associated with an abnormal reaction to anaesthetic agents 
without evidence of neuromuscular weakness. In CMS-GH, there was a history of 
hypercalciuria. 
 
In this cohort, Sanger sequencing was used to screen for mutations in known CMS 
gens that could not be excluded by haplotype analysis.  It is worth noting that 
particular genes like AGRN, LAMB2 and SCNA4 were not routinely sequenced. 
Furthermore, haplotype analysis included microsatellite loci for AGRN after 2009 and 
GFPT1 after 2011.  Therefore the extent of CMS gene screening varied between 
patients and expanded with the discovery of new CMS disease causing genes.  
 
In CMS-NO, CGH array was carried out given the presence of moderate learning 
difficulties in the affected sister.  This revealed a large hemizygous deletion in the X 
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chromosome. More details on this are discussed in chapter 8.  In CMS-OV family, 
consanguinity was reported in two generations (paternal grandparents related) and the 
father himself may have been symptomatic with both pseudoesterase deficiency and 
fatigable ptosis.  It was subsequently confirmed that the father had evidence of 
decrement in keeping with NMJ disorder.   
 
 
6.4 Exome sequencing data 
 
The coverage of the coding regions using BWA aligner was comparable across all 12 
individuals with most bases being covered at least 1-fold. In this study, the filter was 
set at 5-fold coverage for homozygous variants and 10-fold for heterozygous variants 
(figure 6.3).  
 
6.4.1. Coverage of exome data 
 
 
Figure 6.3. Coverage of consensus coding sequence (CCDS) bases across different individuals. 
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6.4.2 Coverage of known CMS genes 
 
Although patients had already been screen for known CMS genes, it was important to 
ensure that these were also excluded by exome sequencing.  In the first instance, the 
coverage of CMS genes was assessed.  Inconsistent coverage was noted in some of 
the CMS genes, notably AGRN and CHRNE (figure 6.4 A and B).  In AGRN, only one 
patient out of the cohort of 12 individuals had partial sequencing of exon 1.  
 
 
 
 
 
 
Figure 6.4.  Coverage of AGRN, RAPSN, CHRNB1 and CHRNE genes.  
A 
B 
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6.4.3 Sensitivity and specificity of called variants 
 
The sensitivity and specificity of the SNP predictions were evaluated based on a panel 
of SNPs with HapMap frequencies (table 6.3).  Sensitivity was variable across 
different families and between siblings.  The specificity of SNP predictions appeared 
to be more consistent across the group. 
 
Patient Sequence Aligner Estimated 
Sensitivity
+
 
Estimated 
Specificity
+
 
CMS_EN1 BWA 0.692302 0.998699 
CMS_EN2 0.695829 0.999262 
CMS_NO1 0.695191 0.998673 
CMS_NO2 0.700991 0.998695 
CMS_GH1 0.673925 0.997389 
CMS_GH2 0.694720 0.997655 
CMS_OV1 0.670149 0.997918 
CMS_OV2 0.672444 0.997803 
CMS_SC1 0.709786 0.998827 
CMS_SC2 0.687046 0.998651 
CMS_MA1 0.698994 0.997885 
CMS_MA2 0.695727 0.998178 
 
Table 6.3. Sensitivity and Specificity of SNP predictions  
 
 
 
6.4.4 Prediction of variants 
 
Good quality variants were selected for being 62Mb targets +/- 500bp and detected on 
both DNA strands with a minimum depth of coverage of 5-fold.  Common variants 
(MAF>0.01) found in dbSNP135 or 1000 Genomes (Feb 2012 download) and 
variants identified in an in-house list of 60 unrelated controls were removed.  For 
consanguineous families, the filtering was limited to homozygous variants, whilst for 
non-consanguineous families, both homozygous and compound heterozygous were 
prioritized.  Table 6.6 shows the total number of variants generated for each patient 
and the final number of variant prioritized.  It is worth noting that no variants were 
prioritized in CMS-MA and CMS-SC (table 6.4).  
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Patient Aligner Variant 
Type 
Total 
predicted 
(*) 
On 
Target 
(a) 
dbSNP135 
& 1000 
Genomes 
(b) 
Rare/Novel 
Variants (c) 
Shared 
Rare/Novel 
(d) 
Number of Genes 
Comp Het Comp 
Het - 
Protein 
Altering 
Comp Het- 
Predicted 
disease 
causing (e) 
Hom Hom- 
Protein 
Altering 
Hom - 
Predicted 
disease 
causing (e) 
CMS_EN1 
BWA 
SNV 
5,091,951 66,632 56,691 7,930 
1,621 
168 26 26 22 2 3 
CMS_EN2 5,065,829 66,736 57,038 7,722 
CMS_EN1 
Indel 
28,180 6,515 3,698 573 
161 
CMS_EN2 25,860 6,546 3,717 562 
CMS_SC1 
SNV 
5,526,108 67,958 57,319 8,643 
1,790 
223 35 30 16 0 0 
CMS_SC2 4,956,825 67,320 56,447 8,996 
CMS_SC1 
Indel 
28,131 6,649 3,812 506 
141 
CMS_SC2 27,303 6,418 3,673 530 
CMS_MA1 
SNV 
5,096,255 71,276 58,227 10,998 
2,552 
351 54 45 11 0 0 
CMS_MA2 5,269,379 73,219 58,032 13,111 
CMS_MA1 
Indel 
25,540 6,458 3,779 520 
136 
CMS_MA2 25,026 6,367 3,703 520 
 
Table 6.4 a. Number of Variant Predictions: non-consanguineous families.  SNV; single nucleotide variant, indel; small insertion or deletion, Hom; homozygous, Het; 
heterozygous. 
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Patient Aligner Variant 
type 
Total 
predicted 
(*) 
On 
Target 
(a) 
dbSNP135 
& 1000 
Genomes 
(b) 
Rare/Novel 
Variants (c) 
Shared 
Rare/Novel 
(d) 
Number of Genes 
Comp Het Comp 
Het - 
Protein 
Altering 
Comp Het- 
Predicted 
disease 
causing (e) 
Hom Hom- 
Protein 
Altering 
Hom - 
Predicted 
disease 
causing (e) 
CMS_NO1 
BWA 
SNV 
5,045,879 66,418 23,242 92 
25 
- - - 28 4 4 
CMS_NO2 4,729,958 66,565 23,399 92 
CMS_NO1 
Indel 
27,396 6,495 1,561 49 
3 
CMS_NO2 27,695 6,367 1,558 57 
CMS_GH1 
SNV 
4,613,050 65,928 22,286 109 
15 
- - - 20 1 1 
CMS_GH2 5,270,469 70,653 22,738 85 
CMS_GH1 
Indel 
23,037 6,114 1,458 48 
5 
CMS_GH2 25,955 6,493 1,516 46 
CMS_OV1 
SNV 
5,204,509 67,558 25,301 219 
77 
- - - 99 16 10 
CMS_OV2 5,469,740 66,847 25,222 228 
CMS_OV1 
Indel 
25,918 6,429 1,739 79 
22 
CMS_OV2 30,129 6,533 1,751 88 
 
Table 6.4 b. (Cont.) Number of Variant Predictions: consanguineous families
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6.5 Homozygosis mapping 
 
Genome wide SNP genotyping identified several large homozygous blocks (table 6.5) 
in the three consanguineous families (CMS-NO, CMS-OV and CMS-GH).    
 
 
 
Consanguineous 
kinship 
Chr
. 
Position start 
(bp) 
Position end 
(bp) 
Size 
(Mb) 
SNP start SNP end 
CMS-NO 5 2725775 10699490 7.97 rs1039161 rs2930049 
CMS-NO 13 74746182 94173688 19.43 rs7990716 rs9301891 
CMS-NO 16 31860504 48879322 17.02 rs11150644 rs4785552 
CMS-NO 22 17255335 27855335 10.62 rs16984825 rs2342945 
           
CMS-OV 4 31307699 37604570 6.3 rs9985891 rs2973280 
CMS-OV 4 124286915 143220613 18.93 rs12512633 rs10002445 
CMS-OV 6 91393320 100642650 9.25 rs1923064 rs7738443 
CMS-OV 10 13328248 78713115 65.38 rs500800 rs10824473 
CMS-OV 11 44550047 66081211 21.53 rs2863104 rs10791867 
           
CMS-GH 3 87834410 93588564 5.75 rs2046796 rs9683303 
CMS-GH 5 113149886 119795765 6.65 rs10055433 rs6883068 
CMS-GH 9 101168637 110238361 9.07 rs10986125 rs17725250 
CMS-GH 16 31814299 48556573 16.74 rs8060086 rs9933187 
 
Table 6.5. Blocks of homozygosity in consanguineous families. Bp; base pair, chr; chromosome. 
 
 
 
 
6.6 Prioritized variants in known CMS genes 
 
Non synonymous variants that were mapped on target and seen on both strands at a 
coverage of 5-fold or more were prioritized based on their MAF <0.01 and in silico 
predictions. Variants in known CMS genes were reviewed first.  Variants in AGRN were 
identified in two kinships: CMS-EN and CMS-GH.  
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6.6.1 CMS-EN kinship 
 
This was a non-consanguineous family from Norway.  A novel homozygous variant 
(AGRN; c.G226A:p.G76S) was identified.  This variant was predicted to be disease 
causing by different in silico prediction tools.  It is worth noting that the coverage of 
this variant was limited on the reverse strand and may have been missed should a higher 
level of depth of coverage was applied to the filtering pipeline (figure 6.5). 
 
 
 
 
Figure 6.5 AGRN variant in CMS-EN kinship (visualized using UCSC browser, accessed February 2012) 
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6.6.2 CMS-GH kinship 
 
This was a consanguineous Iranian family.  Compound heterozygous variant in AGRN 
were prioritized (c.A3404G; p.Q1135R) and (c.G5687A; p.S1896N).  The former was 
previously reported in dbSNP with a low frequency (MAF 0.005 in 1000 genomes) and 
was predicted to be benign.  The second variant was novel but also predicted to be non-
deleterious. 
  
 
6.6.3 Prioritized variants in non CMS genes in CMS-NO kinship 
 
This was a consanguineous family from England.  Only one novel homozygous variant 
in the SLC25A1 gene (c.G740A; p.R247Q) was identified and predicted to be disease 
causing.  The gene SLC25A1 encodes a citrate transporter that has recently been linked 
to human disease.  The final list of filtered variants in this family is available on request.  
Of note, a change in CLTL1 was shortlisted.  This gene encodes a clathrin related 
protein involved in synaptic vesicle cycle.  The prioritized variant was not predicted to 
alter protein structure or cause disease.   In addition, it was found in both dbSNP and 
exome variant databases at a MAF 0.07%.  Accordingly, it was presumed that this 
variant was a benign polymorphism. 
 
 
6.6.4 Other variants in CMS-OV kinship 
 
In CMS-OV, a novel frameshift homozygous variant (BCHE; c.436_437insG:p.F146fs), 
predicted to be damaging was found.  Mutations in this gene have been associated with 
pseudo-cholinesterase deficiency.  In a homozygous state, mutations in this gene cause 
respiratory complication after administration of particular muscle relaxants during 
anaesthesia. This particular family was known to have this disorder although this was 
never confirmed genetically.  In the absence of triggers, the patient is asymptomatic.   
  
In CMS-MA, CMS-SC and CMS-OV families, the current filtering pipeline did not 
allow the identification of candidate variants causing CMS.  
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6.7 Confirmation of prioritized variants  
 
6.7.1 AGRN variant in CMS-EN kinship 
 
Sanger sequencing in both affected siblings confirmed this variant. The first step to 
ascertain pathogenicity of this variant was to check its segregation with the disease 
phenotype. The mother was found to be heterozygous for the mutant allele whilst the 
father and healthy brother were homozygous for the wild type allele (figure 6.6). 
 
 
 
 
 
 
Figure 6.6. Segregation of the AGRN variant in CMS-EN. 
 
 
The seemingly homozygous state of the father for the wild type allele could not account 
for the homozygous state for the mutant allele in both off springs.  One possible 
explanation was that the father harbours a deletion or rearrangement spanning exon 2 of 
the AGRN gene (position of our mutation).  This would prevent PCR amplification of 
the mutant allele and result in “an apparent” homozygous state in the father and both 
affected siblings.  It is worth noting that PCR amplification and sequencing were 
repeated using a fresh DNA sample from the father to confirm sample identity and 
paternity of the father was confirmed based on previous haplotype results (not shown).  
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To look for evidence of chromosomal deletions or rearrangements involving the AGRN 
gene, CGH array analysis was carried out looking for copy number variations. This 
confirmed evidence of a 461 kb heterozygous deletion on chr1:746,649-1,207,683 
(figure 6.7).  The deleted region included AGRN. Using a read depth approach 
comparing the number of reads mapping to a particular region between a test and a set 
of reference samples, it was possible to detect this copy number variants using the 
exome data in combination with a statistical mode 
  
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7.  CGH array in CMS-EN kinship.  Evidence of loss of chromosomal material on chr1. 
 
 
6.7.2 AGRN variants in CMS-GH kinship 
 
Sanger sequencing in both affected siblings confirmed this variant. However, the variant 
did not segregate with the disease since the asymptomatic mother and both affect 
siblings with compound heterozygous for the same AGRN variants (data not shown).  
Bearing in mind that these variants were predicted to be benign, it seems unlikely that 
these are pathogenic in this family.   
 
 
 
 
Figure 6.6: Segregation analysis of AGRN variant in CMS-EN family.  
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6.7.3 SLC25A1 variant in CMS-NO kinship  
 
Sanger sequencing in both affected siblings confirmed this novel homozygous variant. 
Segregation analysis of this variant showed that both parents were heterozygous for the 
mutant allele whilst the brother was homozygous for the wild type allele (figure 6.7). 
 
Figure 6.8. Segregation of SLC25A1 variant in CMS-NO family.
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6.8 Discussion 
 
In this study, six pairs of affected siblings were selected from the Munich and 
Newcastle CMS cohorts. Three of these were from consanguineous families.  The 
choice of these families relied on a high clinical suspicion of CMS and an extensive 
screening for known CMS genes using conventional methods. Whenever possible, 
patients with unusual phenotypic features, potentially caused by novel molecular 
mechanisms, were prioritized.  For instance, CMS-EN exhibited marked pre-synaptic 
defects and distal muscle atrophy and weakness both very unusual in CMS.  In the 
CMS-NO family, the affected siblings exhibited some intellectual disability and 
psychiatric tendencies.  
 
In this study, disease causing variants, related to the CMS phenotype, were successfully 
identified in two out of the six families.  One of the variant was in a known CMS gene 
(AGRN) that was not excluded in this family either by Sanger sequencing or linkage.  
The latter had been carried out before the discovery that AGRN mutations cause CMS.  
Although the AGRN variant was detected in one of the siblings during the initial 
filtering, this had been excluded in the second sibling due to poor coverage.  This 
variant was therefore not prioritized during data intersection aimed at collating shared 
candidate variants between the two siblings.  Reducing the filter setting for a read depth 
of 10 to 5-fold allowed the resolution of this issue.   
 
The other important finding in CMS-EN, was the presence of a large hemizygous 
deletion on chromosome 1, which contained AGRN and resulted in loss of 
heterozygosity in this non-consanguineous family.  The detection of copy number 
variants using exome sequencing is an evolving field, which is intrinsically linked to 
optimum coverage and is likely to be superseded by whole genome sequencing. 
 
Based on the phenotypic features of this family, an additional three patients have been 
identified with AGRN mutations.  The details of these and the functional work carried 
out to prove pathogenicity of the AGRN variant are described in chapter 7. 
 
The second candidate variant identified was in the CMS-NO family.  This was the only 
novel homozygous variant predicted to be disease causing.  It also segregated with the 
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phenotype.  This gene has recently been linked to human disease in 13 kinships. One of 
the patients was shown to have impaired neuromuscular transmission.  The full details 
of these patients and the functional work carried are presented in chapter 8. 
 
The variant identified in BCHE gene in the CMS-OV family accounts for the 
pseudoesterase deficiency but not for the myasthenic syndrome.  Therefore, exome 
sequencing was only able to solve two out of the six families selected. 
 
One inherent limitation to exome sequencing is failure to detect intronic mutations and 
regulatory elements of the genes. These undiagnosed families may have harboured 
mutations in the non-coding regions.  An alternative possibility is that these families 
harboured copy number variants missed by exome sequencing.  Families have since 
been screened for copy number variants suing CGH array and none was found.  
Although whole-genome sequencing will in part overcome this challenge, the true 
limitation seems to relate to the lack of understanding of the biology of these genomic 
entities and how they interact with each other.   
 
Regardless of the platform applied, the first step of exome sequencing consists of DNA 
library preparation.  This is designed to generate DNA fragments that can be chemically 
enriched to allow the capture of the coding regions of the genome.  These are then 
amplified and sequenced using different signals to determine each nucleotide (Cooper 
and Shendure, 2011).  In this project, the platform used was for paired-end sequencing, 
which has the advantage of generating forward and reverse strands for each template 
fragment. This in turn should improve the quality of the sequencing and provide 
information on the position of the read in relation to the reference sequence, thus 
facilitating the mapping process.  Nonetheless, one can expect some errors related to 
suboptimal DNA library preparation and sequencing bias. 
 
The quality of exome sequencing is intrinsically linked to the coverage of the coding 
regions and the accuracy (sensitivity and specificity) of the variants called (Metzker, 
2010).  The current bioinformatics tools available, although very effective, are not 
perfect.  It is recognized that the quality of alignment and mapping of the sequence 
reads have a direct impact on the coverage as well as sensitivity and specificity of the 
called variants. If variants are not covered they cannot be found and if they are poorly 
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covered they cannot be accurately annotated (Flicek and Birney, 2009, Li and Homer, 
2010).  
 
In this project, the filtering pipeline initial objective was to shortlist good quality 
variants i.e. variants positioned within or near exonic regions, with at least 5-fold 
coverage and present on both forward and reverse strands.  The next step was aimed at 
prioritizing rare disease causing variants using established public variant databases and 
in silico prediction tools.  These provide a score based on the physical properties and 
conservation across species of residues. 
 
The use of public databases to remove common polymorphisms can be limited by the 
lack of accurate frequency data which are essential for optimum restriction of variants 
to a manageable number.  Setting the minimum allele frequency to less than 1% seems 
an arbitrary choice that should probably be adjusted based on the prevalence of the 
disease and the penetrance of phenotype.  In this study, the CMS-GH siblings were 
compound heterozygous for 2 variants in AGRN but only one of the variants was 
prioritized in the rare variant list because the MAF of the other change in 1000 genomes 
database was exactly 0.01.  
 
Data filtering may also have been limited by the degree of ethnic diversity within public 
databases.  In this study, two out of the four undiagnosed families were from Turkey 
and Iran.  This issue may be overcome with the use of ethnically matched public 
databases.  Prioritization of variants is also reliant on the accuracy of the prediction 
software used. In this study, a very large number of variants were prioritized as disease 
causing, which suggests that the current prediction tools are over estimating the impact 
of these changes on protein function. One way to tackle this issue has been introduction 
of additional parameters like gene ontology data and phenotypic data from animal 
models that would provide some additional information on gene function and 
phenotypic characteristics in other species.  
 
Finally, it is likely that some of the limitations of this strategy are secondary to the 
biology of Mendelian diseases.  Incomplete penetrance is one example that would 
impact on the accuracy and interpretation of data derived from public databases.  
Although, stringent criteria were used to ensure that patients exhibited clinical features 
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of CMS, some of these undiagnosed patients may have an alternative genetic diagnosis. 
Indeed, CMS can overlap with other neuromuscular conditions such congenital 
myopathies.  In this study, screening of 275 known neuromuscular genes did not detect 
any disease causing variants (Kaplan, 2011).  A deeper phenotyping of patients to 
determine more specific clinical features and biomarkers seem crucial to distinguish 
phenocopies. In the next two chapters, the clinical features and functional work carried 
out in relation to the novel AGRN and SLC25A1 variants are presented. 
  
   
138 
 
Chapter 7. AGRN related CMS with distal muscle weakness and 
wasting 
 
7.1 Introduction and aims
60
 
 
In this chapter, I discuss the CMS-EN family in whom candidate disease causing 
variants in AGRN were found.  As covered in chapter 6, this Norwegian non-
consanguineous family exhibited marked distal muscle wasting and weakness with 
decrement and marked increment on repetitive nerve stimulation, in keeping with a 
presynaptic defect.  Based on the distinct phenotype of this family, I was able to identify 
a second French family via the French CMS network.  This family was previously 
reported by Professor Bruno Eymard during the ENMC CMS workshop (Chaouch et al., 
2012a).  Subsequently, a third independent kinship from Turkey was shown to share the 
same phenotype and to carry mutations in AGRN. 
 
Neuronal agrin is an extracellular matrix proteoglycan, which is key in organizing and 
maintaining the neuromuscular junction.  McMahan was the first to speculate that agrin 
may have such properties and postulated that this glycoprotein may be implicated in the 
stabilization and maintenance of the nascent postsynaptic receptors, transiently formed 
on the muscle membrane.  McMahan’s agrin hypothesis was later shown to be 
essentially accurate (Bezakova and Ruegg, 2003, McMahan, 1990, Singhal and Martin, 
2011).  
 
Several agrin isoforms are generated through alternative splicing.  The neuronal form is 
synthesized in the presynaptic compartment and released into the synaptic cleft.  In the 
basal lamina, agrin attaches to a low-density lipoprotein (LRP4) via its C terminal 
domain.  LRP4 then binds and activates MuSK, a muscle specific kinase.  The latter 
mediates the concentration and anchorage of the nascent, aneurally formed AChRs, to 
the postsynaptic membrane.  MuSK also allows the clustering of other postsynaptic 
proteins including new AChRs (Kim et al., 2008).  
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 Adapted from Nicole et al 2014 (URL: http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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In the C terminal of agrin, an additional binding site was identified.  This attaches to -
dystroglycan via the LG2 domain.  The N terminal was shown, in vitro, to bind 
laminins.   It is unclear whether these basement membrane proteins interconnection are 
primarily aimed at maintaining structural stability or whether other functions are at play 
(Stetefeld et al., 2001, Gesemann et al., 1998, Yamada et al., 1996, Burgess et al., 
2000). 
 
It is worth noting that the biological properties of agrin were studies with great interest 
prior to the discovery of any patients with mutations in the AGRN gene.  Before the 
publication of this series, only three patients had been reported in the literature with 
mutations in AGRN in association with congenital myasthenic syndrome (Huze et al., 
2009, Maselli et al., 2012).  The clinical phenotype of these patients was typical of CMS 
with evidence of generalized neuromuscular weakness, fatigability and ptosis.  One of 
the patients had a severe phenotype with recurrent respiratory crises in childhood 
needing tracheostomy, whilst the other two cases had fairly mild disease.  Response to 
AChE inhibitors and ephedrine was variable.  Patients harboured missense mutations in 
the C terminal of agrin except for the patient with the more severe phenotype.  It is 
unclear if the discrepancy in phenotypic expression is related to the null allele 
(p.Q353X) in the more severe case. 
 
Moreover, different patterns of muscle involvement often correlate with different 
clinical entities, for instance proximal symmetrical weakness in myopathies.  Distal 
muscle weakness is unusual feature in congenital myasthenia as most patients present 
with global and sometimes predominantly proximal weakness, as seen in LG-CMS.  
Distal muscle weakness is rare and has only been reported in slow channel syndrome 
(see chapter 4).  Distal neuromuscular weakness is also typically seen in neuropathies 
and in some rare inherited myopathies.  More than twenty distal myopathy subtypes 
have been reported so far, many of which remain genetically undiagnosed (Udd, 2012).  
Distal myopathies have been categorized based on the following criteria (Mastaglia et 
al., 2005):  
 
1- Age at onset.  
2- Distribution of muscle weakness. 
3- Cardiac and respiratory involvement. 
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4- Muscle biopsy features.  
5- Family history. 
 
This chapter will discuss the results of the exome sequencing carried out in family 
CMS-EN in which compound heterozygous mutations in the AGRN gene were 
identified.  I also describe two additional kinships that harboured mutations in AGRN 
and shared strikingly similar clinical and electrophysiological features. 
 
 
7.2 Results 
 
7.2.1 Patient data
61
 
 
In this chapter, the two affected siblings (CMS-EN1 and CMS-EN2) will be referred to 
as patient 1 and patient 2 respectively.  In this Norwegian kinship two of the three 
siblings were affected with no parental consanguinity.  The two affected siblings share a 
similar phenotype, were the product of a normal pregnancy and birth, and reported 
normal motor milestone and no autonomic symptoms. 
 
The elder affected sister, who is now 45 years old had normal psychomotor 
development.  She presented at the age of 15 years with simultaneous bilateral distal 
lower limb atrophy and weakness and recurrent falls.  There was no suggestion of 
swallowing difficulties, visual or sphincter disturbance.  Her disease course was slowly 
progressive.  Three years after her presentation, this patient developed wasting and 
weakness of both distal upper limbs and later noted weakness of her shoulder and hip 
girdle muscles.   
 
Clinical assessment at the age of 43 years showed no evidence of cranio-bulbar 
weakness.  Shoulder abduction was marginally weak.  The Biceps, triceps, forearm 
flexors and extensors were preserved.  In the hands, she had a split pattern of muscle 
atrophy with marked wasting of the thenar and dorsal interossei muscles whilst the 
hypothenar muscles including abductor digiti minimi were preserved.  There was global 
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and symmetrical weakness of all the small muscles of both hands.  In the legs, she had a 
non-pyramidal pattern of muscle weakness, more marked distally with weakness of toe 
extension and foot eversion.  She also showed some mild hip flexion weakness with 
some suggestion of a waddling gait.  Foot dorsiflexion and knee extension were affected 
to a lesser degree.  This patient reported no benefit from AChE inhibitors. 
 
Patient 2 is the younger affected brother of Patient 1. He presented at the age of 15 years 
with difficulties running and recurrent falls.  He later reported difficulties with both 
hands with marked muscle wasting. There was no history of visual disturbance, 
swallowing difficulties or sphincter disturbance. He also had no symptoms suggestive 
of nocturnal hyperpnoea.  Although, he reported some progression in symptoms, there 
was no evidence of any significant change in the last ten years. 
 
Neurological evaluation revealed no evidence of cranio-bulbar weakness. Neck flexion 
was normal.  In the upper limbs, the salient findings were confined to both hands. He 
had marked wasting of the thenar and dorsal interossei muscles with sparing of his 
hypothenar eminence.  Power was paradoxically preserved in the small muscle of both 
hands except for thumb abduction, which was weak.  In the lower limbs, foot 
dorsiflexion and plantarflexion and to a lesser extent knee extension were affected.   
The patient was unable to walk on his heels and toes.  Similar to his sister, the patient 
reported no benefit from AChE inhibitors and later declined alternative treatments given 
the lack of progression in his disease
62
.  
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142 
 
 
 
 
.
P2 
P3 
Figure 7.1. Distal limb involvement, 
Patient 2 (top) and patient 3 (bottom). 
Reproduced from Nicole et al 2014 (URL: 
http://brain.oxfordjournals.org/content/earl
y/2014/06/20/brain.awu160.full) 
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To exclude potential mimics of CMS, a number of investigations was carried out in both 
siblings.  An autoimmune screen including anti-AChR and anti-MuSK antibodies and 
creatine kinase levels were checked and were shown to be negative or normal.  Cardiac 
evaluation, which comprised a baseline ECG and echocardiography were satisfactory.  
In addition, a muscle biopsy from vastus lateralis was performed at the age of 33 years. 
This biopsy transferred to Newcastle for further immune staining in 2002 and was used 
for the ultrastructural analysis described below.  Histological study of this muscle 
revealed chronic myopathic features with type 2 fibre atrophy and evidence of clusters 
of atrophic muscle fibres, which encircled a number of hypertrophic muscles fibres.  
Immunostaining for dystrophin, sarcoglycan, laminin 2, telethonin, caveolin 3, emerin, 
lamin A/C, calpain and dysferlin was reported as normal. Both the basement membrane 
and sarcolemma morphology appeared intact.    
 
To assess the extent of muscle involvement, a muscle MRI of the lower limbs was 
carried out in Patient 2 at the age of 42 years.  Three muscles were preferentially 
affected with evidence of atrophy and fat infiltration of semitendinosus bilaterally 
(figure. 7.2B). There was asymmetrical and bilateral fat infiltration in medial 
gastrocnemius, more prominent on the right. The right medial soleus muscle was also 
involved with evidence of central muscle atrophy and fat infiltration.
63
 
 
 
                                                 
63
 Adapted from Nicole et al 2014 (URL: http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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Figure 7.2: Muscle MRI of the lower limbs of Patients 2, 4 and 5. P2:  Evidence of soleus, medial 
gastrocnemius (left) and semitendinosus atrophy (right). P4 and 5: evidence of Gastrocnemius atrophy 
bilaterally. The thigh muscles were spared in Patients 4 and 5. Reproduced from Nicole et al 2014 
(URL:http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full). 
 
 
 
 
 
 
P2 
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The second kinship (Patients 3 and 4) was first reported in 2012 during the CMS 
workshop in Naarden, 2012.  Based on a strikingly similar phenotype consisting of 
distal muscle weakness and wasting and presynaptic features on repetitive nerve 
stimulation, I was able to liaise with the French CMS network and check if AGRN 
mutations were screened in this family and indeed they were.  The full details of their 
mutation status will be discussed below. 
 
Similar to the CMS-EN kinship, this was a non-consanguineous family in which two 
out of the five siblings were affected.  Both parents were healthy.  Patient 3 was a male 
patient who was the product of normal pregnancy and delivery and displayed normal 
developmental milestones.  He was 36-year-old when the diagnosis was confirmed. 
During early infancy, around two years of age, he developed recurrent apnoeic episodes, 
which spontaneously resolved through his childhood.  From the age of seven years, he 
noted fatigable lower limb weakness and distal wasting which were slowly progressive 
and subsequently warranted the introduction of foot splints.  The patient reported 
extension of his symptoms to both upper limbs at the age of nineteen years with clear 
bilateral thinning and weakness of both hands and forearms.  In addition, he later 
developed intermittent stridor, suggestive of upper airway obstruction, as well as 
intermittent dyspnoea that were often triggered by physical activity.  The patient did not 
report any swallowing difficulties, visual disturbance or autonomic features. 
 
The course of his illness was slowly progressive with a stepwise decline often preceded 
by a relapse necessitating medical attention.  This patient required hospital admission at 
the age of fourteen, nineteen, thirty and thirty two years. At the age of 30 years, his 
neuromuscular exacerbation was associated with marked respiratory insufficiency for 
which he was admitted to intensive care for ventilator support. The patient has been 
dependent on non-invasive ventilation ever since. It is worth noting that in between 
these episodes, the patient experienced marked diurnal variations in his symptoms 
similar to what is seen in myasthenia gravis.
64
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His latest marked neuromuscular relapse was at the age of thirty two years. This was 
associated with marked reduction in his exercise tolerance and loss of hand function.  
This patient was able to walk two hundred metres with a stick before needing to stop
65
.  
 
Neurological assessment carried out at the age of thirty three showed normal cranial 
nerves.  In particular, he had no ptosis, ophthalmoparesis or bulbar difficulties.  Neck 
flexion was also normal.  He had mild scapular wining but no evidence of any spinal 
deformities or contractures. His forced vital capacity was marginally low in sitting at 
58% of predicted value.  
 
In the limbs, he had distinct distal muscle wasting and weakness (figure. 7.1).  In the 
arms, similar to the first kinship described, there was evidence of bilateral multifocal 
involvement with preferential weakness of the extensors of the wrists, thumbs and 
fingers.  The right arm was more affected than the left and the third and fourth fingers 
were most affected (MRC grade 1/5).  The forearm flexors were also involved with 
striking weakness of the pincer movement of the thumb and index finger, reminiscent of 
an anterior interosseus syndrome.  Elbow flexion and extension were minimally 
affected as were shoulder abduction and adduction with an MRC grading ranging from 
4+ to 5/5.  Bilateral and symmetrical scapular winging was present but mild.  The 
patient was able to elevate both arms at ninety degrees for more than two minutes.  In 
the lower limbs, he had marked wasting distally.  Proximal power was normal.  Knee 
flexion and extension were minimally weak (MRC grade 4/5) with marked ankle 
dorsiflexion and plantarflexion involvement (MRC grade 1/5).  The patient was unable 
to heel or toe walk.
65
 
 
AChE inhibitors were initially introduced at the age of twenty four with little benefit.  A 
similar negative response was reported with 3,4-DAP, which was later instigated at the 
age of twenty nine.  By contrast, ephedrine correlated with a clear instantaneous benefit 
with marked increase in his exercise tolerance (increasing from 50 to 200 metres) along 
with improvement in his ability to carry out activities of daily living.  The patient was 
able to mobilise with no aids or foot splints although objectively, distal muscle power 
did not dramatically improve.  Despite improvement in his forced vital capacity from 59 
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147 
 
to 78%, he remained dependent on nocturnal non-invasive ventilation, which reflects 
residual diaphragmatic weakness. This improvement was maintained for three years 
after instigating this treatment.  Ephedrine was titrated from 45mg up 135mg with no 
reported side effects.  
 
In terms of investigations, baseline cardiac assessment including ECG and transthoracic 
echocardiography were normal. Screening for anti-AChR and anti-MuSK antibodies 
were negative and creatine kinase levels were within the normal range.  A deltoid 
muscle biopsy was performed at the age of thirty six years.  Histochemical analysis of 
this biopsy showed some variation in fibre size with type 2 fibre atrophy and type 1 
fibre predominance.  It is worth noting that this muscle was minimally affected 
clinically (figure 7.3).
66
  
 
 
 
 
Figure 7.3. Histochemical analysis of muscle biopsy of P3 (top) and P5 (bottom).  H&E staining shows 
occasional fibre size variation and fibre type grouping.  Adapted from Nicole et al 2014 (URL: 
http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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Patient 4 was twenty seven years old and was the second affected offspring in the 
French kinship and first presented to the French CMS network at the age of twenty-
three years.  She was the product of normal pregnancy and birth and exhibited normal 
psychomotor development. Notably, she was noted to have stridor in the neonatal 
period, which was self-limiting.  She subsequently sought medical attention at the age 
of seven years with fluctuating exercise related dyspnoea.  By the age of eleven years, 
the patient had suffered a number of falls, which were attributed to worsening bilateral 
foot weakness.  She started complaining of difficulties with hand function at the age of 
sixteen years and struggled to blow up her cheeks or whistle from the age of eighteen 
years.  Fluctuations in her symptoms were reported since the onset of her illness and 
often evolved over days and weakness, instead of the diurnal variations typically seen in 
myasthenia gravis.  Particular triggers like hot weather were noted
67
.  
 
Clinical examination at the age of twenty three years revealed no evidence of ptosis or 
ophthalmoparesis.  She had mild eye closure and mouth closure weakness.  She was 
unable to whistle.  She had some bulbar difficulties but respiratory function was 
preserved with a forced vital capacity in sitting of 98% of predicted value.  In the upper 
limbs, she had clear atrophy of both thenar eminences and first dorsal interossei 
muscles.  Proximal power was normal.  Extension of the fingers and forearm flexors 
were weak (MRC grade 3/5).  Similar to her brother, the patient was unable to perform 
pincer movement of her thumb and index finger.  Finger extensors and pinch grip 
(thumb-index finger) were weak (MRC grade 3).   In the legs, she had marked distal and 
symmetric muscle wasting of both anterior and posterior compartments.  Proximal 
power, knee flexion and extension were normal.  Similar to her affected sibling, she had 
bilateral foot drop with marked weakness of ankle dorsiflexion, plantarflexion and 
eversion (MRC grade 1/5).  Toe extension was also weak (MRC grade 2/5).
67
 
 
Akin to her affected brother, the patient reported no benefit from AChE inhibitors or 
3,4-DAP.  By contrast, ephedrine was associated with a favourable response with 
marked improvement in her exercise tolerance and activities of daily living. This agent 
was commenced at the age of twenty-four years at a dose of 45mg daily.  
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Baseline ECG was normal.  Autoantibody screen for anti AChR and and MuSK was 
negative.  A muscle biopsy of the deltoid was carried out at the age of eighteen and was 
reported as normal.  Of note, this muscle was not affected clinically.  Muscle MRI 
(figure 7.2) showed selective muscle atrophy with fat infiltration of the soleus, the inner 
portion of tibialis anterior and extensor digitorum muscles.  Correlating with the 
clinical evaluation, there was no suggestion of more proximal muscle involvement 
including pelvic girdle, quadriceps and hamstring muscles
68
.  
 
Patient 5 was a 34 year old male who was identified via the French CMS network.  He 
was the only affected offspring in a consanguineous Turkish kinship.  The patient was 
the product of normal pregnancy and birth and reported normal motor milestones.  
There was no history of early respiratory difficulties.  Disease onset was at the age of 
five years when the patient noted myalgia and weakness in relation to exercise. The 
course of his disease was slowly progressive with clear rapid deterioration over the past 
three years and increasing difficulties walking and climbing stairs.  From a baseline 
exercise tolerance of 5 kilometers he can now barely walk 100 meters.  Fatigability has 
become a more prominent feature over the recent past, often associated with exertional 
dyspnea.  The patient never required ventilator support nor did he report any visual, 
bulbar or autonomic symptoms.  
 
Neurological assessment at the age of thirty one years showed some limitation of eye 
movements but no ptosis.  Cranial nerves were otherwise normal.  Neck flexion and 
extension were intact.  Upper limb examination revealed minimal wasting of the hands 
with moderate weakness of finger extension (MRC grade 3+/5).  The remaining muscle 
groups were normal in the upper limbs.  In the legs, he had moderate and more diffuse 
muscle atrophy of the posterior more than the anterior compartments.  Proximal power 
was marginally weak with hip flexion scoring 4+/5 and knee extension 4/5 (MRC 
grade).  The patient displayed some difficulties standing from a sitting position.  In the 
foot, ankle dorsiflexion was weak (MRC grade 3+/5) as were ankle plantarflexion and 
eversion 3-4/5.
68
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A similar battery of screening tests was carried out in this patient, comprising ECG, 
creatine kinase levels and autoantibody screening which were normal or negative.  
Sequential muscle biopsies of the deltoid were carried out at the age of thirty one and 
thirty four years.  These revealed some atrophied fibres with fibre type grouping (figure 
7.3).  Muscle involvement was more marked in the posterior compartment of both 
forelegs on muscle MRI.  There was bilateral soleus and gastrocnemius atrophy with fat 
infiltration sparing of the medial right gastrocnemius muscle (figure 7.2). This patient 
was recently commenced on a 6 mg daily dose of salbutamol with moderate 
improvement in his neuromuscular weakness and in particular in his exercise tolerance 
and ability to climb stairs
69
.  
 
 
7.2.2 Neurophysiological studies
69
 
 
Nerve conduction studies showed no evidence of  large fibre neuropathy with preserved 
conduction velocities and distal latencies.  EMG in patient 1 showed myopathic features 
with short moderately polyphasic motor units and fibrillation potentials with positive 
sharp waves in several muscle groups, most noticeable in abductor pollicis brevis 
muscle (figure 7.4A).  In contrast to the deltoid and vastus lateralis muscles that seemed 
to exhibit the least abnormalities.   
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Figure 7.4. A. EMG findings in P1.  Polyphasic short complexes reminiscent of myopathy. B. Percentage 
of decrement induced by repetitive nerve stimulation. Reproduced from Nicole et al 2014 (URL: 
http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
 
 
 
Repetitive nerve stimulation at 3 Hz demonstrated decrement in both upper and lower 
limbs, more marked in the distal muscles (table 7.1, figures 7.4 and 7.5).  Marginal 
decrement was detected in abductor digiti minimi and no decrement was seen in the 
facial muscles. Notably, baseline amplitude of CMAP was reduced in some muscle 
groups (figure 7.5). 
 
In the majority of muscles, increment was detected following ten seconds of sustained 
muscle contraction. This was most noticeable in the tibialis anterior muscle.  In some 
muscles like abductor pollicis brevis, sustained muscle contraction for ten seconds was 
associated with decrement, which was later followed by significant increment (+ 58%) 
after twenty seconds muscle activation.  The decrement did not alter with the 
intravenous administration of edrophonium, a short acting AChE inhibitor.  Of note, 
progressive reduction in the amplitude of trains of motor responses was seen in several 
muscles including tibialis anterior
70
.   
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SFEMG showed variable and patchy changes across individual muscles (data not 
shown), which did not necessarily correlate with the results of repetitive nerve 
stimulation.  Whilst SFEMG was normal in extensor digitorum, marked jitter with block 
was detected in the tibialis anterior muscle.  Furthermore, repetitive nerve stimulation 
in the same hand (with normal SFEMG) displayed clear decrement in abductor pollicis 
brevis.  A similar pattern of variable and patchy muscle and NMJ involvement was also 
noted in patient 2 (table 7.1, figures 7.4 and 7.5)
71
.  
 
 
 
 
 
Figure 7.5 (A) Repetitive nerve stimulation (3 Hz) in P1 showed marked decrement in several muscles 
with no improvement after edrophonium.  There is also increment after 20 s sustained muscle contraction 
in APB (68%) and TA (500%). Decrement was also seen without increment in ADM. (B) P3. Decrement 
with post-exercise facilitation in TA.  APB; abductor policis brevis, TA; tibialis anterior, ADM; abductor 
digiti minimi.  Reproduced from Nicole et al 2014 (URL: 
http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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Patient Anconeus 
(3Hz) 
TA (mV) 
at rest 
TA 
(3Hz) 
TA (post-
exercise) 
EDB (mV) 
at rest 
EDB 
(3Hz) 
EDB (post-
exercise) 
1 -8% 0.9 -33% 133% 1.6 -27% 23% 
2 -16% 0.3 -67% 267% 2.8 -20% 25% 
3 -29% 1.3 -55% 87% 0.9 -72% 126% 
4 -10% 0.1 -53% 285% 4.7 -22% 32% 
5 -9% 1.5 -22% 67% 1.8 -33% 47% 
 
Table 7.1 Repetitive nerve stimulation. Amplitude of compound muscle action potential in one proximal 
and two distal muscles in relation to repetitive nerve stimulation and brief exercise in P1, 2, 3, 4, 5. TA; 
tibialis anterior, EDB ; extensor digitorum brevis.  Reproduced from Nicole et al 2014 (URL: 
http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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Neurophysiological studies in patients 3, 4 and 5 recruited through the French CMS 
network also showed similar results.  Nerve conduction studies showed no evidence of 
large fibre neuropathy with persevered motor conduction velocities and distal latencies.  
EMG study of all three patients revealed myopathic features with no spontaneous 
activity.  These myopathic changes were most noticeable in the distal muscles.  
Decrement on repetitive nerve stimulation was detected in several muscle groups.  
Similar to patients 1 and 2, such finding was more marked in distal muscles (figure 7.5 
and table 7.1).  Furthermore, sustained muscle contraction was associated with 
significant increment (285% tibialis anterior) consistent with a presynaptic defect.
72
 
 
 
7.2.3 Morphological studies of the NMJ
72
  
 
Muscles biopsies from patients 3 and 5 were selected for this study.  The deltoid muscle 
was sampled in both patients as this was one of the least affected muscles in which NMJ 
structure was less likely to be affected secondary to muscle atrophy.  
 
In both patients’ biopsies, pre and postsynaptic variations were detected using 
fluorescent immunostaining on whole-mount preparations (figure 7.6A).  In total, 33 
NMJs from patient 3 and 43 NMJs from patient 5 were analysed.  None of the synapses 
retained their normal architecture.  There was evidence of disjointed and occasionally 
dispersed postsynaptic grooves along with irregular AChR staining reflected by the 
postsynaptic streaky pattern of staining.  This unusual pattern of staining was more 
prominent in patient 3.  Neurofilament staining was completely (full NMJ) or partially 
(some postsynaptic gutters only) absent in six out of eight NMJs in patient 3 and 8 out 
of twenty two NMJs in patient 5.  Some NMJs displayed extensive branching of 
terminal axons with nodal, terminal or en passant sprouting that innervated individual 
groups of AChR.  S100 immunostaining revealed hypertrophic or phantom-like terminal 
Schwann cells apposing synaptic gutters.  This pattern has occasionally been reported 
during active denervation re-innervation processes (figure 7.6B).  
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Ultrastructural analysis of three NMJs sampled from patient 5 exhibited synaptic folds 
with no associated apposing nerve terminal or Schwann cell (figure 7.6C).  This feature 
can be seen in neurogenic pathology.  Terminal nerves appeared morphologically intact 
but contained a higher number of mitochondria, synaptic vesicles, and active zones 
compared to control.  The secondary junctional folds were poorly formed.  It is worth 
noting that the motor endplates analysed were sampled from a proximal minimally 
affected muscle.  Therefore the marked abnormalities seen are likely to represent a 
primary NMJ defect as opposed to secondary changes due to muscle pathology
73
.
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Figure 7.6 (A) Immunofluorescence analysis of NMJ 
on teased muscle fibres from control subject, P3 and 
P5. Staining of postsynaptic AChR with α-
bungarotoxin (red) showed a well-organized 
postsynaptic element innervated by one axonal branch 
(NF168 stain, green) with one terminal arborization in 
the control sample. In P3 and P5, marked 
disorganization of postsynaptic AChR was seen with 
fragmented postsynaptic structures and each AChR 
cluster was covered either by a thin axonal branch or 
no axon at all. Terminal and en passant axonal 
sprouting (arrow) was also visible.  An unusual 
streaky pattern of postsynaptic AChR staining was 
seen in P3 and to a lesser extent in P5. Scale bar = 10 
mm. (B) Schwann cell staining (S100, green) showed 
terminal Schwann cells with cytoplasmic extensions 
(P5) or no terminal Schwann cells (P3) in some 
NMJs. Scale bar = 10 mm. (C) Electron microscopy 
of two NMJs in P5 showed denervation of 
postsynaptic structures which neither nerve terminal 
or terminal Schwann cells (top, asterisk), or 
incomplete apposition between the postsynaptic 
element and nerve terminal (bottom, arrow). When 
present, nerve terminals were filled with synaptic 
vesicles and mitochondria, and were covered by 
terminal Schwann cells. Well-defined synaptic 
basement membrane and active zones facing the crest 
of the postsynaptic folds (arrowhead) were observed 
in some terminal nerves at higher magnification. 
Scale bar = 2 mm (top) and 500nm (bottom). NF; 
neurofilament. Reproduced from Nicole et al 2014 
(URL: 
http://brain.oxfordjournals.org/content/early/2014/06/
20/brain.awu160.full) 
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7.2.4 Confirmation of exome variants 
74
 
 
As shown in the exome chapter, patient 1 and 2 had been extensively screened for 
known CMS genes using both Sanger sequencing and linkage studies.   
This was a non-consanguineous family in which both parents were healthy and had two 
affected offspring.  Based on this pedigree and the predominance of recessive mutations 
in association with CMS, I used a recessive model in this filtering analysis searching for 
both compound heterozygous or homozygous variants in the same gene. 
 
On target good quality variants were categorized based on their genomic location, 
frequency in public databases and in silico predictions of pathogenicity.  A total of three 
candidate variants were prioritized with one located in the known CMS causing gene 
AGRN.  Of note, none of the short listed variants were associated with a known 
neuromuscular disorder and in particular with any myopathies or neuropathies 
characterized by marked distal muscle weakness (phenocopies).  Surprisingly, we 
identified a seemingly novel homozygous mutation AGRN; c.226G>A; p.G76S in  
exon 2.  This variant results in the substitution of a conserved hydrophobic glycine 
residue to a polar serine in the N-terminal domain.   
 
Segregation analysis of this variant using Sanger sequencing showed that the mother 
was heterozygous for the pathogenic allele whereas the father and the healthy brother 
were homozygous for the wild-type allele c.266G.  This seemingly wild type 
homozygous state of the father could not account for the homozygous state of both 
offspring for the mutant allele c.226A. I was able to exclude non-paternity based on 
previous haplotype reports and exome data.  An ExomeDepth analysis looking for copy 
number variants successfully detected a ~0.48 Mb hemizygous deletion on chromosome 
1, shared between both affected siblings, which contained a total of 236 exons, 
including the entire AGRN gene (table 7.2).  To confirm this finding, a standard CGH 
was carried out on patient 1 and confirmed the presence of a 461 kb hemizygous 
deletion on chromosome 1 comprising twenty-two genes (1p36.33, position 0,746,649-
1,207,683 Mb). 
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For the French family, a “trio approach” was carried in which both parents and one 
affected offspring (patient 3) underwent exome sequencing.  The filtering strategy in 
this family focussed on genes where either homozygous or more than two heterozygous 
defects were transmitted from each parent.  Thereafter, rare or novel exonic and splice 
site variant predicted to be deleterious were prioritized.  A total of eighteen variants 
were identified.  Similar to patient 1 and 2, disease causing variants were identified in 
AGRN and none of the other variants were positioned in genes associated with known 
neuromuscular disorders where distal weakness and atrophy are a feature.  Patient 3 was 
shown to be heterozygous for a missense mutation (c.314A>T; p.N105I) in exon 2 on 
the maternal allele and a frameshift mutation resulting from one nucleotide duplication 
(c.1362dupC; p.S455Qfs*8) in exon 7 on the paternal allele.  Sanger sequencing of both 
patents and offspring confirmed the variants and revealed appropriate segregation of 
these two AGRN variants with the disease (figure 7.7A).  
 
In summary, in the Norwegian family, both affected siblings were compound 
heterozygous for a missense mutation (p.G76S) and a large hemizygous deletion 
containing AGRN.  This would imply that the only agrin protein expressed would 
contain the N terminal mutation.  Similarly, in the French family, both affected siblings 
were compound heterozygous for a missense mutation in the N terminal and a 
frameshift mutation in AGRN, which would suggest that the phenotype is dictated by 
the N terminal mutation in AGRN.
75
 
 
Based on the striking clinical phenotype of the first two families, patient 5 was selected 
via the French CMS network.  He was the only affected offspring from a Turkish 
consanguineous family.  Using Sanger sequencing, two homozygous missense variants 
were identified in AGRN. The first was positioned in exon 12 (c.2234C>T; p.A745V) 
and predicted to be a benign polymorphism by in silico software (Mutation Taster).  The 
second defect was a substitution found in exon 32 (c.5611G>A; p.G1871R) in the LG3 
domain of agrin.  This variant segregated with the disease in the family and involved a 
well conserved residue of the C terminal of agrin.  The substitution of Glycine to 
                                                 
75
 Adapted from Nicole et al 2014 (URL: http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
 
   
159 
 
Arginine in position 1871 was predicted to be deleterious and most likely to be the 
disease causing mutation in this patient (figure. 7.7B). 
76
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Figure 7.7 (A) AGRN mutations (families 1, 2 and Patient 5).  These segregated with the disease in each 
kinship. (B) All three mutated residues were highly conserved. (C) Schematic representation of agrin and 
its important functional domains and binding partners. The position of the missense mutations linked to 
congenital myasthenic syndrome with distal muscle weakness and atrophy position of the novel mutations 
identified in this cohort (red) and previously reported mutations in AGRN related CMS patients (blue). 
SS: signal sequence; TM: transmembrane segment, FS: follistatin-like domain, LE: laminin EGF-like 
domain, S/T: serine/threonine-rich region; SEA: sperm protein, enterokinase and agrin domain; EG: 
epidermal growth factor domain; LG: laminin globular domain.  Reproduced from Nicole et al 2014 
(URL: http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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7.2.5 Functional effect of the mutations on agrin function
77
 
 
Mutations p.G76S and p.N105I (figure 7.7C) are the first N terminal agrin mutations 
reported in relation to human disease. The precise role of this functional domain within 
the NMJ is unclear.  The normal staining of agrin in the NMJ of patient 3 and 5 suggests 
that these mutations did not significantly alter protein expression and deposition in the 
synaptic basement membrane (figure 7.8A).  Furthermore, immunostaining of the 
binding partners of agrin (laminin 2 and LRP4) did not display any abnormalities 
when compared to control (figure 7.9).  
 
AGRN mutations described so far have been shown to alter the ability of agrin to cluster 
postsynaptic AChRs (Huze et al., 2009, Maselli et al., 2012).  Therefore the in vitro 
ability of the two NtA mutant agrins (p.G76S and p.N105I) to aggregate AChRs in 
C2C12 myotubes was tested.  C2C12 myotubes were treated with conditioned media 
from 293 EBNA cells transiently transfected with the wild type or the NtA mutant agrin 
constructs.  The number of AChR clusters was then calculated.  Both NtA agrin mutant-
containing media showed reduction in the number of AChR clusters compared to wild 
type, suggesting that these mutations can, in vitro, impair clustering properties of agrin 
and result in loss of function (figure 7. 5B and C).
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Figure 7.8 (A) Impact of mutation on agrin expression 
and clustering ability.  Immunostaining performed on 
transversal muscle sections of P2 and 3 showed no 
reduction in agrin (green) at the NMJ (stained red with 
bungarotoxin. Scale bar = 5 mm. (B) C2C12 myotubes 
labelled with Alexa Fluor 594-conjugated -
bungarotoxin and DAPI for nuclei (blue). Conditioned 
medium containing wild-type agrin (wild-type, b) 
induced numerous clusters of AChR when compared to 
the medium conditioned by untransfected cells 
(control, a). AChR clustering was reduced when 
C2C12 myotubes were incubated with conditioned 
media containing the p.Gly76Ser (c) and the 
p.Asn105Ile (d) NtA mutant agrins. (C) Estimation of 
the numbers of AChR clusters formed by myotube 
(expressed as the proportion of the AChR cluster 
number/myotube in response to conditioned culture 
medium containing wild-type agrin) showed reduced 
AChR clustering in response to conditioned media 
containing the p.Gly76Ser and p.Asn105Ile mutant 
agrins. This difference was statistically significant for 
the p.Gly76Ser mutation (*P50.02, 2 test) as compared 
to the wild-type but not for the p.Asn105Ile mutation 
(P40.05,2 test). AChR clustering in response to mutant 
agrins was nevertheless still higher than conditioned 
medium from untransfected cells (control). Each bar 
graph epresents the mean SEM of AChR clusters per 
myotube. Reproduced from Nicole et al 2014 (URL: 
http://brain.oxfordjournals.org/content/early/2014/06/2
0/brain.awu160.full) 
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Figure 7.9 (A) laminin beta 2, lrp4, SV2 immuno-staining.  This was performed on transversal muscle sections of P 2 and 3 and showed normal labelling.  
Reproduced from Nicole et al 2014 (URL: http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full) 
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7.3 Discussion
78
 
 
Congenital myasthenic syndromes are a heterogeneous group of genetic disorders 
associated with defects in transmission between the nerve terminal and the muscle fibre.  
To date, nineteen genes have been associated with CMS, including AGRN, which seems 
distinct in its involvement with all three compartments of the NMJ.  Indeed, this protein 
is synthesized and released from the presynaptic nerve terminal into the basement 
membrane and is thought to have a significant role in the maintenance postsynaptic 
structures (Hantai et al., 2013, Ohkawara et al., 2013).  
 
Agrin associated CMS is very rare and has been reported in two unrelated kinships 
(Huze et al., 2009, Maselli et al., 2012).  The first report was of a 42-year-old female, 
who presented with ptosis and early motor difficulties, being unable to run with her 
peers (Huze et al., 2009).  Clinically, she had bilateral ptosis with global limb weakness 
and muscle atrophy of the trunk.  She had no ophthalmoplegia, bulbar difficulties or 
respiratory insufficiency.  EMG showed mild myopathic features.  Repetitive nerve 
stimulation showed clear decrement with no facilitation post exercise or supra maximal 
stimulation.  Her brother who was also affected, presented with a similar mild 
phenotype with clear decrement on neurophysiology.  The patients were homozygous 
for the G1907R in the LG2 domain of agrin.  A second kinship with AGRN was 
subsequently described (Maselli et al., 2012).  In this family, the patient presented with 
ophthalmoparesis, facial and generalised limb weakness with clear fluctuations.  He 
developed chronic respiratory insufficiency.  Electrophysiological studies revealed clear 
presynaptic defects; although conventional repetitive stimulation showed decrement 
usually suggestive of postsynaptic defects in the absence of reduced CMAP amplitude 
or increment.  This patient was compound heterozygote for a nonsense mutation 
(Q353X) and a missense mutation (V1727F) in in the LG2 domain of agrin. 
 
In contrast to the relatively severe and heterogeneous phenotype described previously, 
the three kinships described in this chapter show a milder and more consistent 
phenotype (table 8.2) associated with:  
 Onset in the lower limbs with progression to the upper limbs evolving over years. 
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 Differential muscle weakness being more marked in the legs relative to the arms. 
 Distal neuromuscular weakness and atrophy. 
 Absence of ptosis, ophthalmoparesis or swallowing difficulties. 
 Evidence of asymmetric distal and proximal muscle atrophy in the legs on MRI. 
 A negative response to AChE inhibitors  
 A positive response to ephedrine and salbutamol. 
 Evidence of decrement in several muscles, sometimes associated with jitter but 
not always. 
  Evidence of increment, sometimes marked, in several muscles. 
 
However, it is worth noting that some of the patients in this cohort exhibited a more 
severe phenotype as seen in patient 3 who presented in the neonatal period with 
respiratory involvement transiently needing respiratory support or the presence of 
marked fatigability.  Furthermore, marked facial weakness was reported in patient 4 but 
was not a feature in the remaining patients.  
 
It is remarkable that most of the patients described in this cohort were initially 
diagnosed with a distal form of myopathy.  In addition to the overlapping phenotype, 
these patients exhibited myopathic features on EMG and to a lesser degree on muscle 
biopsy as well as atrophic muscles on MRI, which may, in a clinical setting, point 
towards such a diagnosis.  
 
Distal myopathies are a diverse group of inherited disorders where molecular diagnosis 
can be a challenge and is often guided by the pattern of inheritance, histo-pathological 
changes, muscle MRI appearance and evidence of cardio respiratory disease.  There are 
least three subtypes of distal myopathies that overlap with the phenotype described in 
this cohort.
79
 
1- Laing myopathy, which results from defects in MYH7 gene.  It is typically 
associated with distal muscle weakness and wasting, preferentially involving the 
anterior compartment.  By contrast to this cohort, Laing myopathy is a dominant 
form of distal myopathy that can be associated with a cardiomyopathy (Laing et 
al., 1995). 
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2- Distal nebulin myopathy, which is allelic with Rod myopathy, is a recessive 
disorder that also results in distal anterior compartment muscle wasting and 
weakness. The muscle biopsy is often unremarkable but EM study can show Z 
line streaming (Wallgren-Pettersson et al., 2007). 
 
3- Distal myopathy with mutations in DNM2 is a dominant disorder typically 
involves the posterior compartment of the lower limbs but almost half of the 
patients will exhibit ophthalmoparesis and have markedly abnormal muscle 
biopsies showing central nuclei and core like lesions (Bohm et al., 2012).  
 
Distal muscle weakness and wasting have been reported in one subtype of CMS, 
namely slow channel syndrome.  This form is associated with dominant kinetic 
mutations in the subunits of AChR and characteristically affects the long finger flexors 
of the forearms.  By contrast to this cohort, slow channel CMS does not present with 
distal leg wasting and weakness and patients will often have a more global pattern of 
muscle involvement with cervical and ocular muscle weakness (Chaouch et al., 2011).  
Single nerve stimulation can show repetitive CMAP and muscle biopsy may reveal an 
endplate myopathy.  Slow channel CMS patients benefit from fluoxetine and quinidine 
but not AChE inhibitors.  It is worth noting that none of the variants prioritized using 
exome sequencing was located in known CMS or distal myopathy genes.  Additionally, 
screening of twenty patients with undiagnosed distal myopathy and 12 patients with 
suspected CMS and marked distal decrement was negative for mutations in the N 
terminal domain of agrin.  This portion of the AGRN gene was sequenced as this 
seemed to dictate the phenotype in two out of the three families described in this 
chapter.  In this cohort, fatigability and respiratory failure in infancy were useful cues to 
make the correct diagnosis of CMS.
80
 
 
The neurophysiological findings in all three kinships have emerged as important 
indicators to the correct diagnosis.  Interestingly, despite finding decrement in some 
muscles (tibialis anterior), SFEMG did not detect abnormal jitter in the same muscle 
group.  This is in contrast to what is typically seen in other forms of CMS and 
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autoimmune myasthenia gravis.  The clear presynaptic features of low amplitude motor 
units at rest and marked facilitation (up to 500%) seen in several muscles was striking 
and reminiscent of Lambert Eaton syndrome caused by an aberrant immune response 
targeting pre-synaptic (P/Q) voltage gated calcium channel receptors.   
 
Inherited pre-synaptic defects in neuromuscular transmission are very rare in CMS.  
These have been reported in the context of episodic ataxia caused by CACNA1 
mutations.  The phenotype of these patients is distinct with fluctuating cerebellar signs, 
triggered by exercise and stress.  Patients respond well to acetazolamide.  The 
neurophysiological presynaptic features are probably the result of great abundance of 
Cav1.2 receptors at the neuromuscular junction.  An additional two cases have been 
reported in the literature that remains genetically undiagnosed.  These exhibited 
ophthalmoplegia with marked global limb weakness with respiratory compromise in 
one patient.  None had cerebellar features (Milone et al., 2006)
80
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Patient/Age/Gender Age 
at 
onset 
Symptoms/ Course Fluctuation:  
Daily/Long term 
exacerbation/ 
Other 
Signs: 
Ocular/Face/ 
Bulbar/ 
Cervical 
Signs Response to 
treatment 
CK EMG pattern 
Signs Distal Fatigue Res-
piratory 
Other 
features 
1/45y/Female 15y Weakness in feet, trips, 
muscle wasting, hand 3 years 
later, proximal 
weaknessweakness and 
wasting. Few years later, 
waddling gait 
No -/-/-/- UL+; 
LL+ 
UL+; 
LL++ 
- - Atrophy 
thenar and 
inter-ossei 
muscles 
Pyrodostigmine - N Myopathic changes 
with fibrillation 
potentials and positive 
sharp waves (distal); 
Decrement (distal); 
Post exercise 
increment in some 
muscle groups 
2/43y/Male 15y Weakness in feet, trips, 
difficulties running, hand 
wasting and weakness few 
years later 
No -/-/-/- UL-, LL 
- 
UL+, 
LL++ 
  - Atrophy of 
thenar and 
inter-ossei 
muscles. 
Pyrodostigmine - N Myopathic changes 
with fibrillation 
potentials and positive 
sharp waves (distal); 
Decrement (distal); 
Post exercise 
increment in some 
muscle groups 
3/32y/Male 2y Episodic apnea; Weakness in 
feet (7y) and hands (23y); 
Respiratory failure (30 y); 
Progressive worsening 
 -/ + / - -/-/-/- UL-; LL- 
(except 
knee 
flexor) 
UL+++; 
LL+++ 
+ ++ NIV Atrophy of 
thenar and 
inter-ossei 
muscles, 
legs 
AChE inhibitors -; 
3,4 DAP -; 
Ephedrine +70% 
(proximal muscles) 
N Myopathic pattern 
(distal); Decrement, 
post exercise 
increment (distal) 
4/23y/Female Birth Isolated stridor at birth; 
Exercise fatigability (7y); 
Stumble due to feet weakness 
(11y);Distal upper limb 
weakness and atrophy (16y); 
Progressive worsening 
-/-/hot 
atmosphere 
worsening 
-/+/mild 
swallowing/- 
UL-; LL- 
(except 
right 
knee 
flexor) 
UL++; 
LL++ 
+ - Atrophy of 
thenar and 
inter-ossei 
muscles, 
legs 
AChE inhibitors -; 
3,4 DAP -; 
Ephedrine +70% 
(proximal muscles) 
N Myopathic pattern 
(distal); Decrement, 
post exercise 
increment (distal) 
5/25y/Male 5y Exercise fatigability (5y); 
Distal lower limb weakness 
worsening since the age of 
20y; Successive periods of 
rapid worsening without 
regression (step pattern) 
 -/ + / - Mild 
questionable/-/-
/- 
UL-; LL- UL+; 
LL++ 
+ - No hand 
atrophy but 
lower limbs 
atrophy 
Salbutamol + 40% 
(distal muscles) 
N Myopathic pattern 
with reduced motor 
unit potential (distal); 
Decrement, post-
exercise increment 
(distal) 
Table 7.2: Clinical details of all five patients. N ; normal values, UL; upper limbs ; LL ; lower limbs ; NIV; non-invasive ventilation, - ; absent, + ; mild, ++ ; moderate, +++ ; severe. 
Reproduced from Nicole et al 2014 (URL: http://brain.oxfordjournals.org/content/early/2014/06/20/brain.awu160.full)  
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All patients harboured at least one missense mutation in AGRN, which suggests some 
correlation between genotype and a phenotype of distal muscle weakness and atrophy.  
Importantly, this is the first report of N terminal mutations of agrin causing disease 
since two of the three missense mutations were positioned in this domain.  Of note, all 
previously reported cases harboured mutations in the C terminal domain (LG2) of 
agrin.
81
 
 
In mice, alternative splicing of agrin at the N terminal generates two discrete isoforms. 
These seem to differ in terms of length of the initial peptide sequence, which can 
comprise either 49 short (SN) or 150 long N-terminal (LN) amino acids attached to a 
1,900 peptide chain of shared amino acid sequence. Alternative splicing at the N 
terminal is pivotal for agrin localization, tissue distribution and functional properties. 
The LN isoform localizes to the basement membrane of the neuromuscular junction as 
well as other tissues apart from the brain where the alternative splice isoform “SN” is 
expressed as a transmembrane protein. In the neuromuscular junction, the N terminal 
domain contains a signal peptide that allows the secretion of agrin into the basement 
membrane (Kammerer et al., 1999, Burgess et al., 2000).
 82
  
 
X ray crystallography of the chicken NtA-portion of agrin (figure 7.10) revealed a β-
barrel fold with a high content of charged amino acids, which is bordered on either side 
by α-helices (Stetefeld et al., 2001).   
None of the mutations identified in this cohort involved residues shown to directly bind 
to the laminin γ1 subunit. Although the mutations reported here did not directly alter the 
charge of the amino acid, the residues involved exhibit some distinctive features.  
Mutation G76S implicated a highly conserved Glycine residue, which has the unique 
property of containing hydrogen at its side chain that provides conformational flexibility 
to glycine and allows it to reside in portions of the protein where other residue would 
not tolerate.  The second mutation involved a highly conserved Asparagine residue, 
which is a polar amino acid which has the tendency to lie on the surface of proteins 
close to aqueous elements. Its substitution with the aliphatic hydrophobic Isoleucine, 
which is thought to have less conformational flexibility because of its non-hydrogen 
substituents, may well be significant.  Therefore, it seems plausible that the novel  
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N terminal mutations would influence the conformational properties of agrin and can 
either alter its binding ability to laminin 1 or result in protein misfolding which would 
ultimately diminish the content of functional agrin in the neuromuscular junction. 
82
  
 
 
 
 
Figure: 7.10 A, Schematic diagram of the NtA structure of agrin. β-strands are represented in red and 
numbered from S1 to S5. α-helices (H1–H3) and the 310-helix in loop L4–5 are in blue. The loops joining 
strands S1 and S2 (L1–2), strands S3 and S4 (L3–4), and strands S4 and S5 (L4–5) are oriented to the 
identical surface of the protein.  B, Alignment of known NtA sequences.  Sequence numbers correspond 
to the mature protein. Helix H3 comprises a splice insert, residues Glu 126–Ala 132 (demarcated by the 
green bar), whose function is yet unknown.  Blue arrows show the two residues mutated (G76S and 
N105I) in our cohort.  Adapted from Stetefeld et al, (2001). Nature Structural Biology. 8, 705 - 709 
(2001) doi:10.1038/90422 
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As regard the latter, the results of agrin immunostaining in the patient tissue suggest 
otherwise. Indeed, there was no reduction in agrin labeling in muscle biopsies.  
Nevertheless, a more quantitative approach such as western blotting may be more 
accurate in this setting.  Lastly, the AChR binding assay showed altered clustering of 
the receptors with both N terminal mutants of agrin, more marked with the G76S 
mutation. This suggests that these novel N terminal mutations may result in loss-of-
function effect, similar to previous reports related to mutations in the C terminal domain 
of agrin (Huze et al., 2009, Maselli et al., 2012).  Nevertheless, this consequence 
appears to be subtle and it is likely that other functions of agrin are compromised by 
defects in the N terminal domain.  Clearly, specific in vitro experimental work focused 
on the N terminal binding properties of the mutant agrin are required to make this study 
more comprehensive.
83
   
 
The phenotype of all three kinships was characterized by marked distal muscle atrophy, 
which was confirmed on muscle MRI.  Nevertheless, the muscle biopsies available in 
patients 2 (vastus lateralis), 3, 4 and 5, did not show sufficient myopathic changes to 
account for such muscle wasting. One can therefore speculate that defective 
neuromuscular junction was the primary drive of this phenomenon, caused in this 
instance by mutations in agrin.  One may also suggest that this length dependent pattern 
of neuromuscular weakness with evidence of fibre type grouping in the least affected 
deltoid muscles is reminiscent of a neurogenic process.  Morphology of NMJs in the 
clinically not affected deltoid muscle of two unrelated patients supports active 
denervation re-innervation events with partial denervation of synaptic gutters, nerve 
sprouting, and Schwann cell extension. Therefore mutations in agrin may be related to 
abnormal motor nerve terminals and one can speculate that the primary 
pathomechanism is pre synaptic neuronal dysfunction.  
 
In addition to widespread denervation-re-innervation events, a remarkable though 
nonspecific streaky pattern of post-synaptic AChRs was detected. Based on the EM 
findings in patient 5, this streaky pattern may have resulted from secondary synaptic 
folds that were not covered by terminal motor axons or Schwann cells as observed in 
patient 5. This in turn suggests aberrant presynaptic differentiation which correlates 
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with the significant increment observed in several muscles following high frequency 
stimulation or sustained muscle contraction.
84
   
 
Bearing in mind that several alternatively spliced AGRIN isoforms are synthesized by 
muscle and nerve and that all patients exhibited marked distal muscle atrophy, one may 
need to consider the impact of these novel mutations in muscle AGRIN.  Muscle 
AGRIN transcripts lack inserts at the C terminal which markedly reduces the AChR 
clustering properties of these isoforms. Muscle AGRIN N-terminal sequence is 
homolougous to the neuronal one.  Therefore, muscle AGRIN is expected to carry the N 
terminal mutations as would the neuronal isoform.  Muscle AGRIN, which is expressed 
on the muscle cell surface, was shown not to be essential for synapse differentiation 
(Burgess et al., 1999, Fallon and Gelfman, 1989).  It has also been shown that muscle 
AGRIN can bind more avidly to α dystroglycan than its neuronal counterpart (Yamada 
et al., 1996, Sugiyama et al., 1994).  α dystroglycan is a heavily glycosylated protein 
that has AGRIN and laminin as binding partners in the extracellular matrix and the 
trans-membraneous β dystroglycan.  Both α and β dystroglycans in association with 
several other proteins form the dystrophin glycoprotein complex, which is believed to 
be a key structure underlying the pathogenesis of muscular dystrophies (Leite et al., 
2008).   This complex is thought to confer mechanical stability to the muscle fibre by 
linking the extracellular matrix to the muscle fibre basement membrane (Lapidos et al., 
2004).  Defects in muscle AGRIN may therefore destabilise this complex and result in 
muscle abnormalities.  It is worth noting that the CK levels were normal in all patients 
with AGRIN associated CMS with distal weakness and atrophy, by contrast to the high 
levels found in α dystroglycan mediated muscular dystrophies”. 
 
Time-induced deletion has showed that whole agrin is required for the postsynaptic 
maintenance in adult mice, and that the postsynaptic alterations progressively lead to 
presynaptic changes (Samuel et al., 2012). The missense mutations identified here may 
also point towards domains critical for presynaptic function of agrin.   
 
Agrin knockout mice exhibit early respiratory failure and limb weakness and die within 
days regardless of the position of the mutations introduced in AGRN (Burgess et al., 
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2000, Gautam et al., 1996).  Recently, a mouse model homozygous for a point mutation 
(p.F1061S) in the SEA domain (agrinnmf387) was shown to be a viable model that 
appears to accurately replicate human disease showing variable and patchy pre and post 
synaptic changes with muscle atrophy.  The mutation causes partial loss of protein 
function with abnormal posttranslational glycosylation and diminished protein cleavage 
and retention within the cell (Bogdanik and Burgess, 2011). This animal model may 
shed light into some of the molecular mechanisms accounting for the distinct phenotype 
in these patients.   
It has been shown that the disruption of the interaction between laminin β2 and the 
Cav2.1 leads to fragmentation of the presynaptic active zones parallel to what is 
observed in Lambert-Eaton myasthenic syndrome (Nishimune et al., 2004).  Through 
this interaction, the laminins may be critical to the organization of the presynaptic 
machinery within the active zone to maintain its configuration in relation to the 
corresponding postsynaptic structures in the muscle fibre.  One may therefore postulate 
that this trans-synaptic platform necessitates agrin and involves several of its functional 
domains including the N terminal portion.  Through its N terminal binding partners 
(laminins), agrin may partake in the specialization of the presynaptic compartment 
within the active zone and ensure their alignment with postsynaptic specializations. In 
the patients harbouring mutations in the N terminal domain, laminin 2 immunostaining 
was comparable to control.  However, no motor endplates were available for EM 
analysis to corroborate this hypothesis.   
 
In patient 5 who harboured a homozygous mutation in the LG3 domain of agrin, EM 
analysis was available and showed preserved arrangement of the active zone with 
normal content of synaptic vesicles within the motor nerve ends.  Given the marked 
streaky pattern of nerve sprouting shared between these patients, one may need to 
explore the direct influence of mutant agrin on the development and differentiation of 
the motor nerve which were shown to be implicated in vitro studies (Campagna et al., 
1997, Wu et al., 2012). Lrp4 was recently shown to be a crucial retrograde signal that 
modulates presynaptic growth and function (Yumoto et al., 2012, Wu et al., 2012).  
Through this mechanism, one may be able to explain some of the features seen in 
patient 5.  Furthermore, given the similarities in phenotype between patients, one may 
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hypothesize that agrin with lrp4 is an important retrograde signal for pre synaptic 
differentiation
85
.  
 
In this study, three CMS families with a distinct distal myopathy phenotype and 
presynaptic features on neurophysiology are reported. All three families harboured 
novel mutations in AGRN with two families sharing a strikingly similar genotype since 
both were compound heterozygous for a missense mutation in the N terminal domain of 
agrin and a null allele.  Although, the morphological changes seen at the level of the 
neuromuscular junction hint to both pre and post synaptic derangement, there seems to 
be a peculiar pathology in the motor nerve terminal that clearly requires further 
characterization
85
. 
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Chapter 8. Mutations in SLC25A1 Cause Impaired Neuromuscular 
Transmission 
 
8.1 Introduction and aims
86
 
 
Whole exome sequencing was performed in an affected sib pair from an English 
consanguineous family (CMS-NO). These patients had remained genetically 
undiagnosed for more than 23 years, having had a suspected clinical diagnosis of 
congenital myasthenia with a reported response to pharmacotherapy.  In this chapter, I 
present the diagnostic strategy and the evidence collected to support the pathogenicity 
of the novel SLC25A1 homozygous variants. 
 
A sizable fraction of CMS patients are without genetic diagnosis (Chaouch et al., 
2012a). One may conjecture that some of these genetically undetermined patients may 
be carriers of extremely rare private mutations in a gene selectively expressed in the 
NMJ.  On the other hand, affected individuals may harbour mutations in genes encoding 
proteins abundantly expressed in different tissues which may manifest mainly as an 
NMJ defect but may also be associated with a much more diverse disease spectrum.   
The recently discovered glycosylation defects in relation to LG-CMS are a good 
paradigm for this.  These defects were until recently primarily linked to congenital 
glycosylation disorders (Belaya et al., 2012, Cossins et al., 2013).  Other examples 
include mutations in PLEC1 and LAMB2 genes in which mutations can lead to a CMS 
phenotype combined with cutaneous and renal disease respectively (Forrest et al., 2010, 
Maselli et al., 2009). 
 
Whilst mitochondrial gene defects can result in a multitudinous of neurological 
disorders such as myopathies and neuropathies, they have not been explicitly implicated 
in defects of the NMJ (McFarland et al., 2010, Ly and Verstreken, 2006).  SLC25A1 is 
a mitochondrial citrate carrier thought to play a pivotal role in fatty acid and sterol 
biosynthesis, gluconeogenesis and glycolysis (Kaplan et al., 1993).  More recently, it 
has been proposed that it may also play a part in the maintenance of chromosome 
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integrity and in the regulation of autophagy (Morciano et al., 2009, Catalina-Rodriguez 
et al., 2012). 
 
In mitochondria, SLC25A1 mediates the exchange of mitochondrial citrate/isocitrate 
with cytosolic malate.  ATP-citrate lyase cleaves the exported citrate into acetyl-
coenzyme-A and oxaloacetate (Kaplan et al., 1993, Moraes and Reithmeier, 2012).  
Acetyl-coenzyme A, is the main substrate for lipid and sterol biosynthesis in the cell 
whilst oxaloacetate is usually reduced to malate and recycled back into the mitochondria 
for further exchange with mitochondrial citrate.  Citrate can also indirectly influence the 
rate of glycolysis in the cell by inhibiting cytosolic phosphofructokinase 1.  Citrate and 
malate are both involved in modulating NADPH cellular content (Sun et al., 2010, 
Moraes and Reithmeier, 2012). 
 
The recent identification of several patients with mutations in this mitochondrial carrier 
has underscored the critical biological importance of this protein in humans (Edvardson 
et al., 2013, Nota et al., 2013).  The first report was of a patient presenting with a 
neurodevelopmental disorder manifesting as profound psychomotor retardation, 
hypotonia, apnoeic crises, poor feeding, epilepsy, postnatal microcephaly, sensori-
neural deafness, agenesis of the corpus callosum (ACC) and hypoplastic optic nerves. 
He had raised urinary hydroxyglutaric acid levels and Krebs metabolites (Edvardson et 
al., 2013).  Subsequently, a series of 12 individuals with mutations in SLC25A1 were 
described.  These patients were from twelve independent kinships and presented with a 
homogenous, often lethal, clinical phenotype and recessive SLC25A1 mutations (Nota et 
al., 2013).  Eight of these patients died in the neonatal period whilst the others survived 
until early infancy (range 1month - 5years 1month).  All displayed delayed 
psychomotor milestones, hypotonia and seizures (Nota et al., 2013).  A large peak of 2 
hydroxyglutaric acid was identified in the 13 patients previously reported with 
SLC25A1 mutations with no variants identified in L2 or D2 hydroxyglutaric acid gene 
which implies that this metabolic disturbance is a consequence of mutations in 
SLC25A1.
87
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8.2 Results  
8.2.1 Clinical phenotype
88
 
 
This was a consanguineous English family (first cousins) with two affected siblings and 
one healthy offspring.  The parents were reportedly both healthy.  The index case was a 
33-year-old man who was the product of normal pregnancy and birth but displayed 
speech and motor developmental delay.Early in his childhood, he experienced 
intermittent, exercise induced leg weakness that improved with rest. He had no ocular, 
bulbar or respiratory involvement.  He had mild intellectual disability but was able to 
attend mainstream schooling and attain full time employment in a passport office.  His 
neuromuscular symptoms have remained stable over the intervening years. Most 
recently, a neuropsychiatric picture has emerged in this patient with obsessive 
compulsive tendencies.  Clinical examination revealed mild bilateral ptosis but no 
ophthalmoplegia.  He was dysarthric with fatigable speech.  Muscle tone and power 
(MRC grade 4) were normal at rest with inducible fatigability on exertion.  He had 
bilateral pes cavus as well as calf hypertrophy bilaterally.  Reflexes were reduced at rest 
with clear potentiation with exercise (table 8.1). 
 
His sibling, who is now 19 year old, is the product of normal pregnancy and birth.  She 
exhibited more marked delayed psychomotor milestones, compared to her brother.  She 
sustained multiple falls in early infancy with clear fatigable weakness in all four limbs. 
She had no bulbar or respiratory symptoms but she complained of intermittent double 
vision.  The course of her illness remained static.  Neurological assessment showed mild 
facial weakness with no ophthalmoplegia or ptosis.  She had mild neck flexion 
weakness (MRC4) with fatigable arm and leg weakness that did not impede her ability 
to mobilise.  Tendon reflexes were preserved.  She has moderate learning disability and 
presently attends a special needs college (table 8.1). 
 
In the presence of intellectual disability and evidence of jitter with block on SFEMG, 
the differential diagnosis included a congenital myasthenic syndrome or a mitochondrial 
disorder.  Mitochondrial disorders have been associated with abnormal jitter in some 
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patients in the absence of a large fibre neuropathy or significant myopathy (Girlanda et 
al., 1999). 
MRI brain together with MR spectroscopy were normal.  Blood and CSF lactate levels 
were within the normal range.  Genetic screening for MELAS, MERRF, LHON, and 
NARP was negative.  Free and total carnitine levels were normal.  Acetylcholine 
receptor antibodies were negative.  While the index case had normal karyotype, we 
identified a 30.4 Mb deletion Xq25 to Xq28, position 122,440,897-154,886,079 using 
CGH array in the affected sister.  The parents have not yet been tested for this deletion.  
Histo-chemical analysis of an earlier muscle biopsy was reported as normal with no 
abnormalities in respiratory enzyme chain activity (cytochrome oxidase, succinate 
dehydrogenase and NADH).  There was also no evidence of multiple mitochondrial 
DNA deletions on muscle analysis.  Of note, EM analysis reportedly showed increased 
number and size of mitochondria in the same muscle.  Unfortunately, there was no 
record of the site of the muscle sampled nor was the full biopsy report available.   
 
Neurophysiological studies were carried out in the index case at aged 20 and 21 years. 
At age 20, repetitive nerve stimulation of ADM and anconeus at 3 Hz stimulation 
showed no decrement of CMAP and no facilitation after maximum voluntary muscle 
contraction for 20 seconds.  SFEMG on EDC showed evidence of increased jitter in 
52% of fibre pairs (25% were normal); 20% showed block, from twenty-five pairs 
tested.  Jitter MCD (mean consecutive difference) from non-blocking pairs was 78.5 +/- 
44.4 (microsec +/- ISD).  Subsequent repetitive nerve stimulation (3Hz) of ADM and 
anconeus, at age 21 years showed no decrement.  SFEMG on EDC showed 81% of 
potential pairs had increased jitter or jitter with blocking (19% were normal, 62% were 
increased, 19% were blocking (n=16 pairs; mean MCD was 71.6% +/- 27.8).  It is worth 
noting that nerve conduction studies showed no evidence of a large fibre neuropathy 
and EMG showed no significant myopathy.  The findings of SFEMG were not assessed 
in relation to the treatment prescribed.
89
  
 
A basic evaluation of endplate morphology in the earlier biopsy revealed increased size 
of motor endplates.  The density of post synaptic AChR was found to be normal on 
repeat muscle biopsy (anconeus muscle).  Microelectrode studies showed preserved pre 
and post synaptic function with normal MEPP amplitude and quantal content. 
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The index case was initially treated with pyridostigmine with no clear benefit.  He was 
later instigated on 3,4-DAP with a favourable response.  His sister received 
pyridostigmine since early childhood, which she continues to this date.  It is unclear 
whether she has any benefit from this treatment
90
. 
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8.2.2 Confirmation of exome variant
91
 
 
Since these two affected siblings were born to healthy consanguineous parents 
suggesting recessive Mendelian inheritance, the following CMS genes were excluded 
by targeted linkage analysis: COLQ, CHRNA1, CHRNB1, CHRNE, CHAT, RAPSN, 
MUSK, SCN4A, DOK7 and GFPT1.  Sanger sequencing was then carried out to further 
exclude CHRNA1, CHRNB1, CHRND, CHRNE, RAPSN, CHAT, DOK7 and COLQ. 
Four large homozygous segments were delineated using homozygosity mapping.  These 
were shared between the two siblings and located on chromosome 5 (7.97Mb); 
chromosome 13 (19.43Mb); chromosome 16 (17.02Mb) and chromosome 22 
(10.62Mb). Given the significant size of these homozygous regions, exome sequencing 
was carried out to restrict the number of candidate variants. 
 
Whole exome sequencing generated an average of 8.73 Gb of mappable sequences per 
patient and 53.92% of reads mapped to target.  87% of targeted variants had a 10-fold 
coverage, which was used for variant calling in our filtering pipeline.  Filtering of 
variants shared by both siblings by restricting the search to coding, rare (frequency 
<1%), predicted to be deleterious changes, allowed the shortlisting of one homozygous 
missense mutation in the SLC25A1 gene (exon7: c.740G>A; p.R247Q, GenBank: 
NM_005984).  This variant was located in a large homozygous block on chromosome 
22 and led to the substitution of a highly conserved positively charged arginine residue 
to a neutral glutamine residue.  Of note, the same mutation was identified by the Oxford 
Group using whole genome sequencing on the older sibling.  A second variant in 
CLTL1 (c.A719G; p.N240S), involved in synaptic vesicle cycle was also identified.  
However, this variant was predicted to be non deleterious and was subsequently 
identified in other public databases, which suggests that it was likely to be a benign 
polymorphism.  
 
The SLC25A1 variant (c.740G>A; p.R247Q) segregated with the disease in the family. 
Both parents were heterozygous for the mutant allele whilst the unaffected brother was 
homozygous for the wild type allele.  Screening of 58 patients from an extended CMS 
cohort (Munich, Newcastle and Oxford) did not identify any other candidate disease 
causing variants in SLC25A1.  Exome sequencing of a further 100 undiagnosed 
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neuromuscular patients including CMS cases did not detect any other SCL25A1 
variants. 
 
Shortly after the results of exome sequencing became available, a patient with 
compound heterozygous mutations in SLC25A1 gene was reported in the literature 
(Edvardson et al., 2013).  This patient was compound heterozygous for two SLC25A1 
variants, Chr.22:19163734 C->T resulting in (p.R282H) and Chr.22:19165292 C->T 
resulting in (p.G130D).  This patient exhibited some clinical features reminiscent of 
abnormal neuromuscular transmission including hypotonia, bulbar and respiratory 
difficulties.  The authors of the report were therefore contacted to check if the patient 
had evidence of decrement or abnormal jitter.  SFEMG at the age of 2 years revealed 
markedly increased jitter and blocking in the muscles studies.  This patient is now aged 
3 years and was the only affected offspring of a non-consanguineous Ashkenazi Jewish 
family.  She presented in the neonatal period with poor suck, hypotonia, recurrent 
apnoea and apathy.  Due to her recurrent apnoeic crises and persistent respiratory 
insufficiency, this patient had a tracheostomy inserted and was commenced on non-
invasive ventilation.  She exhibited marked psychomotor developmental delay with 
diminished spontaneous movements.  She also suffered several generalised tonic clonic 
seizures.  After establishing that the patient had impaired neuromuscular transmission 
based on SFEMG results, she was given a trial of AChE inhibitors, 3,4-DAP and 
ephedrine with little benefit. 
 
In terms of her investigation results, her MRI brain showed corpus callosum agenesis 
and optic atrophy.  Analysis of urinary organic acids revealed a large peak of 2-
hydroxyglutaric acid and Krebs cycle intermediates.  Mitochondrial function was 
assessed in cultured skin fibroblasts and revealed reduced growth in glucose free 
medium, elevated ROS biosynthesis and decreased mitochondrial membrane potential. 
ATP content was normal in mitochondria
92
.   
 
The kinetic properties of mutations (p.R282H) and (p.G130D) were studied using 
mutant recombinant protein into liposomes.  This revealed complete loss of transport 
function with the former variant and a minor residual activity with the latter (table 8.1).  
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Case 1 Case 2 Case 3 
Gender/age/ethnicity Male/33y/English Female/19y/English Female/18m/Israeli 
Mutation Rg247Q R247Q G130D; R282H 
Progression 
Stable with some long term 
fluctuations 
Stable Progressive 
Age at onset Less than 2 years Less than 2 years 10 days 
Symptoms at onset Fluctuating leg weakness 
Fluctuating arm and 
leg weakness 
Poor suck, hypotonia, 
apneoas 
Psychomotor 
delay/intellectual 
disability 
No but developed 
obsessive compulsive 
disorder in adulthood 
Yes Yes 
Ocular involvement Ptosis Ptosis 
Optic nerve 
hypoplasia 
Bulbar weakness No No Yes 
Apneic crises No No Yes 
Epilepsy  No No Yes 
Agenesis of the corpus 
callosum 
No No Yes 
Hearing loss No No Yes 
Elevated urinary organic 
acids  
No No Yes 
Abnormal jitter with 
block 
Yes  Not done Yes 
Positive response to 
treatment 
Yes Equivocal  No 
 
Table 8.1: Clinical features of patients with mutations in the SLC25A1 gene. Reproduced from Chaouch 
et al 2014 (URL:http://iospress.metapress.com/content/l36500736v3r4132)
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8.2.3 Biochemical properties of the SLC25A1 variants
93
 
 
SLC25A1 contains eight exons, which encode the 311 amino acid mitochondrial citrate 
carrier protein.  The percentage of identical amino acids between the yeast and the 
mammalian orthologous mitochondrial carriers is usually comparable to that observed 
across the different members of the mitochondrial carrier family (25-30% of identical 
amino acids (Palmieri et al., 2006).  Remarkably, the yeast Ctp1p shares the 37% of 
sequence identity (52% of sequence similarity) with the human citrate transporter coded 
by SLC25A1.  Nonetheless, S. cerevisae was shown to be useful for assessing the 
functional impact of pathogenic mutations in human mitochondrial transporters which 
have often proved problematic as regard their over-expression in bacteria (Fontanesi et 
al., 2004, Edvardson et al., 2013). 
 
The amino acid arginine 247 is highly conserved in SLC25A1 of fungi and metazoan as 
well as in numerous other mitochondrial carriers (figure 8.1A, 8.1B).  This residue 
(arginine 247) is part of the transmembrane helix 5 and correlates with the second basic 
amino acid of the sequence motif [D/E]GxxxxAr[R/K]G.  This motif is characteristic of 
members of the mitochondrial carrier family (Palmieri, 2013).  
 
Using the crystallized structure of the ADP/ATP carrier (Pebay-Peyroula et al., 2003), 
one can extrapolate that residue R247 is implicated in ionic exchanges with the acidic 
residues of the second portion of the MCF sequence motif [D/E]Gx5Ar[K/R]G located 
at the start of even transmembrane helices (figure 8.1c).  Two other amino acids of the 
citrate carrier positioned at the same height on transmembrane helix 1 (Q52) and 3 
(K149) share this same property.  During substrate transport cycle, alternate closing and 
opening of the carrier on the matrix side is believed to be facilitated via these intra-
repeat interactions (Palmieri and Pierri, 2010).  
                                                 
93
 Adapted from Chaouch et al 2014 (URL:http://iospress.metapress.com/content/l36500736v3r4132) 
   
184 
 
Figure 8.1: Sequence alignment of mitochondrial citrate carrier (SLC25A1) 
from different organisms (panel A) and other members of mitochondrial 
carrier family (panel B). Accession numbers for each species/carrier is 
given. Panel C shows structural comparative model of human CIC and 
docking of citrate. The 3D comparative model of human CIC is reported in 
white cartoon representation. The six transmembrane helices are indicated 
by black labels (H1-H6). Two of the three helices parallel to the membrane 
planes are also labelled (h12 and h56). The citrate ligand is shown in cyan 
licorice. The pathogenic mutations R247Q (this work) G130D, R282H 
(Edvardson et al., 2013) are displayed in red surf representation.  
Reproduced from Chaouch et al 2014 
(URL:http://iospress.metapress.com/content/l36500736v3r4132) 
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Kinetic studies of the R241Q Ctp1p mutant were carried out after reconstitution of 
purified recombinant protein into liposomes.  The substitution of R241 with glutamine, 
which correlates with the substitution of residue R247 in the human mitochondrial 
transporter, was associated with significant reduction in transporter activity when 
compared to WT Ctp1p (figure 8.2).   It is worth noting in spite of this reduction, some 
residual activity of the transporter was detected. Furthermore, this reduction was 
partially corrected by incorporating more SLC25A1 protein (approximately 30%) as 
shown in figure 8.3.  This Western Blotting analysis was performed using cultured skin 
fibroblasts of the index case and control cells.  A small (not significant p>0.05) 
reduction in membrane potential of mitochondria was detected in the patient cultured 
fibroblasts when compared to control (data not shown).  On the other hand, 
mitochondrial content and network morphology showed no abnormalities.   
 
 
 
Figure 8.2: Functional characterization of the wild-type (WT) and the p.R241Q Ctp1 p. The uptake rate of 
(14C) citrate was measured by adding 0.1 mM of (14C) citrate to proteoliposomes reconstituted with 
purified WT or with the mutated Ctp1 protein. The proteoliposomes were preloaded internally with 10 
mM of citrate. The means and SDs from five independent experiments are shown (*p<0.01, two-tailed 
unpaired Student's t-test). Reproducedfrom Chaouch et al 2014 
(URL:http://iospress.metapress.com/content/l36500736v3r4132) 
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Recently, in silico evaluation the evolutionary limitation of individual amino acid 
residues in the human mitochondrial carriers was shown to successfully predict the 
impact of this residue in conserving the function of the mitochondrial transporter (Pierri 
et al., 2014). When reviewing the 216 residues formerly scored for the mitochondrial 
carrier SLC25A1 (Pierri et al., 2014), residue R247 lies lower than a median threshold 
of 4.68 (i.e. in the bottom 50% of all scores).  Accordingly, this scoring method 
suggests that the R247 residue of SLC25A1 bears less functional impact compared to 
other mutations in SLC25A1 residues.  This would be in keeping with the higher protein 
activity seen in the context of a milder clinical phenotype of the two affected siblings 
and the normal ranges of urinary 2-hydroxyglutarate (table 8.2).  
It is worth noting that all previously reported disease causing mutations in SLC25A1 
scored above the median threshold of 4.68 and were indeed present in patients with a 
much more severe often lethal phenotype.  This includes the previously studied 
mutations G130D and R282H identified in patient 3 (table 8.2, figure 8.4).  
 
 
Figure 8.3:  Western blot analysis of patient fibroblast cells (and control). Upon separation by SDS-PAGE 
and SLC25A1 (~31-kDa) and β-ATPase (~55-kDa) levels were determined by densitometric analysis. 
The relative ratio was calculated and the means and SDs from three independent experiments are shown 
(*p<0.01, two-tailed unpaired Student's t-test).  Reproduced from Chaouch et al 2014 
(URL:http://iospress.metapress.com/content/l36500736v3r4132) 
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Table 8.2: Phenotype genotype correlation.  Phenotype and mutations of patients affected by SLC25A1-associated pathologies (Edvardson et al., 2013, Nota et al., 2013). A 
prediction of the functional relevance of each residue is also reported (residue-specific score), as calculated in (Pierri et al., 2014).(a) agenesis of the corpus callosum and optic nerve 
hypoplasia with marked jitter on SFEMG (b) neonatal epileptic encephalopathy and absence of developmental progress. (c) Percentage of activity of the mutated yeast orthologous 
protein compared to the yeast wild-type protein [(Edvardson et al., 2013) and this study]. (d) Percentage of citrate export in human mutated fibroblasts compared to human control 
fibroblasts (Nota et al., 2013).  2-HG: urinary 2- hydroxyglutarate.  Reproduced from Chaouch et al 2014 (URL:http://iospress.metapress.com/content/l36500736v3r4132).
Patients 
Clinical 
phenotype 
2-HG 
levels 
Human 
mutation 
SLC25A1 Activity 
(%) 
Residue-specific 
score 
Present study mild normal R247Q 40 (c) 3,38 
(Edvardson et al., 2013) severe (a) high 
G130D 25(c) 5,50 
R282H 0 (c) 5,61 
(Nota et al., 2013) patient 1 severe (b) high S193W 12.9 (d) 5,51 
(Nota et al., 2013) patient 2 - high R282G 12.3 (d) 5,61 
(Nota et al., 2013) patient 3 severe (b) high R282C 6.1 (d) 5,61 
(Nota et al., 2013) patient 5 severe (b) high G167R 19.8 (d) 5,10 
(Nota et al., 2013) patient 6 severe (b) high P45L - 5,00 
(Nota et al., 2013) patient 8 severe (b) high E144Q - 5,04 
(Nota et al., 2013) patient 
10 
severe (b) high 
M202T - 5,33 
Y297C - 4,89 
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Figure 8.4: Transport assay of wild type (WT) and mutated SLC25A1 protein into liposomes. At time 
zero 0.1 mM (
14
C) citrate was added to liposomes reconstituted with the recombinant wild-type or 
mutants and containing 10mM citrate. At the indicated times, the uptake of the labeled substrate was 
terminated by adding 20 mM pyridoxal 5′-phosphate and 20 mM bathophenanthroline. Similar results 
were obtained in four independent experiments.  Reproduced from Chaouch et al 2014 
(URL:http://iospress.metapress.com/content/l36500736v3r4132) 
 
 
8.2.4 Zebrafish SLC25A1 knockdown
94
 
 
The influence of reduced expression of SLC25A1 on the neuromuscular junction was 
assessed using zebrafish knockdown of this mitochondrial carrier.  In zebrafish 
embryos, two orthologues (SLC25A1a and SLC25A1b) were shown to be expressed.  
Injection of both SLC25A1a and SLC25A1b antisense MOs into the embryos produced 
mis-spliced transcripts in addition to the wild-type transcript at 48hpf (data not shown).  
 
Typically, knockdown of neuromuscular junction proteins impacts on the motility and 
swimming behaviour of injected embryos.  MO-injected embryos exhibited abnormal 
tail morphology, swimming and touch-evoked escape responses at 48 hpf (figure 8.5).  
Muscle fibres appeared normal on histochemical analysis in contrast to the NMJ 
morphology, which was clearly disrupted (figure 8.6, 7).  Synapse development was 
often incomplete with marked abnormalities noted in the presynaptic compartment.  The 
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motor nerve terminals appeared short with evidence of haphazard outgrowth in the 
direction of the muscle fibre (figure 8.6).  In embryos injected with a standard control 
MO and non-injected wild type embryos, the structure and function of NMJ were 
indistinguishable (data not shown).  There was also evidence of multi organ 
involvement with knockdown embryos frequently exhibiting oedema of the hindbrain, 
heart, yolk sac and tail (figure 8.5).  Cardiac abnormalities correlated with the severity 
of the phenotype and were associated with diminished blood flow to the tail.  
Knockdown embryos displayed these characteristics in both the presence and absence of 
the apoptotic suppressing anti-p53 MO (data not shown).
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Figure 8.5: Phenotype of 
SLC25A1 knockdown 
zebrafish. Live embryos imaged 
at 48hpf following co-injection 
of SLC25A1a (5ng) and 
SLC25A1b (2.5ng). Injected 
embryos demonstrate a range of 
phenotypes with mild to severe 
morphological abnormalities. 
Embryos exhibit a 
developmental delay with 
curvature and shortening of the 
tail and also oedema of the 
hindbrain, heart, yolk sac and 
tail. Scale bars: 500 μm 
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Figure 8.6: Neuromuscular junctions 
following injection with SLC25A1 
MOs. Non-injected control Wild 
Type Golden embryos (left) and 
SLC25A1 MO injected embryos 
were stained for postsynaptic AChR 
(α-bungarotoxin, red staining) and 
presynaptic nerve endings (SV2 
antibody, green staining). Combined 
SLC25A1 MO (a 5ng & b 2.5ng) 
injected 48hpf embryos demonstrate 
short motor axons and erratic 
outgrowth toward the muscle fibre. 
Scale bar: 50 μm.  Adapted from 
Chaouch et al 2014 
(URL:http://iospress.metapress.com/
content/l36500736v3r4132) 
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Figure 8.7: Muscle morphology following injection with SLC25A1 MOs. WT and control MO injected embryos (left) and SLC25A1 MO injected embryos (centre and right) were 
stained for F-actin with Alexa Fluor® 594 conjugated phalloidin (5 μg/ml). WT embryos and those injected with a standard control MO showed normal muscle morphology. 
Combined SLC25A1 MO with and without the addition of anti-p53 MO also demonstrate normal muscle morphology. Scale bar: 50 μm.  Adapted from Chaouch et al 2014 
(URL:http://iospress.metapress.com/content/l36500736v3r4132
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8.3 Discussion
95
 
 
The hallmarks of congenital myasthenic syndrome are fatigable neuromuscular 
weakness, neurophysiological evidence of abnormal NMJ transmission, absence of anti 
AChR and anti-MuSK antibodies and response to recommended treatment (Beeson et 
al., 2005, Hantai et al., 2013).  The affected patients reported in this study exhibited all 
these features, which prompted the working diagnosis of CMS.  SFEMG in the index 
case revealed that a significant proportion of myofiber pairs showed increased jitter 
with block, in keeping with defective neuromuscular transmission.  Both patients 
exhibited little fluctuations or progression in their neuromuscular symptoms; with no 
bulbar or respiratory compromise and remain ambulant to this date.  Accordingly, the 
disease course in this kinship seems less severe compared to other CMS categories 
(Chaouch et al., 2012a). 
 
To define the molecular defect in this family, homozygosity mapping and whole exome 
sequencing were carried out and successfully identified a novel homozygous missense 
mutation in the SLC25A1 gene.  This variant was the sole novel variant which involved 
a highly conserved amino acid predicted to be deleterious and was shown to be 
expressed in both nerve and muscle tissues.  
 
One unusual feature in this family was the presence of intellectual disability of varying 
severity in both siblings.  The X chromosomal deletion confirmed in the female patient 
may have contributed to this.  This 30 Mb large heterozygous deletion comprised 273 
deleted genes including Fragile X Mental Retardation gene (FMR1).  It has been shown 
that trinucleotide repeat expansions of this gene cause fragile-X-syndrome which is a 
common cause of intellectual disability in boys.  Given the large size of this 
hemizygous deletion, a much more severe or probably lethal phenotype would be 
expected.  In the affected female patient, a non-random X-inactivation was confirmed 
which may point towards a female manifestation of this syndrome triggered by selective 
inactivation of the intact X (Schmidt et al., 1990). 
 
Dysfunction of SLC25A1 has recently been shown to affect brain, eye and perhaps 
neuromuscular development, as well as producing an idiosyncratic urinary organic acid 
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profile.  It is currently unclear whether this metabolic derangement is solely responsible 
for CMS like novel phenotype but it may be that additional factors such as oxidative 
stress, ROS toxicity and cellular NADPH content are also pertinent. 
Establishing that one of the previously reported patients with mutations in SLC25A1 had 
abnormal neuromuscular transmission, provided further supportive evidence that 
mutations in this gene were responsible for the disease phenotype in this family 
(Edvardson et al., 2013).  
 
Of note, the two siblings described in this chapter had a relatively mild phenotype in 
comparison to the previous reports and exhibited no agenesis of the corpus callosum.  
They also exhibited a normal urinary organic acid analysis in keeping with a milder 
clinical phenotype. 
 
SLC25A1 is well conserved across species and was only recently associated with 
disease in humans (Edvardson et al., 2013, Nota et al., 2013).  This mitochondrial 
citrate transporter was shown to be critical in intermediary metabolism, glucose induced 
insulin secretion and chromatin integrity (Catalina-Rodriguez et al., 2012, Palmieri, 
2013, Morciano et al., 2009, Iacobazzi et al., 2009).  The chromosomal location of this 
gene (22q11.2) also attracted some attention as this is either translocated or amplified in 
some tumours and deleted in DiGeorge syndrome and possibly schizophrenia (Maynard 
et al., 2008, Williams et al., 2002).   
 
In this study, the preserved protein expression in patient’s skin fibroblast along with the 
moderately diminished carrier function and the low in silico prediction score suggest 
that the novel pathogenic mutation (p.R247Q) is associated with a less deleterious effect 
in comparison to all the recently described mutations in SLC25A1(Edvardson et al., 
2013, Nota et al., 2013).
96
   
 
Despite significant discrepancies amongst the in silico scores of R247 and other 
previously reported mutated residues like G130 (Edvardson et al., 2013), the transporter 
activity of the yeast orthologous protein carrying either of the two pathogenic mutations 
at corresponding positions only shows 15% reduction in activity, i.e. 40% and 25%, 
respectively (table 8.2 and  figure 8.4).  There are two potential explanations to this 
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observation:  The first relates to the yeast model system used in this experiment which 
may not accurately replicate the in vivo carrier activity of the human mitochondrial 
citrate transporter.  Bearing in mind the marked homology between the human and yeast 
orthologues of SLC25A1, in terms of amino acid sequence and transporter activity, this 
hypothesis seems unlikely.  It is worth noting that the p.G130D mutation is 
heterozygous and the other affected allele carried the p.R282H mutation (Edvardson et 
al., 2013) which completely abolished transport activity and would be associated with a 
more severe phenotype.  Secondly, the in silico prediction score is an evolutionary 
based value, which relies on the strength of natural selection and correlates with the 
fitness of organisms, i.e. the probability of organisms to survive and generate fertile 
progeny (Eyre-Walker and Keightley, 2007).  The presented patients achieved 
reproductive age and may be considered fertile even though the protein activity of the 
p.R247Q mutant was partially reduced.  Accordingly, one expects the prediction score 
of p.R247Q to be much lower compared to any other tested SLC25A1 mutations that 
were instead responsible for lethal phenotype with premature death in neonatal period.  
Correspondingly, this hypothesis may explain the close scores of the previously 
reported mutations G130 and R282 (Edvardson et al., 2013), as well as other previously 
reported pathogenic mutations (Nota et al., 2013), all of which were associated with a 
more severe often lethal phenotype
97
.  
 
Zebrafish has recently been shown to be a useful animal model to assess the impact of 
protein Knockdown on the neuromuscular junction (Muller et al., 2010, Senderek et al., 
2011).  Remarkably, SLC25A1 knockdown confirmed aberrant NMJ development and 
function similar to that seen in the affected patients regardless of the severity of the 
phenotype which ranged from mild, moderate to severe.  Ultra-structural study of the 
NMJ showed intact morphology of post synaptic muscle fibres, with marked anomalies 
in nerve outgrowth and synapse formation.  This observation underscores the role of 
SLC25A1 in development and maintenance of the NMJ.  In addition to the synaptic 
defects, we demonstrate further alteration in brain and heart morphology and 
development in the more severely affected zebrafish morphants, in keeping with a more 
general function of mitochondrial SLC25A1 in various tissues.  It is worth noting that a 
previous report used an SLC25A1 knockdown zebrafish model to assess its influence on 
embryogenesis, the integrity of mitochondrial DNA and autophagy.  However, limited 
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details were available in terms of organ development and synapse formation (Catalina-
Rodriguez et al., 2012)
98
.   
 
One may conjecture that the mild CMS phenotype may have facilitated the detection of 
an NMJ defect in these patients, while this remains undiagnosed in patients with the 
more disabling, often fatal disease form.  Further studies are required to elucidate why 
the NMJ seems to be particularly sensitive to mild SLC25A1 dysfunction, while other 
organs such as the brain remain largely asymptomatic.  Interestingly, the knockdown 
experiments in zebrafish showed a similar dependency of symptoms in relation to the 
knockdown: less severely affected zebrafish morphants showed motility defects and 
NMJ abnormalities, but more severely affected morphants had additional defects of the 
brain and heart compatible with a generalized mitochondrial disorder
100
.  
 
Mitochondria are ubiquitous organelles that mediate a host of cellular functions 
including energy production, cellular metabolism, calcium homeostasis and apoptosis 
(McFarland et al., 2010, Ly and Verstreken, 2006).  The role of mitochondria in synapse 
development and maintenance is probably complex and remains poorly understood.  
How defects in a ubiquitous mitochondrial citrate carrier can manifest primarily as a 
NMJ defect remains to be resolved
100
.  
 
It is worth stressing that SLC25A1 is likely to be an extremely rare cause of a pure CMS 
phenotype.  Screening of undiagnosed CMS patients from extended cohorts did not 
yield other pathogenic mutations in SLC25A.  Furthermore, only fifteen missense 
mutations in SLC25A1 were identified after exome sequencing more than six thousand 
random individuals (Exome Variant Server; http://evs.gs.washington.edu/EVS/, 
accessed April 2014).  Each mutation was heterozygous and present in less than 0.1% of 
the screened population.  Based on the described in silico prediction scoring system, a 
minimum of seven mutations were predicted to significantly impair transporter function 
and would in effect represent an existing pool of pathogenic alleles circulating in the 
human population.  Consequently, while the presence of homozygous or compound 
heterozygous mutations in SLC25A1 is likely to be a rare event, should a patient display 
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fatigable neuromuscular weakness, screening of SLC25A1 mutations may be 
considered.
99
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9. Final conclusions and future directions 
 
Congenital myasthenic syndromes are rare disorders, the phenotype of which primarily 
reflects abnormal transmission across the neuromuscular junction.  Despite being rare, 
this disease entity remains at the centre of research focused on deciphering the 
biological relevance of synaptic proteins and unravelling how particular defects can 
disturb sophisticated mechanisms that ensure reliable neuromuscular transmission.   
 
The review of the nineteen CMS subtypes based on their underlying molecular defects 
revealed significant heterogeneity in terms of clinical phenotype, neurophysiological 
findings and response to treatment.  Nevertheless, there was evidence of some 
correlation between particular symptoms and molecular defects as seen with presence of 
apnoea in CHAT or RAPSN related CMS.   Although decrement is a useful indicator of 
impaired NMJ function, it is less able to predict the underlying molecular defect. 
Nonetheless, certain electrical patterns can be more specific such evidence of repetitive 
CMAP on single nerve stimulation, seen in slow channel CMS and COLQ related CMS.  
In clinical setting, the majority of CMS patients carry defects in the postsynaptic 
proteins with mutations in the CHRNE gene being the commonest and the most 
compatible with life.  The choice of pharmacotherapy is dependent on the molecular 
defect and it is crucial that clinicians approach CMS patients in a holistic fashion with 
attention to respiratory and bulbar difficulties. 
 
 
9.1 Cross sectional study of the Munich CMS cohort 
 
The cross sectional study of the Munich CMS cohort aimed at reporting on the clinical 
and genetic profile of a large cohort of 680 independent patients with suspected CMS.  
It also helped ascertain the efficacy of the chosen diagnostic strategy based upon a step-
by-step Sanger based mutation screening.  In total, disease causing mutations were 
successfully detected in 44% of patients in various known genes, endorsing the marked 
genetic heterogeneity observed in CMS.  Except for the four previously reported 
founder mutations in the CHRNE, DOK7 and RAPSN genes, the majority of molecular 
defects identified were private mutations in isolated kinships.  In the Munich cohort, the 
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mutation c.1267delG in CHRNE in South Eastern European patients was most 
prevalent. 
This study also revealed that in the absence of specific phenotypic clues, one may 
consider screening for the three common mutations in CHRNE, DOK7, and RAPSN.   
 
Based on the current understanding of genotype phenotype correlations in CMS, it was 
possible to confirm the importance of some parameters such as ophthalmoplegia, 
decrement and positive family history, in predicting a higher mutation detection rate.  
These different cues were used to design an algorithm for genetic testing which 
highlighs the importance of close collaboration between health professionals including 
clinicians, genetic counsellors, neurophysiologists and pathologists to ensure accurate 
genetic diagnosis and optimum patient care.  In the context of emerging next generation 
sequencing, this study has reinforced certain concepts of phenotype genotype 
correlation and facilitated the production of a reliable and cost efficient algorithm which 
will be crucial in terms of interpreting the large number of variants likely to be 
generated from next generation sequencing. 
  
 
9.2 Clinical characterization of a slow channel CMS cohort 
 
Slow-channel syndrome is a rare form of CMS and exhibits distinct clinical and genetic 
characteristics. This retrospective study focused on the clinical phenotype, phenotype 
genotype correlation and response to treatment in a sizable cohort of patients.  The data 
revealed some heterogeneity with regard to onset of symptoms, severity of disease and 
mutations.  Nonetheless, patients shared a number of features including the preferential 
involvement of the cervical and forearm extensor muscles and lack of response to 
conventional treatment with AChE inhibitors.  Several mutations were detected, most of 
which were situated in a transmembrane domain or near the binding site of the receptor.  
Although this study endorses the observation that treatment with fluoxetine and 
quinidine are beneficial in most patients; occasionally, patients suffered serious adverse 
effects related to fluoxetine that hampered optimum escalation of the dose.  The current 
lack of alternatives leaves patients vulnerable to potentially life threatening events 
related to this condition.  
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9.3 Clinical characterization of CMS cohort with GFPT1 mutations 
 
Limb girdle myasthenia is a rare and distinct phenotype characterized by fatigable 
proximal muscle weakness with minimal ocular and facial involvement.  Until recently, 
DOK7 mutations were the only known molecular defect associated with this phenotype. 
Mutations in GFPT1 were recently unravelled in a cohort of undiagnosed limb girdle 
myasthenia using positional cloning approach.  This study was able to provide a more 
comprehensive review of the phenotypic spectrum of this disease and highlighted 
differences compared to DOK7 related CMS.  In general, patients with mutations in 
GFPT1 exhibited a homogenous clinico-pathological phenotype with symptoms starting 
within the first decade, a consistent pattern of proximal limb weakness, presence of 
tubular aggregates on muscle biopsy and a positive response to AChE inhibitors.  This 
correlation is likely to contribute to the better diagnosis; treatment and counselling of 
patients with GFPT1 related CMS. 
 
 
9.4 Gene discovery in CMS using whole exome sequencing 
 
Over the past five years, whole exome sequencing has transformed disease gene 
discovery.  This approach relies on a highly sophisticated biotechnology for parallel 
sequencing and relies on a computational analysis aimed at setting filters to restrict the 
search to novel or rare variants, known or predicted to be pathogenic.  The success rate 
from whole exome sequencing is unknown.  In this study, less than 50% of families 
were successfully diagnosed.  Limitations were primarily related to suboptimum 
coverage, evolving in silico prediction tools and public databases that do not always 
provide accurate frequency data nor necessarily reflect the genotype of smaller ethnic 
groups.  
 
 
9.5 AGRN related CMS with distal muscle weakness and wasting  
 
Using exome sequencing, compound heterozygous mutations in the AGRN gene were 
successfully identified in a Norwegian kinship.  These mutations were associated with a 
strikingly homogenous phenotype with impaired neuromuscular transmission and distal 
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muscle weakness and atrophy.  Based on this phenotype, an additional three patients 
from two independent kinships were identified via the French CMS network.  These 
patients shared distal limb muscle wasting and weakness and showed no response to 
AChE inhibitors.  
 
Neurophysiological studies were key in unravelling impaired neuromuscular junction.  
In addition to marked decrement, there was evidence, sometimes, of significant 
increment after sustained muscle contraction (up to 285%), in keeping with a 
presynaptic defect.  The latter is not a common finding in CMS but is a landmark of 
autoimmune Lambert Eaton myasthenic syndrome.  Muscle biopsy showed patchy 
myopathic changes, which may mislead clinicians to a diagnosis of primary myopathy.  
At ultra-structural level, there was evidence of synaptic remodelling with a combination 
of denervation and re-innervation events.  Two of the novel mutations identified were 
situated in the agrin NtA domain and were shown to diminish acetylcholine receptors 
clustering.  The effect of these mutations on laminin binding was not assessed but no 
abnormal labelling of agrin, lrp4 or laminin β2 was noted in the patients’ muscle.  
 
This study expanded the phenotypic spectrum of AGRN related CMS and revealed a 
remarkable correlation between genotype and phenotype.  Accordingly, one can 
stipulate the need to investigate patients with distal myopathy for an underlying 
neuromuscular transmission disorder and to consider genetic testing for AGRN 
mutations.  
 
 
9.6 Mutations in SLC25A1 cause impaired neuromuscular transmission 
 
A novel homozygous variant in the SLC25A1 gene was also identified using exome 
sequencing in a consanguineous English kinship.  This gene encodes the mitochondrial 
citrate carrier.  The phenotype of these patients was suggestive of CMS with fatigable 
weakness and ptosis.  They also exhibited some intellectual disability and 
neuropsychiatric features.  Response to conventional treatment was equivocal.  Of note, 
a previously reported patient with different compound heterozygous missense mutations 
of SLC25A1 was later shown to have abnormal neuromuscular transmission.  This gene 
SLC25A1 had been reported to cause a severe often lethal disease. The two patients 
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described in this study displayed a less severe phenotype manifesting mainly as a 
neuromuscular junction disorder.   
 
To assess the pathogenicity of this novel mutation, mutant SLC25A1 expression in 
yeast and its transporter function were assessed in vitro and a knockdown zebrafish 
model was generated.  These experiments showed normal SLC25A1 protein expression 
with abnormal carrier function in the patient’s tissue.  Additionally, knockdown of 
SLC25A1 expression in zebrafish replicated the human disease, exhibiting variable 
brain and eye abnormalities with impaired motility.  The zebrafish model also 
demonstrated defective development of the neuromuscular junction with abnormal 
axonal outgrowth irrespective of the severity of the phenotype.  
 
 
9.7 Future perspectives 
 
Using traditional methods, a number of CMS patients remain with no genetic diagnosis. 
The introduction of high throughput sequencing technology is likely to improve the 
diagnostic yield in known genes, but will require a collaborative approach to help 
interpret the colossal number of variants generated and refine the diagnostic algorithm.  
The study of very rare disorders such as CMS will continue to be limited by the small 
number of patients available.  The discovery of mutations in GFPT1and more recently 
DPAGT1, ALG2 and ALG14 genes associated with limb girdle myasthenia have 
established the importance of glycosylation in maintaining the integrity of the 
neuromuscular junction.  Given the ubiquitous function of these enzymes, it would be 
worth ascertaining if patients have subclinical involvement of other organs.  The 
presence of variable abnormalities in both the pre and postsynaptic compartments 
suggest that additional mechanisms other than impaired glycosylation of the AChR 
subunit are at play.  The challenge here may be to successfully generate a mammalian 
animal model that can replicate the human disease.  
 
The striking homogenous clinical and neurophysiological features seen in AGRN 
related CMS with distal muscle weakness, are likely to reflect a common molecular 
mechanism.  In the first instance, the effect of N terminal of agrin mutations on laminin 
binding should be assessed followed by further in vivo work to understand the 
   
203 
 
mechanism of presynaptic changes seen in all patients.  Given the marked distal muscle 
atrophy seen in these cases, the expression and function of the muscle isoform of agrin 
would be pertinent to assess.  Finally, the effect of mutant SLC25A1 on the presynaptic 
compartment awaits to be elucidated.  One may consider exploring the impact of the 
mutant protein on the bioenergy of the synapse and transmitter release from the 
presynaptic compartment.  
 
Our report on the treatment of slow channel CMS has underlined the difficulties 
accoutred with conventional treatment.  This is also true of other CMS subgroups.   
One would hope that future progress leads to more specific and safer therapies.   
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A3. SureSelect DNA library preparation and target enrichment capture
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 From SureSelect Human All Exon Kit Protocol (version 1.0.1 October 2009).  
